



Jeevan Scientific Technology Limited

23rd Annual Report 2020 - 2021





UHPLC & LC-MS/MS



Processing Area



Deep Freezers



Centrifuge



QA Team



Clinic

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

CORPORATE INFORMATION

BOARD OF DIRECTORS

Mr. S. S. R. Koteswara Rao	-	Chairman - Independent Director
Mr. K. Krishna Kishore	-	Vice Chairman & Managing Director
Ms. Snigdha Mothukuri	-	CEO & Executive Director
Mr. Y. Nageswar Rao	-	Executive Director
Mr. T. Ravi	-	Non-Executive Director
Mr. G. Bhanu Prakash	-	Independent Director
Mr. K. Rama Krishna Prasad	-	Independent Director
Mr. K. Jeevan Krishna	-	Additional Non-Executive Director

CHIEF FINANCIAL OFFICER

Mr. M. Srikanth Sasidhar

COMPANY SECRETARY

Ms. Sharvari Swapnil Shinde

REGISTERED OFFICE

Plot No. 1 & 2,
Sai Krupa Enclave, Manikonda Jagir,
Near Lanco Hills, Goloconda Post,
Hyderabad, Telangana -500008.
Ph No 040-67364700, Fax: 040-67364707

STATUTORY AUDITORS

M/s. Pavuluri & Co
Chartered Accountants
Plot No. 48, Flat No. 301,
Sucasa, Phase - I,
Kavuri Hills,
Hyderabad - 500 033.

PHARMACOLOGY UNIT

B-17, TIE, Phase II, Balanagar
Hyderabad, Telangana - 500037.
Ph No : 040-23721008

INTERNAL AUDITORS

M/s. KP & Associates
Chartered Accountants
Hyderabad

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

SECRETARIAL AUDITORS

M/s. S. S. Reddy & Associates
Practicing Company Secretaries
Plot No.8-2-603/23/3 & 8-2-603/23, 15
2nd Floor, HSR Summit, Banjara Hills,
Road No. 10, Hyderabad-50003

BANKERS

Karur Vysya Bank Ltd.
Oriental Bank of Commerce.
Andhra Bank.

AUDIT COMMITTEE

Mr. K. Rama Krishna Prasad - Chairman
Mr. S.S.R. Koteswara Rao - Member
Mr. K. Krishna Kishore - Member
Mr. G. Bhanu Prakash - Member

NOMINATION & REMUNERATION COMMITTEE

Mr. K. Rama Krishna Prasad - Chairman
Mr. S. S. R. Koteswara Rao - Member
Mr. T. Ravi Babu – Member

STAKEHOLDERS RELATIONSHIP COMMITTEE

Mr. K. Rama Krishna Prasad - Chairman
Mr. S.S.R. Koteswara Rao - Member
Mr. K. Krishna Kishore - Member
Mr. G. Bhanu Prakash – Member

INDEPENDENT DIRECTORS COMMITTEE

Mr. S. S. R Koteswara Rao - Chairman
Mr. K. Rama Krishna Prasad - Member
Mr. G. Bhanu Prakash – Member

ANTI – SEXUAL HARRASSMENT COMMITTEE

Mrs. N. Krishnaveni - Chairperson
Mrs. Snigdha Mothukuri - Member
Mrs. E. Archana - Member
Dr. K. Rajani - Outside Member

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

REGISTRAR & SHARE TRANSFER AGENTS

M/s. CIL Securities Limited,
214, Raghavaratna Towers,
Chiragali Lane, Hyderabad -500001
Phone Number: 040-23202465 / 66612093
Fax: 040-23203028

CORPORATE IDENTITY NUMBER

L72200TG1999PLC031016

LISTED AT : BSE Limited.

ISIN : INE237B01018

WEBSITE : www.jeevanscientific.com

INVESTOR E-MAIL ID : shareholders@jeevanscientific.com

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

NOTICE

Notice is hereby given that the Twenty Third (23rd) Annual General Meeting of the Members of Jeevan Scientific Technology Limited will be held on Wednesday, the 15th day of September 2021 at 10.30 A.M through video conferencing and other audio-visual means, to transact the following business:

ORDINARY BUSINESS:

1. To receive, consider and adopt the Standalone and Consolidated Audited Balance Sheets as at 31st March 2021, the Statement of Profit & Loss and Cash Flow Statement for the year ended on that date together with the Notes attached thereto, along with the Reports of Auditors and Directors thereon.
2. To declare and confirm dividend of Rs. 0.50/- per share for the financial year 2020-21.
3. To appoint a director in place of Mr. T. Ravi (DIN: 01274099), who retires by rotation and being eligible, offers himself for re-appointment.

SPECIAL BUSINESS:

4. **RE-APPOINTMENT OF MR. K. RAMA KRISHNA PRASAD (DIN: 00754823) AS AN INDEPENDENT DIRECTOR OF THE COMPANY.**

To consider and if thought fit, to pass with or without modification(s), the following resolution as a Special Resolution:

“RESOLVED THAT pursuant to the provisions of Sections 149, 150, 152 read with Schedule IV and recommendation of the Nomination and Remuneration Committee and approval of the Board of Directors in their respective meetings and any other applicable provisions, if any, of the Companies Act, 2013 and the Companies (Appointment and Qualification of Directors) Rules, 2014 and the applicable provisions of Listing Regulations (including any statutory modification(s) or re-enactment thereof for the time being in force), consent of the members of the Company be and is hereby accorded for re-appointment of Mr. K. Rama Krishna Prasad (DIN: 00754823) who has submitted a declaration confirming the criteria of Independence under Section 149(6) of the Companies Act, 2013 read with the SEBI (LODR) Regulations, 2015 as amended from time to time, and who is eligible for re- appointment for a second term as an Independent Director of the Company, whose term shall not be subject to retirement by rotation, to

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

hold office for 5 (five) consecutive years on the Board of the Company w.e.f. 12th February, 2021 up to 11th February, 2026.

RESOLVED FURTHER THAT any of the Board of Directors be and is hereby authorised to do and perform all such acts, deeds, matters or things as may be considered necessary, appropriate, expedient or desirable including filing of necessary form with the office of the Registrar of Companies as maybe applicable to give effect to above resolution.”

5. APPOINTMENT OF MRS. SNIGDHA MOTHUKURI (DIN: 08934860) AS A DIRECTOR AND EXECUTIVE DIRECTOR OF THE COMPANY:

To consider and if thought fit, to pass with or without modification(s), the following resolution as Ordinary Resolution:

"RESOLVED THAT pursuant to the provisions of Section 149,152 and other applicable provisions, if any, of the Companies Act, 2013 ('the Act') read with the Companies (Appointment and Qualification of Directors) Rules, 2014 ('the Rules') including any statutory modification(s) or re-enactment thereof, Mrs. Snigdha Mothukuri who was appointed by the Board of Directors as an Additional Director (category-Executive) of the Company on the recommendation of Nomination and Remuneration Committee with effect from 02.11.2020 and who holds office up to the date of this Annual General Meeting or the last date on which the Annual General Meeting should have been held, whichever is earlier in terms of Section 161 of the Act and Articles of Association of the Company be and is hereby appointed as a Director of the Company and shall also be eligible to retire by rotation.

RESOLVED FURTHER THAT pursuant to the provisions of Sections 196, 197, read with Schedule V and other applicable provisions if any, of the Companies Act, 2013 including any statutory modification(s) or re-enactment thereof for the time being in force and Articles of Association of the Company, the consent of the members of the company be and is hereby accorded to appoint Mrs. Snigdha Mothukuri (DIN: 08934860) as Executive Director of the Company for a period of three years with effect from 02.11.2020 to 01.11.2023 at a remuneration of Rs. 4,00,000 p.m. and the Board of Directors be and is hereby authorized to vary or increase the remuneration, perquisites, and allowances etc. within such prescribed limits in terms of Schedule V of the Companies Act, 2013, as amended from time to time.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

RESOLVED FURTHER THAT in the event of losses or inadequacy of profits in any financial year during her tenure the Company shall pay to Mrs. Snigdha Mothukuri, remuneration by way of salaries and allowances as specified above as minimum remuneration and in accordance with the limits specified under the Companies Act, 2013 read with Schedule V to the Companies Act 2013, or such other limit as may be prescribed by the Government from time to time.

RESOLVED FURTHER THAT any of the Board of Directors be and is hereby authorized to do all such acts, deeds, matters and things as may be considered necessary, appropriate expedient or desirable including filing of necessary form with the office of the Registrar of Companies as maybe applicable to give effect to above resolution.”

6. APPOINTMENT OF MR. JEEVAN KRISHNA KUCHIPUDI (DIN: 08207809) AS NON –EXECUTIVE DIRECTOR OF THE COMPANY.

To consider and if thought fit, to pass with or without modification(s), the following resolution as Ordinary Resolution:

"RESOLVED THAT pursuant to the provisions of Section 152 and other applicable provisions, if any, of the Companies Act, 2013 ('the Act') read with the Companies (Appointment and Qualification of Directors) Rules, 2014 ('the Rules') including any statutory modification(s) or re-enactment thereof, Mr. Jeevan Krishna Kuchipudi (DIN: 08207809) who was appointed by the Board of Directors as an Additional Director (category-Non- Executive) of the Company on the recommendation of Nomination and Remuneration Committee with effect from 02.11.2020 and who holds office up to the date of this Annual General Meeting or the last date on which the Annual General Meeting should have been held, whichever is earlier in terms of Section 161 of the Act and Articles of Association of the Company and who is eligible for appointment as a Director be and is hereby appointed as a Director (category-Non-Executive) of the Company and shall also be eligible to retire by rotation.

RESOLVED FURTHER THAT any of the Director of the Company be and is hereby authorised to do and perform all such acts, deeds, matters or things as may be considered necessary, appropriate, expedient or desirable including filing of necessary form with the office of the Registrar of Companies as maybe applicable to give effect to above resolution.”

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

7. **APPOINTMENT OF MR. NAGESWAR RAO YARLLAGADDA (DIN: 00293474) AS A DIRECTOR AND AN EXECUTIVE DIRECTOR – ADMINISTRATION OF THE COMPANY**

To consider and if thought fit, to pass with or without modification(s), the following resolution as an Ordinary Resolution:

"RESOLVED THAT pursuant to the provisions of Section 149, 152 and other applicable provisions, if any, of the Companies Act, 2013 ('the Act') read with the Companies (Appointment and Qualification of Directors) Rules, 2014 ('the Rules') including any statutory modification(s) or re-enactment thereof, Mr. Y. Nageswar Rao who was appointed by the Board of Directors as an Additional Director (category-Executive) of the Company on the recommendation of Nomination and Remuneration Committee with effect from 23.06.2021 and who holds office up to the date of this Annual General Meeting or the last date on which the Annual General Meeting should have been held, whichever is earlier in terms of Section 161 of the Act and Articles of Association of the Company be and is hereby appointed as a Director of the Company and shall also be eligible to retire by rotation.

RESOLVED FURTHER THAT pursuant to the provisions of Sections 196, 197 read with Schedule V and other applicable provisions if any, of the Companies Act, 2013 including any statutory modification(s) or re-enactment thereof for the time being in force and Articles of Association of the Company, the consent of the members of the company be and is hereby accorded to appoint Mr. Y. Nageswar Rao (DIN: 00293474) as Executive Director – Administration of the Company for a period of three years with effect from 23.06.2021 to 22.06.2024 at a remuneration of Rs. 15,00,000 per annum and the Board of Directors be and is hereby authorized to vary or increase the remuneration, perquisites, and allowances etc. within such prescribed limits in terms of Schedule V of the Companies Act, 2013, as amended from time to time.

"RESOLVED FURTHER THAT in the event of losses or inadequacy of profits in any financial year during her tenure the Company shall pay to Mr. Y. Nageswar Rao, remuneration by way of salaries and allowances as specified above as minimum remuneration and in accordance with the limits specified under the Companies Act, 2013 read with Schedule V to the Companies Act 2013, or such other limit as may be prescribed by the Government from time to time".

RESOLVED FURTHER THAT any of the Board of Directors be and is hereby authorized to do all such acts, deeds, matters and things as may be considered necessary, appropriate expedient or desirable including

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

filing of necessary form with the office of the Registrar of Companies as maybe applicable to give effect to above resolution.”

8. REVISION IN REMUNERATION OF MR. K. KRISHNA KISHORE, VICE CHAIRMAN AND MANAGING DIRECTOR OF THE COMPANY OF THE COMPANY:

To consider and if thought fit, to pass with or without modification(s), the following resolution as Special Resolution:

“**RESOLVED THAT** pursuant to the provisions of Sections 196, 197, 203 and any other applicable provisions of the Companies Act, 2013 and the rules made there under (including any statutory modification(s) or re-enactment thereof) and pursuant to Articles of Association of the Company, the consent of the members of the Company be and is hereby accorded for revision / increase of monthly remuneration of Mr. K. Krishna Kishore (DIN 00876539), Executive Vice-Chairman and Managing Director of the Company to Rs. 9,00,000 p.m.”

RESOLVED FURTHER THAT in terms of Schedule V of the Companies Act, 2013, as amended from time to time, the Board of Directors be and hereby authorized to vary or increase the remuneration including Basic Salary, Commission, Perquisites, and Allowances etc. within such prescribed limits.

RESOLVED FURTHER THAT in the event of losses or inadequacy of profits in any financial year during his tenure the Company shall pay to Mr. K. Krishna Kishore, remuneration by way of salaries and allowances as specified above as minimum remuneration and in accordance with the limits specified under the Companies Act, 2013 read with Schedule V to the Companies Act 2013, or such other limit as may be prescribed by the Government from time to time.

RESOLVED FURTHER THAT any of the Board of Directors be and is hereby authorized to do all such acts, deeds, matters and things as may be considered necessary, appropriate expedient or desirable including filing of necessary form with the office of the Registrar of Companies as maybe applicable to give effect to above resolution.”

**For and on behalf of the Board of
Jeevan Scientific Technology Limited**

Sd/-

K. Krishna Kishore

**Vice Chairman and Managing Director
(DIN: 00876539)**

**Place: Hyderabad
Date: 09.08.2021**

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Notes:

1. In view of the continuing Covid-19 pandemic and consequential restrictions imposed on the movements of people, the Ministry of Corporate Affairs (“MCA”) has vide its General Circular No. 02/2021 dated January 13, 2021 read with Circular No. 20/2020 dated May 05, 2020 in conjunction with Circular No. 14/2020 dated April 08, 2020 and Circular No. 17/2020 dated April 13, 2020, (collectively referred to as “MCA Circulars”) and SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/79 dated May 12, 2020 and SEBI/HO/CFD/CMD2/CIR/P/2021/11 dated January 15, 2021, Regulation 44 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), the MCA Circulars granted certain relaxations and thus permitted the holding of Annual General Meeting (“AGM”) of the companies through VC/OAVM viz. without the physical presence of the Members at a common venue. Hence in compliance with the provisions of the Companies Act, 2013 (“Act”), SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) and MCA / SEBI Circulars, as applicable, the AGM of the Company is being held through VC / OAVM (e-AGM).
2. The Deemed Venue of the 23rd AGM of the Company shall be its Registered Office.
3. Since the AGM will be held through VC / OAVM (e-AGM), the Route Map for venue of AGM is not annexed to the Notice.
4. Members attending the AGM through VC / OAVM shall be counted for the purpose of reckoning the quorum of the AGM under Section 103 of the Act.
5. Explanatory Statement pursuant to Section 102 of the Companies Act, 2013, in respect of the Ordinary/Special Business to be transacted at the Annual General Meeting as set out in the Notice is annexed hereto.
6. In pursuance of Regulation 36 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard on General Meetings, details in respect of the Directors seeking appointment/ re-appointment at the AGM, form part of this Annual Report.
7. Pursuant to Section 91 of the Companies Act, 2013, the Register of Members and Share Transfer Books of the Company will remain closed from 09.09.2021 to 15.09.2021 (Both days inclusive).

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

8. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended), and MCA Circulars dated April 08, 2020, April 13, 2020 and May 05, 2020 the Company is providing facility of remote e-voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with Central Depository Services (India) Limited (CDSL) for facilitating voting through electronic means, as the authorized e-Voting's agency. The facility of casting votes by a member using remote e-voting as well as the e-voting system on the date of the AGM will be provided by CDSL.
9. The Members can join the AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC/OAVM will be made available to at least 1000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first come first served basis.
10. The attendance of the Members attending the AGM through VC/OAVM will be counted for the purpose of ascertaining the quorum under Section 103 of the Companies Act, 2013.
11. Pursuant to MCA Circular No. 14/2020 dated April 08, 2020, the facility to appoint proxy to attend and cast vote for the members is not available for this AGM. However, in pursuance of Section 112 and Section 113 of the Companies Act, 2013, representatives of the members such as the President of India or the Governor of a State or body corporate can attend the AGM through VC/OAVM and cast their votes through e-voting.
12. In line with the Ministry of Corporate Affairs (MCA) Circular No. 17/2020 dated April 13, 2020, the Notice calling the AGM has been uploaded on the website of the Company at www.jeevanscientific.com. The Notice can also be accessed from the websites of the Stock Exchanges i.e. BSE Limited at www.bseindia.com. The AGM Notice is also disseminated on the website of CDSL (agency for providing the Remote e-Voting facility and e-voting system during the AGM) i.e. www.evotingindia.com.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

13. The AGM is being convened through VC/OAVM in compliance with applicable provisions of the Companies Act, 2013 read with MCA Circular No. 14/2020 dated April 8, 2020 and MCA Circular No. 17/2020 dated April 13, 2020 and MCA Circular No. 20/2020 dated May 05, 2020.
14. In continuation of this Ministry's **General Circular No. 20/2020**, dated 05th May, 2020 and after due examination, it has been decided to allow companies whose AGMs were due to be held in the year 2020, or become due in the year 2021, to conduct their AGMs on or before 31.12.2021, in accordance with the requirements provided in paragraphs 3 and 4 of the General Circular No. 20/2020 as per MCA circular no. 02/2021 dated January, 13, 2021.
15. Pursuant to Finance Act 2020, dividend income will be taxable in the hands of shareholders w.e.f. April 01, 2020 and the Company is required to deduct tax at source from dividend paid to shareholders at the prescribed rates. For the prescribed rates as applicable to various categories, the shareholders are requested to refer to the Finance Act, 2020 and amendments made thereto from time to time. Some of the major features of the latest tax provisions on dividend distribution are stated as hereunder for a quick reference.

For resident Shareholders, tax shall be deducted at source under Section 194 of the Income Tax Act, 1961 at 10% on the amount of Dividend declared and paid by the Company during financial year 2021-22 provided PAN is provided by the shareholder. If PAN is not submitted, TDS would be deducted @ 20% as per Section 206AA of the Income Tax Act, 1961.

However, no TDS shall be deducted on the dividend payable to a resident Individual if the total dividend to be received by them during Financial Year 2021-2022 does not exceed Rs. 5,000/-. Please note that this includes the previous dividend(s) paid, if any, and future dividend(s) which may be paid, during the Financial Year 2021-2022, if declared.

- i. To all the Beneficial Owners in respect of shares held in dematerialized form as per the data as may be made available by the Depositories viz. National Securities Depository Limited (NSDL) and the Central Depository Services (India) Limited (CDSL) as at the close of business hours on Wednesday, September 08, 2021 (viz. the "Record Date");
- ii. To all the Members in respect of shares held in physical form after giving effect to their valid transfer or transmission or transposition requests lodged with the Company, if any, as at the close of business hours on Wednesday, September 08, 2021.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

In cases where the shareholder provides Form 15G (applicable to any person other than a Company or a Firm) / Form 15H (applicable to an Individual above the age of 60 years), provided that the eligibility conditions are being met, no tax at source shall be deducted.

Apart from the above, since the TDS/ Withholding rates are different for resident and non-resident shareholders, members are requested to confirm their residential status as per the provisions of the Income Tax Act 1961, by sending an email at rta@cilsecurities.com with cc to shareholders@jeevanscientific.com

Company shall arrange to email the soft copy of TDS certificate of the Members at their registered email ID in due course, post payment of the dividend amount and in remaining cases where no email ID is registered, TDS certificates shall be posted to the Members when the postal services function normally.

In view of the above provisions, the shareholders are requested to update their PAN with the Company/R&T Agent (in case shares held in physical mode) and with the depositories (in case of shares held in demat mode). A Resident individual shareholder with PAN but not liable to pay income tax can submit a yearly declaration in Form No. 15G/15H in the aforesaid manner, to avail the benefit of non-deduction of tax at source, by sending email to shareholders@jeevanscientific.com upto 5.00 p.m. (IST) on September 08, 2021. Non-resident shareholders can avail beneficial rates under tax treaty between India and their country of residence, subject to providing necessary documents i.e. No Permanent Establishment and Beneficial Ownership Declaration, Tax Residency Certificate, Form 10F or any other document which may be required to avail the tax treaty benefits under the provisions of Income Tax Act, 1961 by sending an email to shareholders@jeevanscientific.com upto 5.00 p.m. (IST) on September 08, 2021.

16. Members are further requested to note that pursuant to the provisions of Section 124 and 125 of Companies Act, 2013, the dividends if not encashed for a period of 7 years from the date of transfer to Unpaid Dividend Account of the Company, are liable to be transferred to the Investor Education and Protection Fund (IEPF) and the shares in respect of which dividends remain unclaimed for seven consecutive years are also liable to be transferred to the demat account of the IEPF Authority and no claim with the Company shall lie in respect thereof. In view of this, Members are requested to claim their dividends from the Company, within the stipulated timeline.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

THE INTRUCTIONS OF SHAREHOLDERS FOR REMOTE E-VOTING AND E- VOTING DURING AGM AND JOINING MEETING THROUGH VC/OAVM ARE AS UNDER:

- (i) The voting period begins on 12.09.2021 at 09.00 A.M and ends on 14.09.2021 at 05.00 P.M. During this period shareholders' of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date (record date) 08.09.2021 may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter.
- (ii) Shareholders who have already voted prior to the meeting date would not be entitled to vote at the meeting venue.
- (iii) Pursuant to SEBI Circular No. **SEBI/HO/CFD/CMD/CIR/P/2020/242** dated 09.12.2020, under Regulation 44 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, listed entities are required to provide remote e-voting facility to its shareholders, in respect of all shareholders' resolutions. However, it has been observed that the participation by the public non-institutional shareholders/retail shareholders is at a negligible level.

Currently, there are multiple e-voting service providers (ESPs) providing e-voting facility to listed entities in India. This necessitates registration on various ESPs and maintenance of multiple user IDs and passwords by the shareholders.

In order to increase the efficiency of the voting process, pursuant to a public consultation, it has been decided to enable e-voting to all the demat account holders, by way of a single login credential, through their demat accounts/ websites of Depositories/ Depository Participants. Demat account holders would be able to cast their vote without having to register again with the ESPs, thereby, not only facilitating seamless authentication but also enhancing ease and convenience of participating in e-voting process.

- (iv) In terms of SEBI circular no. **SEBI/HO/CFD/CMD/CIR/P/2020/242** dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Pursuant to abovesaid SEBI Circular, Login method for e-Voting and joining virtual meetings **for Individual shareholders holding securities in Demat mode** is given below:

Type of shareholders	Login Method
<p>Individual Shareholders holding securities in Demat mode with CDSL</p>	<ol style="list-style-type: none"> <li data-bbox="451 370 958 695">1) Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The URL for users to login to Easi / E a s i e s t a r e https://web.cdslindia.com/myeasi/home/login or v i s i t www.cdslindia.com and click on Login icon and select New System Myeasi. <li data-bbox="451 721 958 1247">2) After successful login the Easi / Easiest user will be able to see the e- Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers i.e. CDSL/ NSDL/ KARVY/LINKINTIME, so that the user can visit the e-Voting service providers' website directly. <li data-bbox="451 1273 958 1416">3) If the user is not registered for Easi/Easiest, option to register is a v a i l a b l e a t https://web.cdslindia.com/myeasi/Registration/EasiRegistration <li data-bbox="451 1442 958 1474">4) Alternatively, the user can directly

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

	<p>access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e- Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.</p>
<p>Individual Shareholders holding securities in demat mode with NSDL</p>	<ol style="list-style-type: none">1) If you are already registered for NSDL IDeAS facility, please visit the e-Services website of NSDL. Open web browser by typing the following URL: https://eservices.nsd.com either on a Personal Computer or on a mobile. Once the home page of e-Services is launched, click on the “Beneficial Owner” icon under “Login” which is available under ‘IDeAS’ section. A new screen will open. You will have to enter your User ID and Password. After successful authentication, you will be able to see e-Voting services. Click on “Access to e-Voting” under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider name and you will be re-directed to e- Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.2) If the user is not registered for IDeAS e-Services, option to register is available at https://eservices.nsd.com. Select “Register Online for IDeAS

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

	<p>“Portal or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp</p> <p>3) Visit the e-Voting website of NSDL. Open web browser by typing the following URL : https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be redirected to e- Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting</p>
<p>Individual Shareholders (holding securities in demat mode) login through their Depository Participants</p>	<p>You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. After Successful login, you will be able to see e-Voting option. Once you click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.</p>

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. CDSL and NSDL

Login type	Helpdesk details
Individual Shareholders holding securities in Demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at 022- 23058738 and 22-23058542-43.
Individual Shareholders holding securities in Demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at toll free no.: 1800 1020 990 and 1800 22 44 30

- (v) Login method for e-Voting and joining virtual meeting for **shareholders other than individual shareholders holding in Demat form & physical shareholders.**
- 1) The shareholders should log on to the e-voting website www.evotingindia.com.
 - 2) Click on “Shareholders” module.
 - 3) Now enter your User ID
 - a. For CDSL: 16 digits beneficiary ID,
 - b. For NSDL: 8 Character DP ID followed by 8 Digits Client ID,
 - c. Shareholders holding shares in Physical Form should enter Folio Number registered with the Company.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- 4) Next enter the Image Verification as displayed and Click on Login.
- 5) If you are holding shares in demat form and had logged on to www.evotingindia.com and voted on an earlier e-voting of any company, then your existing password is to be used.
- 6) If you are a first-time user follow the steps given below:

	For Shareholders holding shares in Demat Form other than individual and Physical Form
PAN	<p>Enter your 10 digit alpha-numeric *PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders)</p> <ul style="list-style-type: none">• Shareholders who have not updated their PAN with the Company/Depository Participant are requested to use the sequence number sent by Company/RTA or contact Company/RTA.
Dividend Bank Details OR Date of Birth (DOB)	<p>Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your demat account or in the company records in order to login.</p> <ul style="list-style-type: none">• If both the details are not recorded with the depository or company please enter the member id / folio number in the Dividend Bank details field as mentioned in instruction (v).

- (vi) After entering these details appropriately, click on “SUBMIT” tab.
- (vii) Shareholders holding shares in physical form will then directly reach the Company selection screen. However, shareholders holding shares in demat form will now reach ‘Password Creation’ menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
- (viii) For shareholders holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.
- (ix) Click on the EVSN for the relevant <Company Name> on which you choose to vote.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- (x) On the voting page, you will see “RESOLUTION DESCRIPTION” and against the same the option “YES/NO” for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.
- (xi) Click on the “RESOLUTIONS FILE LINK” if you wish to view the entire Resolution details.
- (xii) After selecting the resolution, you have decided to vote on, click on “SUBMIT”. A confirmation box will be displayed. If you wish to confirm your vote, click on “OK”, else to change your vote, click on “CANCEL” and accordingly modify your vote.
- (xiii) Once you “CONFIRM” your vote on the resolution, you will not be allowed to modify your vote.
- (xiv) You can also take a print of the votes cast by clicking on “Click here to print” option on the Voting page.
- (xv) If a demat account holder has forgotten the login password then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.

(xvi) Facility for Non – Individual Shareholders and Custodians –Remote Voting

- Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodians are required to log on to www.evotingindia.com and register themselves in the “Corporates” module.
- A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to helpdesk.evoting@cdslindia.com.
- After receiving the login details a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.
- The list of accounts linked in the login should be mailed to helpdesk.evoting@cdslindia.com and on approval of the accounts they would be able to cast their vote.
- A scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- Alternatively Non Individual shareholders are required to send the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory who are authorized to vote, to the Scrutinizer and to the Company at the email address viz; shareholders@jeevanscientific.com (designated email address by company) , if they have voted from individual tab & not uploaded same in the CDSL e-voting system for the scrutinizer to verify the same.

INSTRUCTIONS FOR SHAREHOLDERS ATTENDING THE AGM THROUGH VC/OAVM & E-VOTING DURING MEETING ARE AS UNDER:

1. The procedure for attending meeting & e-Voting on the day of the AGM is same as the instructions mentioned above for Remote e-voting.
2. The link for VC/OAVM to attend meeting will be available where the EVSN of Company will be displayed after successful login as per the instructions mentioned above for Remote e-voting.
3. Shareholders who have voted through Remote e-Voting will be eligible to attend the meeting. However, they will not be eligible to vote at the AGM.
4. Shareholders are encouraged to join the Meeting through Laptops / IPads for better experience.
5. Further shareholders will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
6. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
7. Shareholders who would like to express their views/ask questions during the meeting may register themselves as a speaker by sending their request in advance at least 3 days prior to meeting mentioning their name, demat account number/folio number, email id, mobile number at shareholders@jeevanscientific.com. The shareholders who do not wish to speak during the AGM but have queries may send their queries in advance 3 days prior to meeting mentioning their name, demat account number/folio number, email id, mobile number at shareholders@jeevanscientific.com . These queries will be replied to by the company suitably by email.
8. Those shareholders who have registered themselves as a speaker will only be allowed to express their views/ask questions during the meeting.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

9. Only those shareholders, who are present in the AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system available during the AGM.
10. If any Votes are cast by the shareholders through the e-voting available during the AGM and if the same shareholders have not participated in the meeting through VC/OAVM facility, then the votes cast by such shareholders shall be considered invalid as the facility of e-voting during the meeting is available only to the shareholders attending the meeting.

PROCESS FOR THOSE SHAREHOLDERS WHOSE EMAIL/MOBILE NO. ARE NOT REGISTERED WITH THE COMPANY/DEPOSITORIES.

1. For Physical shareholders- please provide necessary details like Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to Company/RTA email id.
2. For Demat shareholders -, Please update your email id & mobile no. with your respective Depository Participant (DP)
3. For Individual Demat shareholders – Please update your email id & mobile no. with your respective Depository Participant (DP) which is mandatory while e-Voting & joining virtual meetings through Depository.

If you have any queries or issues regarding attending AGM & e-Voting from the CDSL e- Voting System, you can write an email to helpdesk.evoting@cdslindia.com or contact at 022- 23058738 and 022-23058542/43.

All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, Sr. Manager, (CDSL,) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to helpdesk.evoting@cdslindia.com or call on 022- 23058542/43.

**For and on behalf of the Board of
Jeevan Scientific Technology Limited**

Sd/-

K. Krishna Kishore

**Vice Chairman and Managing Director
(DIN: 00876539)**

**Place: Hyderabad
Date: 09.08.2021**

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

EXPLANATORY STATEMENT

[Pursuant to Section 102 of the Companies Act, 2013]

ITEM NO.4:

RE-APPOINTMENT OF MR. K. RAMA KRISHNA PRASAD (DIN: 00754823) AS AN INDEPENDENT DIRECTOR OF THE COMPANY.

Mr. K. Rama Krishna Prasad was appointed as Independent Director for the term of Five Years w.e.f. 12.02.2016 to 11.02.2021 in the Annual General Meeting held on 30.09.2016.

Pursuant to the provisions of Sections 149, 152 read with Schedule IV and other applicable provisions, if any, of the Companies Act, 2013 and Rules framed thereunder Mr. K. Rama Krishna Prasad is eligible for re-appointment for second term of 5 years.

Based on the recommendation of the Nomination and Remuneration Committee and the Board of Directors in their respective meetings held on 27.01.2021 and pursuant to the provisions of Sections 149, 150, 152 read with Schedule IV and any other applicable provisions, if any, of the Companies Act, 2013 and the Companies (Appointment and Qualification of Directors) Rules, 2014 and the applicable provisions of the SEBI (LODR) Regulations, 2015 (including any statutory modification(s) or re-enactment thereof for the time being in force) and based on his skills, rich experience, knowledge, contributions, continued valuable guidance to the management made by him during his tenure and outcome of performance evaluation of the Independent Directors, the approval of the Members of the Company be and is hereby sought for re-appointment of Mr. K. Rama Krishna Prasad (DIN: 00754823) as an Independent Non-Executive Director of the Company for the second term of 5 (five) years w.e.f. 12th February, 2021 up to 11th February, 2026 who shall not be liable to retire by rotation as provided under Section 152(6) of the Companies Act, 2013.

The Company has received a declaration from Mr. K. Rama Krishna Prasad confirming the criteria of Independence as prescribed under Section 149(6) of the Companies Act, 2013 and under Regulation 16(b) of the SEBI (LODR) Regulations, 2015 as amended from time to time. Mr. K. Rama Krishna Prasad is not disqualified from being appointed as Director in terms of Section 164 of the Companies Act, 2013, as amended from time to time. In the opinion of the Board, he fulfills the conditions specified in the Companies Act, 2013 and is independent of the management.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Except Mr. K. Rama Krishna Prasad, being an appointee, none of the other Directors and Key Managerial Personnel of the Company and their relatives is concerned or interested, financially or otherwise, in the resolution set out at Item No. 4 of the notice.

ITEM NO.5:

Board of Directors of the Company at the meeting held on 02.11.2020, on the recommendation of the Nomination & Remuneration Committee, appointed Mrs. Snigdha Mothukuri as an Additional Director of the Company with effect from 02.11.2020 who holds office up to the date of this Annual General Meeting or the last date on which the annual general meeting should have been held, whichever is earlier, pursuant to the provisions of Section 161(1) of the Companies Act, 2013 ('the Act') and the Articles of Association of the Company and be eligible for appointment to the office of a Director at General Meeting.

Accordingly, in terms of the requirements of the provisions of Companies Act, 2013 approval of the members of the Company is required for regularization of Mrs. Snigdha Mothukuri as Director of the Company and also eligible to retire by rotation under section 152 of Companies Act, 2013.

Based on the recommendations of the Nomination and Remuneration Committee, the Board of Directors of the Company at their meeting held on 02.11.2020 also approved the appointment of Mrs. Snigdha Mothukuri as Executive Director of the Company for a term of three years commencing from 02.11.2020 to 01.11.2023 with a remuneration of Rs. 4,00,000 p.m. as per the provisions of the Companies Act, 2013 including Schedule V which is subject to the approval of the members of the Company.

Accordingly, the Board of Directors recommends the passing of the above resolution as an Ordinary Resolution set out in the item no. 5 of the notice for appointment of Mrs. Snigdha Motukuri as Director and Executive Director of the Company.

Save and except Mrs. Snigdha Motukuri, being an appointee and Mr. K. Jeevan Krishna, Non Executive Director and Mr. K. Krishna Kishore, Managing Director being her relatives, none of the other Directors/Key Managerial Personnel and their relatives is in any way interested or concerned financially or otherwise, in the Resolution set out in the notice.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Information in accordance with Schedule V of Companies Act, 2013

I. GENERAL INFORMATION

1	Nature of Industry: Clinical Research			
2	Date or expected date of commencement of commercial: The Company started its commercial operations on 02.02.1999.			
3	In case of new companies, expected date of commencement of business activities as per project approved by financial institutions appearing in the prospects: NotApplicable			
4	Financial performance based on given indications			
	Particulars	2020-21 (Rs.in lakhs)	2019-20 (Rs.in lakhs)	2018-19 (Rs.in lakhs)
	Turnover	4284.79	2308.85	2640.13
	Net profit after Tax	1131.90	(783.90)	137.34
5	Foreign investments or collaborations, if any: Subsidiary Co. – Enhops Inc.			

II. INFORMATION ABOUT THE APPOINTEE:

1.	<p>Background Details: Mrs. Snigdha Mothukuri is a honors graduate from the finest educational institutions across the globe in the field of Management Science from a leading Ivy Leagues School - Columbia University in New York and the other is Bachelor of Technology in Civil Engineering from IIT Madras.</p> <p>She was a part of reputed organizations like Lansum Estates LLP, Louis Vuitton, University of British Columbia, Aarvee Associates and Visakhapatnam Steel Plant. She worked with global teams in highly distributed environments and gained industry experience in various domains ranging from Civil Engineering, Transportation, Supply Chain to Operations and Finance.</p>
2.	Past Remuneration: NA
3.	Recognition or awards : --
4.	Job Profile and her suitability: Based on her work experience and suitability it was proposed to appoint Mrs. Snigdha Mothukuri as Executive Director of the Company.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

5.	Remuneration proposed: As set out in the resolutions for the item No.5 the remuneration to Mrs. Snigdha Motukuri, Executive Director has the approval of the Nomination and Remuneration Committee and Board of Directors and is within the limits specified under Schedule V of the Companies Act, 2013.
6.	Comparative remuneration profile with respect to industry, size of the company profile of the position and person (in case of expatriates the relevant details would be w.r.t. the country of his origin): Taking into consideration of the size of the Company, the profile of Mrs. Snigdha Motukuri and the responsibilities shouldered by her the aforesaid remuneration package is commensurate with the remuneration package paid to managerial positions in other companies.
7.	Pecuniary relationship directly or indirectly with the Company, or relationship with the managerial personnel, if any: Besides the remuneration, she is not holding any Equity Shares of the Company.

III. OTHER INFORMATION:

1. Reasons for inadequate profits: NA
2. Steps taken or proposed to be taken for improvement: NA
3. Expected increase in productivity and profit in measurable terms: NA

ITEM NO.6:

The Board of Directors in the meeting held on 02.11.2020, appointed Mr. Jeevan Krishna Kuchipudi as an Additional Director (Category –Non-Executive) of the Company with effect from 02.11.2020 who holds office upto the date of this Annual General Meeting or the last date on which the annual general meeting should have been held, whichever is earlier pursuant to the provisions of Section 161(1) of the Companies Act, 2013 ('the Act') and the Articles of Association of the Company.

Accordingly, in terms of the requirements of the provisions of Companies Act, 2013 approval of the members of the Company is required for regularization of Mr. Jeevan Krishna Kuchipudi as Non-Executive Director of the Company and also eligible to retire by rotation under section 152 of Companies Act, 2013.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Jeevan Krishna Kuchipudi is a passionate leader and a honors business graduate with diverse global experience, exceptionally in IT, Operations and Finance. Currently serving as the CEO & Executive Director of Enhops Solutions Private Limited. He pursued undergraduate program for engineering in Computer Science from VNR Vignana Jyothi Institute of Engineering & Technology and Masters in Business Administration (MBA) in Finance from San Diego State University.

Accordingly, the Board of Directors recommends the passing of the above resolution as an Ordinary Resolution set out in the item no. 6 of the notice for appointment of Mr. Jeevan Krishna Kuchipudi as Non-Executive and Non Independent Director of the Company.

Save and except Mr. K. Jeevan Krishna, being an appointee and Mrs. Snigdha Mothukuri, Executive Director and Mr. K. Krishna Kishore, Managing Director being his relatives, none of the other Directors/Key Managerial Personnel and their relatives is in any way interested or concerned financially or otherwise, in the Resolution set out in the notice.

ITEM NO.7:

Board of Directors of the Company at its meeting held on 23.06.2021, on the recommendation of the Nomination & Remuneration Committee, appointed Mr. Y. Nageswar Rao as an Additional Director of the Company with effect from 23.06.2021 who holds office up to the date of this Annual General Meeting or the last date on which the annual general meeting should have been held, whichever is earlier, pursuant to the provisions of Section 161(1) of the Companies Act, 2013 ('the Act') and the Articles of Association of the Company and be eligible for appointment to the office of a Director at General Meeting.

Accordingly, in terms of the requirements of the provisions of Companies Act, 2013 approval of the members of the Company is required for regularization of Mr. Y. Nageswar Rao as Director of the Company and also eligible to retire by rotation under section 152 of Companies Act, 2013.

Based on the recommendations of the Nomination and Remuneration Committee, the Board of Directors of the Company at their meeting held on 23.06.2021, approved the appointment of Mr. Y. Nageswar Rao as Executive Director –Administration of the Company for a term of three years commencing from 23.06.2021 to 22.06.2024 with a remuneration of Rs. 15,00,000 per annum as per the provisions of the Companies Act, 2013 including schedule V which is subject to the approval of the members of the Company.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Accordingly, the Board of Directors recommends the passing of the above resolution as an Ordinary Resolution set out in the item no. 7 of the notice for appointment of Mr. Y. Nageswar Rao as Executive Director – Administration.

Save and except Mr. Nageswar Rao being an appointee, none of the other Directors/Key Managerial Personnel and their relatives is in any way interested or concerned financially or otherwise, in the Resolution set out in the notice.

Information in accordance with Schedule V of Companies Act, 2013

I. GENERAL INFORMATION

1	Nature of Industry: Clinical Research			
2	Date or expected date of commencement of commercial: The Company started its commercial operations on 02.02.1999.			
3	In case of new companies, expected date of commencement of business activities as per project approved by financial institutions appearing in the prospects: Not Applicable			
4	Financial performance based on given indications			
	Particulars	2020-21 (Rs.in lakhs)	2019-20 (Rs.in lakhs)	2018-19 (Rs.in lakhs)
	Turnover	4284.79	2308.85	2640.13
	Net profit after Tax	1131.90	(783.90)	137.34
5	Foreign investments or collaborations, if any: Subsidiary Co. – Enhops Inc.			

II. INFORMATION ABOUT THE APPOINTEE:

1.	<p>Background Details: Nageswara Rao is an experienced professional in the areas of Management, Operations, Finance Marketing and Administration. Currently , he is a Director of Sri Surya Wheels Private Limited and has an overall experience of over 30 years successfully managing multiple organisations like– Sri Surya Automobiles, Sri Surya Transport Corporation, Sri Surya Wheels Private Limited, Sri Surya Electronics and Home Appliances.</p> <p>He has gained multiple awards in the field of marketing and has rich experience in managing multiple teams across various levels and locations.</p>
----	--

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

2.	Past Remuneration: NA
3.	Recognition or awards: --
4.	Job Profile and her suitability: Based on his work experience and suitability it was proposed to appoint Mr. Y. Nageswar Rao as Executive Director (Administration) of the Company.
5.	Remuneration proposed: As set out in the resolution for the item No.7 the remuneration to Mr. Y. Nageswar Rao, Executive Director has the approval of the Nomination and Remuneration Committee and Board of Directors which is within the limits specified under Schedule V of Companies Act.
6.	<p>Comparative remuneration profile with respect to industry, size of the company profile of the position and person (in case of expatriates the relevant details would be w.r.t. the country of his origin):</p> <p>Taking into consideration of the size of the Company, the profile of Mr. Y. Nageswar Rao and the responsibilities shouldered by him the aforesaid remuneration package is commensurate with the remuneration package paid to managerial positions in other companies.</p>
7.	Pecuniary relationship directly or indirectly with the Company, or relationship with the managerial personnel, if any: Besides the remuneration, he is not holding any Equity Shares of the Company.

III. OTHER INFORMATION:

1. Reasons for inadequate profits: NA
2. Steps taken or proposed to be taken for improvement: NA
3. Expected increase in productivity and profit in measurable terms NA

Item No. 8:

The Board of Directors at their meeting held on 09.08.2021 has approved the revision of monthly remuneration of Mr. K. Krishna Kishore, Vice Chairman and Managing Director of the Company to Rs. 9,00,000 per month as recommended by the nomination and remuneration committee which is subject to the approval of the shareholders.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Taking into consideration the duties and responsibilities, the prevailing managerial remuneration in industry and based on the recommendation of the nomination and remuneration committee, the Board at their meeting held on 09.08.2021 approved the above revision of remuneration payable to Mr. K. Krishna Kishore which is within the limits of provisions of the Companies Act, 2013 including Schedule V of the Companies Act, 2013 and subject to approval of the shareholders.

Except Mr. K. Krishna Kishore, Mr. Jeevan Krishna Kuchipudi and Mrs. Snigdha Mothukuri, none of the Directors and Key Managerial Personnel of the Company and their relatives is concerned or interested, financially or otherwise, in the resolution set out at Item No. 8.

**For and on behalf of the Board of
Jeevan Scientific Technology Limited**

Sd/-

K. Krishna Kishore

**Vice Chairman and Managing Director
(DIN: 00876539)**

Place: Hyderabad

Date: 09.08.2021

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

DIRECTORS' REPORT

To the Members,

The Directors have pleasure in presenting before you the 23rd Directors' Report of the Company together with the Audited Statements of Accounts for the year ended 31st March, 2021.

1. FINANCIAL SUMMARY/HIGHLIGHTS:

The performance for the period ended 31st March, 2021 is as under:

(Amount in Lakhs)

Particulars	Standalone		Consolidated	
	2020-21	2019-20	2020-21	2019-20
Revenue from Operations	4,139.36	2,056.74	4,787.59	2,394.09
Other Income	92.43	156.30	93.91	157.60
Unbilled Revenue	53.00	95.80	53.00	95.80
Profit/Loss Before Depreciation, finance costs, Exceptional Items and Tax expense	1,885.23	379.82	1,971.13	350.11
Depreciation/Amortisation/Impairment	(395.52)	(390.78)	396.83	392.05
Profit/Loss before finance costs, exceptional items and Tax expense	1,489.71	(10.96)	1,574.30	(41.94)
Less: Finance Costs	(171.86)	(226.82)	(209.36)	(273.13)
Profit/Loss before Exceptional Items and Finance Costs	1,317.85	(237.78)	1,364.94	(315.07)
Add/(Less): Exceptional Items	--	(739.24)	--	(739.24)
Profit/Loss before tax expense	1,317.85	(977.02)	1,364.94	(1054.31)
(Less): Tax Expense (Current & deferred)	(191.92)	195.55	(190.94)	195.71
Profit/(Loss) for the year (1)	1,125.93	(781.47)	1,174	(858.60)
Total Comprehensive Income/(Loss) (2)	5.96	(2.43)	5.96	(2.43)
Total (1+2)	1,131.89	(783.90)	1,179.96	(861.03)
Earnings per share	7.40	(5.12)	7.71	(5.63)

REVIEW OF OPERATIONS:

During the year under review, the Company on a standalone basis has recorded an income of Rs. 4,284.79 Lakhs and profit of Rs. 1,131.89 Lakhs as against the income of Rs. 2,308.84 Lakhs and loss of Rs. 783.90 Lakhs respectively in the previous financial year ending 31.03.2020.

Also, the company on a consolidated basis has recorded an income of Rs. 4,934.50 Lakhs and profit of Rs. 1,179.96 Lakhs as against the income of Rs. 2,647.49 Lakhs and loss of Rs. 861.03 Lakhs respectively in the previous financial year ending 31.03.2020.

BUSINESS UPDATE AND STATE OF COMPANY'S AFFAIRS:

The information on Company's affairs and related aspects is provided under Management Discussion and Analysis report, which has been prepared, inter-alia, in compliance with Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements) regulations, 2015 and forms part of this Report.

2. IMPACT OF COVID – 19:

The COVID-19 created havoc in the world economy and severely affected the health of people at large and held the world at its standstill. Accordingly, the lockdowns that were announced from time to time across India resulting in temporary suspension of operations and temporary closure of offices and plants/manufacturing facilities of the Company in line with the government/local authorities' directions.

However, during the lockdown, your Company continued to provide support to customers with the invaluable support of Employees/workers and Management at various levels. As the restrictions were eased out, your Company while closely monitoring the situation and following safety guideline, started staggered manufacturing at its plants and took all the necessary steps to maintain or achieve the predetermined targets.

3. MATERIAL CHANGES AND COMMITMENTS AFFECTING THE FINANCIAL POSITION OF THE COMPANY:

There were no material changes and commitments affecting financial position of the company between 31st March, 2021 and the date of Board's Report. (i.e. 09.08.2021)

4. CHANGE IN THE NATURE OF BUSINESS, IF ANY:

During the period under review and the date of Board's Report there was no change in the nature of Business.

5. DIVIDEND:

The Board of Directors are pleased to recommend a final dividend of Rs. 0.5/- per equity shares for the financial year 2020-21.

The final dividend is subject to approval of members at the ensuing Annual General Meeting of the Company scheduled to be held on September 15, 2021. The final dividend once approved by shareholders will be paid within the stipulated time subject to deduction of tax at source. The Record Date for the purpose of payment of final dividend will be September 08, 2021.

6. TRANSFER TO RESERVES:

The Closing balance of reserves, including retained earnings, of the Company as at March 31st, 2021 on Standalone basis is Rs. 20,94,73,657/-.

7. BOARD MEETINGS:

The Board of Directors duly met 4 (Four) times on 30.07.2020, 05.09.2020, 02.11.2020 and 27.01.2021 in respect of which meetings, proper notices were given and the proceedings were properly recorded and signed in the Minutes Book maintained for the purpose.

8.a) APPOINTMENT / RE-APPOINTMENT / RESIGNATION / RETIREMENT OF DIRECTORS / CEO/ CFO AND KEY MANAGERIAL PERSONNEL

During the period under review following were the Directors/ Key Managerial Personnel resigned/ appointed during the financial year 2020-21 including between the financial year ended 31st March 2021 and date of Board's report (i.e. 09.08.2021):

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

S. No.	Name of the Directors/KMP	Designation	Purpose	Date of appointment/ Cessation
1	Mr. Jeevan Krishna Kuchipudi	Additional Director	Appointment	02.11.2020
2	Ms. Snigdha Mothukuri	Additional Director	Appointment	02.11.2020
3	Mr. Y. Nageswar Rao	Additional Director	Appointment	23.06.2021
4	Ms. K. Vanaja	Director	Cessation	02.11.2020
5	Ms. Sharvari Swapnil Shinde	Company Secretary	Appointment	24.11.2020
6	Mr. K. Krishna Kishore	CFO	Cessation	16.02.2021
7	Mr. M. Srikanth Sasidhar	CFO	Appointment	16.02.2021
8	Ms. Snigdha Mothukuri	CEO	Appointment	23.06.2021

The Board places on record their appreciation for the invaluable contribution made by Ms. K. Vanaja during her tenure as Director of the Company.

Mr. T. Ravi retires by rotation and being eligible, offers himself for re-appointment. A resolution seeking shareholders' approval for his re-appointment along with other required details forms part of the Notice.

As required under regulation 36 (3) of the SEBI (LODR), Regulations, 2015, brief particulars of the Directors seeking appointment/re-appointment are given as under: -

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Name of the Director	Mr. T. Ravi	Mr. K. Rama Krishna Prasad
Date of Birth	24.01.1968	30.01.1961
Date of Appointment	28.02.2000	12.02.2016
Expertise in specific functional areas	More than two decades of experience in freelancing, specific functional areas advertising and consulting computer graphics and also worked as Director of Cinematography in Indian Broadcasting Company at New York for 4 years.	More than three decades of diversified experience in field of Engineering, Civil Construction, Software Development and Consultancy services.
Qualifications	MBA	Bachelors in engineering
Names of the Listed entities in which the person is holding Directorships or Board Committee Memberships	Nil	Nil
Inter se relationship among Directors	Nil	Nil
Number of shares held in the Company	2,500	Nil

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Name of the Director	Y. Nageswar Rao	Ms. Snigdha Mothukuri	Mr. Jeevan Krishna Kuchipudi
Date of Birth	01.10.1956	09.09.1992	15.05.1990
Date of Appointment	23.06.2021	02.11.2020	02.11.2020
Expertise in specific functional areas	Management, Operations, Finance Marketing and Administration	Management Science, Operations, Civil Engineering	Information Technology, Operations and Finance
Qualifications	Diploma in Polytechnic	Master of Technology (IIT Madras) and Master of Science (Columbia University)	MBA (Finance)
Names of the Listed entities in which the person is holding Directorships or Board Committee Memberships	Nil	Nil	Nil
Inter se relationship among Directors	Nil	Daughter in law of Krishna Kishore and spouse of Jeevan Krishna Kuchipudi	Son of Krishna Kishore Kuchipudi and spouse of Snigdha Mothukuri
Number of shares held in the Company	Nil	--	7,24,300

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

During the year under review, the non-executive directors of the Company had no pecuniary relationship or transactions with the Company other than sitting fees, commission and reimbursement of expenses, if any except Mr. K. Jeevan Krishna, son of Mr. K. Krishna Kishore and husband of Mrs. Snigdha Mothukuri.

8.b) Opinion of the Board with regard to integrity, expertise and experience (including the proficiency) of the independent directors appointed during the year:

During the year, Mr. K. Ramakrishna Kakarla was re-appointed as an Independent Director of the company. The Board's opines that his integrity is unquestionable and expertise and experience have proven to be beneficial to the company.

9. DEPOSITS FROM PUBLIC:

The Company has not accepted any deposits from public and as such no amount on account of principal or interest on deposits from public was outstanding as on the date of the balance sheet.

10. DETAILS OF SIGNIFICANT MATERIAL ORDERS PASSED BY REGULATORS, COURTS, TRIBUNALS, IMPACTING THE GOING CONCERN BASIS OF THE COMPANY:

There were no significant material orders passed by regulators, courts, tribunals, impacting the going concern basis of the Company.

11. CORPORATE GOVERNANCE:

The Company has implemented all of its major stipulations as applicable to the Company. As stipulated under Regulation 34 read with schedule V of SEBI (LODR) Regulations, 2015, a report on Corporate Governance duly audited is appended as **Annexure II** for information of the Members. A requisite certificate from the Secretarial Auditors of the Company confirming compliance with the conditions of Corporate Governance is attached to the Report on Corporate Governance.

12. REVISION OF FINANCIAL STATEMENTS

There was no revision of the financial statements for the year under review.

13. VIGIL MECHANISM

In pursuant to the provisions of Section 177(9) & (10) of the Companies

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Act, 2013 read with Regulation 22 of SEBI (LODR) Regulations, 2015, a vigil Mechanism for Directors and employees to report genuine concerns has been established. It also provides for necessary safeguards for protection against victimization for whistle blowing in good faith.

Vigil Mechanism Policy has been established by the Company for directors and employees to report genuine concerns pursuant to the provisions of section 177(9) of the Companies Act, 2013 and Regulation 46 of SEBI (LODR) Regulations, 2015.

14. POLICY ON DIRECTOR'S APPOINTMENT AND REMUNERATION AND OTHER DETAILS

The assessment and appointment of Members to the Board is based on a combination of criterion that includes ethics, personal and professional stature, domain expertise, gender diversity and specific qualification required for the position. The potential Board Member is also assessed on the basis of independence criteria defined in Section 149(6) of the Companies Act, 2013 and Regulation 27 of SEBI (LODR) Regulations, 2015.

In accordance with Section 178(3) of the Companies Act, 2013 and Regulation 19(4) of SEBI (LODR) Regulations, 2015, on the recommendations of the Nomination and Remuneration Committee, the Board adopted a remuneration policy for Directors, Key Management Personnel (KMPs) and Senior Management.

We affirm that the remuneration paid to the Directors is as per the terms laid down in the Nomination and Remuneration Policy of the Company.

15. INVESTOR EDUCATION AND PROTECTION FUND (IEPF)

Pursuant to the provisions of Section 124 of the Act, Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 ("IEPF Rules") read with the relevant circulars and amendments thereto, the amount of dividend remaining unpaid or unclaimed for a period of seven years from the due date is required to be transferred to the Investor Education and Protection Fund ("IEPF"), constituted by the Central Government.

During the Year, no amount of dividend was unpaid or unclaimed for a period of seven years and therefore no amount is required to be transferred to Investor Education and Provident Fund under the Section 125(1) and Section 125(2) of the Act.

16. MANAGEMENT DISCUSSION AND ANALYSIS REPORT:

The Management Discussion and Analysis Report, pursuant to the SEBI (LODR) Regulation provides an overview of the affairs of the Company, its legal status and autonomy, business environment, mission & objectives, Sectoral and segment-wise operational performance, strengths, opportunities, constraints, strategy and risks and concerns, as well as human resource and internal control systems is appended as **Annexure III** for information of the Members.

17. DECLARATION FROM INDEPENDENT DIRECTORS ON ANNUAL BASIS:

The Company has received declarations from Mr. G. Bhanu Prakash, Mr. S.S.R Koteswara Rao and Mr. K. Ramakrishna Prasad, Independent directors of the company to the effect that they are meeting the criteria of independence as provided in Sub-section (7) of Section 149 of the Companies Act, 2013 and Regulation 25 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Independent Directors have also confirmed that they have complied with the Company's Code of Conduct.

In terms of Regulations 25(8) of the Listing Regulations, the Independent Directors have confirmed that they are not aware of any circumstance or situation, which exists or may be reasonably anticipated, that could impair or impact their ability to discharge their duties with an objective independent judgement and without any external influence.

18. FAMILIARIZATION PROGRAM FOR INDEPENDENT DIRECTORS

Independent Directors are familiarized about the Company's operations and businesses. Interaction with the Business heads and key executives of the Company is also facilitated. Detailed presentations on important policies of the Company is also made to the directors. Direct meetings with the Chairman is further facilitated to familiarize the incumbent Director about the Company/its businesses and the group practices.

19. BOARD EVALUATION:

Evaluation of all Board members is performed on an annual basis. The evaluation is performed by the Board, Nomination and Remuneration Committee and Independent Directors with specific focus on the performance and effective functioning of the Board and Individual Directors.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

In line with Securities and Exchange Board of India Circular No. SEBI/HO/CFD/CMD/CIR/P/2017/004, dated January 5, 2017 and the Companies Amendment Act, 2017 the Company adopted the recommended criteria by Securities and Exchange Board of India.

The criteria for performance evaluation covers the areas relevant to the functioning of the Board and Board Committees such as its composition, oversight and effectiveness, performance, skills and structure etc.

The Board of Directors has carried out an annual evaluation of its own performance, board Committees, and individual directors pursuant to the provisions of the Act and SEBI Listing Regulations.

The performance of the board was evaluated by the board after seeking inputs from all the directors on the basis of criteria such as the board composition and structure, effectiveness of board processes, information and functioning, etc.

The performance of the committees was evaluated by the board after seeking inputs from the committee members on the basis of criteria such as the composition of committees, effectiveness of committee meetings, etc.

The above criteria are based on the Guidance Note on Board Evaluation issued by the Securities and Exchange Board of India.

In a separate meeting of independent directors, performance of non-independent directors, the board as a whole and the Chairman of the Company were evaluated, taking into account the views of executive directors and non-executive directors.

The Board and the Nomination and Remuneration Committee reviewed the performance of individual directors on the basis of criteria such as the contribution of the individual director to the board and committee meetings like preparedness on the issues to be discussed, meaningful and constructive contribution and inputs in meetings, etc.

In the board meeting that followed the meeting of the independent directors and meeting of Nomination and Remuneration Committee, the performance of the board, its committees, and individual directors was also discussed.

Performance evaluation of independent directors was done by the entire board, excluding the independent director being evaluated.

20. ANNUAL RETURN:

As required pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014, an annual return is uploaded on website of the company i.e. <http://www.jeevanscientific.com/>.

21. AUDITORS

a. Statutory Auditors

The members of the Company in accordance with Section 139 of the Companies Act, 2013 have passed a resolution for appointment of M/s. Pavuluri & Co., Chartered Accountants, Hyderabad (Firm Registration No. 008918S) as Statutory Auditors of the Company for a period of 5 years in the AGM held on 27.09.2017 to hold office up to the conclusion of 24th Annual General Meeting of the Company to be held in the year 2022-2023.

The requirement to place the matter relating to appointment of Auditors for ratification by members at every Annual General Meeting is done away with vide notification dated May 7, 2018 issued by the Ministry of Corporate Affairs, New Delhi. Accordingly, no resolution is proposed for ratification of appointment of Auditors, who were appointed in the Annual General Meeting, held on September 27, 2017.

Statutory Auditors Report

The Board has duly reviewed the Statutory Auditor's Report on the Accounts for the year ended March 31, 2021 and has noted that the same does not have any reservation, qualification or adverse remarks. However, the Board decided to further strengthen the existing system and procedures to meet all kinds of challenges and growth in the coming years.

b. Secretarial Auditor

Pursuant to the provisions of Section 134(3) (f) & Section 204 of the Companies Act, 2013, the Board has appointed M/s. S.S Reddy & Associates, Practicing Company Secretaries who have conducted undertaken Secretarial Audit of the Company for financial year ending 31.03.2021. The report of the Secretarial Auditor is enclosed herewith vide **Annexure-I** of this Report.

Secretarial Audit Report

The Board has duly reviewed the Secretarial Audit Report for the year ended March 31, 2021 on the Compliances according to the provisions of Section 204 of the Companies Act, 2013.

Annual Secretarial Compliance Report

The Company has filed the Annual Secretarial Compliance Report for the year 2020-2021 with the BSE Limited, the report was received from a Practicing Company Secretary and filed within the stipulated time as specified under Regulation 24A of the SEBI (LODR) Regulations.

c. Internal Auditor

The Company has appointed M/s. K P & Associates., Chartered Accountants as Internal Auditors of the Company for the Financial Year 2020-2021.

22. AUTHORISED AND PAID UP CAPITAL OF THE COMPANY:

The authorized capital of the company stands at Rs. 21,00,00,000 /- divided into 2,10,00,000 equity shares of Rs.10/- each

The paid up Share capital of the Company stands at Rs.15,30,14,650/- divided into 1,53,01,465 equity shares of 10/- each.

23. DIRECTOR'S RESPONSIBILITY STATEMENT:

In pursuance of section 134 (5) of the Companies Act, 2013, the Directors hereby confirm that:

- a) In the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures;
- b) The Directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit and loss of the company for that period;
- c) The Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- d) The Directors had prepared the annual accounts on a going concern basis; and
- e) The Directors had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and were operating effectively.
- f) The Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

24. INFORMATION ABOUT THE FINANCIAL PERFORMANCE / FINANCIAL POSITION OF THE SUBSIDIARIES / ASSOCIATES:

Enhops Solutions Private Limited and Enhops Inc. (U.S.A) are the Subsidiary Companies of Jeevan Scientific Technologies Limited. In accordance with Section 129(3) of the Companies Act, 2013, a statement containing salient features of the financial statements of the subsidiary companies in Form AOC-1 is as an attachment herewith forming part of the Annual Report. In accordance with third provision to Section 136(1) of the Companies Act, 2013, the Annual Report of your Company, containing therein its audited standalone and the consolidated financial statements has been placed on the website of the Company at www.jeevanscientific.com.

25. COMPANIES WHICH HAVE BECOME OR CEASED TO BE SUBSIDIARIES, ASSOCIATES AND JOINT VENTURES:

During the FY 2020-21, there are no companies which have become or ceased to be the subsidiaries, associates and joint ventures.

26. DETAILS IN REPECT OF FRAUDS REPORTED BY AUDITORS UNDER SUB-SECTION (12) OF SECTION 143 OTHER THAN THOSE WHICH ARE REPORTABLE TO CENTRAL GOVERNMENT:

There were no frauds reported by the auditors as per section 143 (12).

27. CONSOLIDATED FINANCIAL STATEMENTS:

The Consolidated Financial Statements of your Company for the year ended March 31, 2021 have been prepared in accordance with the provisions of Section 129(3) of the Companies Act and applicable Accounting Standards and form part of this report.

Pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with first proviso of Section 129(3) of the

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Companies Act read with Rule 5 of the Companies (Accounts) Rules, 2014, a separate statement containing salient features of the Financial Statements of Subsidiary Companies in Form AOC-1 is enclosed as **Annexure IV** as is appended to this report, which forms part of the Financial Statements. The separate Audited Financial Statements in respect of the Subsidiary are also available on the website of the Company at www.jeevanscientific.com.

28. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE OUTGO:

The required information as per Sec.134 of the Companies Act 2013 is provided hereunder:

A. Conservation of Energy:

The Company's operations are not energy intensive. Adequate measures have been taken to conserve energy wherever possible by using energy efficient computers and purchase of energy efficient equipment.

B. Technology Absorption: All the Factors mentioned in Rule 8 (3)(b) Technology absorption are not applicable to the Company.

- i. Research and Development (R&D): Bioanalytical research laboratory is designed with state of the art facility equipped with advanced analytical instrumentation having 2 processing labs and 4 LC-MS/MS labs, which can accommodate up to 12 LCMS/ MS. Jeevan Scientific offers a unique combination of highly trained workforce enabled with well-equipped bio analytical research and development (R&D) laboratory.
- ii. Technology absorption, adoption and innovation: There was considerable technology absorption, adoption and innovation with the addition of the above equipment in the facility the results of which can be seen in the years to come.

C. Foreign Exchange Earnings and Out Go:

The foreign exchange earned in terms of actual inflows during the year and the foreign exchange outgo during the year in terms of actual outflow is mentioned in financial statements annexed to this report.

29. CORPORATE SOCIAL RESPONSIBILITY POLICY:

The company shall attract the provisions of Corporate Social Responsibility in the next year i.e. FY 2021-2022 u/s 135 of Companies

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Act, 2013 based on the net profit of the company being more than Rs. 5.00 Crores in financial year 2020-2021.

30. SECRETARIAL STANDARDS:

The company is in compliance with Secretarial Standards.

31. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS:

The company has not given loans, Guarantees or made any investments during the financial year under review except to the wholly owned subsidiary co. – Enhops Solutions Private Limited.

32. CREDIT & GUARANTEE FACILITIES:

The Company availed facilities of Credit and Guarantee as and when required, for the business of the Company, from the Karur Vysya Bank for which Personal Guarantees were given by Mr. K. Krishna Kishore, Vice Chairman & Managing Director without any consideration for obtaining Bank Guarantees.

33. INSURANCE

The properties and assets of your Company are adequately insured.

34. INTERNAL AUDIT AND FINANCIAL CONTROLS:

The Company has adequate internal controls consistent with the nature of business and size of the operations, to effectively provide for safety of its assets, reliability of financial transactions with adequate checks and balances, adherence to applicable statutes, accounting policies, approval procedures and to ensure optimum use of available resources. These systems are reviewed and improved on a regular basis. It has a comprehensive budgetary control system to monitor revenue and expenditure against approved budget on an ongoing basis.

35. DISCLOSURE OF ADEQUACY OF INTERNAL FINANCIAL CONTROLS

The Internal Financial Controls with reference to financial statements as designed and implemented by the Company are adequate. The Company maintains appropriate system of internal control, including monitoring procedures, to ensure that all assets are safeguarded against loss from unauthorized use or disposition. Company policies, guidelines and procedures provide for adequate checks and balances, and are meant to ensure that all transactions are authorized, recorded and reported correctly.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

During the period under review, there is no material or serious observations have been noticed for inefficiency or inadequacy of such controls.

Further, details of internal financial control and its adequacy are included in the Management Discussion and Analysis Report and forms part of this Report.

36. RISK MANAGEMENT POLICY:

Business Risk Evaluation and Management is an ongoing process within the Organization. The Company has a robust risk management framework to identify, monitor and minimize risks and also to identify business opportunities. As a process, the risks associated with the business are identified and prioritized based on severity, likelihood and effectiveness of current detection. Such risks are reviewed by the senior management on a quarterly basis.

37. PARTICULARS OF CONTRACTS OR ARRANGEMENTS MADE WITH RELATED PARTIES:

Our Company has formulated a policy on related party transactions which is also available on Company's website at www.jeevanscientific.com. This policy deals with the review and approval of related party transactions.

All related party transactions that were entered into during the financial year were on arm's length basis and were in the ordinary course of business. There were no material significant related party transactions made by the Company with the Promoters, Directors, Key Managerial Personnel or the Senior Management which may have a potential conflict with the interest of the Company at large.

Particulars of contracts or arrangements with related parties referred to in Section 188(1) of the Companies Act, 2013 in the prescribed Form AOC-2 is appended as **Annexure V** which forms part of this Report.

All related party transactions were placed before the Audit Committee/Board for approval. Prior approval of the Audit Committee was obtained for the transactions which are foreseen and are in repetitive in nature.

38. COMMITTEES

(I). AUDIT COMMITTEE

The Audit Committee of the Company is constituted and is in line with the provisions of Regulation 18(1) of SEBI (LODR) Regulations read with Section 177 of the Companies Act, 2013 are included in the Corporate Governance report, which forms part of this report.

(II). NOMINATION AND REMUNERATION COMMITTEE

The Nomination and Remuneration Committee of the Company is constituted and is in line with the provisions of Regulation 19(1) of SEBI (LODR) Regulations with the Stock Exchanges read with Section 178 of the Companies Act, 2013 are included in the Corporate Governance report, which forms part of this report.

(III). STAKEHOLDERS RELATIONSHIP COMMITTEE

The Stakeholders Relationship Committee of the Company is constituted and is in line with the provisions of Regulation 20 of SEBI (LODR) Regulations with the Stock Exchanges read with Section 178 of the Companies Act, 2013 are included in the Corporate Governance report, which forms part of this report.

39. DISCLOSURE ABOUT COST AUDIT:

Cost Audit is not applicable for the financial year 2020-21.

40. POLICIES:

The SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 mandated the formulation of certain policies for all listed companies. All the policies are available on our website. www.jeevanscientific.com

41. ENVIRONMENTS AND HUMAN RESOURCE DEVELOPMENT:

Your Company always believes in keeping the environment pollution free and is fully committed to its social responsibility. The Company has been taking utmost care in complying with all pollution control measures from time to time strictly as per the directions of the Government.

We would like to place on record our appreciation for the efforts made by the management and the keen interest shown by the Employees of your Company in this regard.

42. STATUTORY COMPLIANCE:

The Company has complied with the required provisions relating to statutory compliance with regard to the affairs of the Company in all respects.

43. NON-EXECUTIVE DIRECTORS' COMPENSATION AND DISCLOSURES:

None of the Independent/Non-Executive Directors has any pecuniary relationship or transactions with the Company which in the Judgement of the Board may affect the independence of the Directors except Mr. Jeevan Krishna Kuchipudi who is a promoter of the company and has a pecuniary relationship to the extent of shares held by her in the company.

44. PARTICULARS OF EMPLOYEES:

A table containing the particulars in accordance with the provisions of Section 197(12) of the Act, read with Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is appended as **Annexure VI (a)** to this Report.

A statement showing the names of the top ten employees in terms of remuneration drawn and the name of every employee is annexed to this Annual report as **Annexure VI (b)**.

None of the employees is drawing Rs. 8,50,000/- and above per month or Rs.1,02,00,000/- and above in aggregate per annum, the limits prescribed under Section 197(12) of the act read with rules 5(2) and 5(3) of the companies (Appointment and remuneration of Managerial personnel) Rules 2014 of the Companies Act, 2013.

45. RATIO OF REMUNERATION TO EACH DIRECTOR:

Under section 197(12) of the Companies Act, 2013, and Rule 5(1) (2) & (3) of the Companies (Appointment & Remuneration) Rules, 2014, the ratio of remuneration to maiden employees is 1:0.04 in case of Mr. K. Krishna Kishore, Vice Chairman and Managing Director, Mr. Rajendra Prasad, Whole time Director and Ms. Snigdha Mothukuri, Executive Director and CEO of the Company

46. INDUSTRY BASED DISCLOSURES AS MANDATED BY THE RESPECTIVE LAWS GOVERNING THE COMPANY:

The Company is not a NBFC, Housing Companies etc., and hence Industry based disclosures is not required.

47. CODE OF CONDUCT COMPLIANCE:

All Members of the Board and Senior Management have affirmed compliance to the Code of Conduct for the Financial Year 2020-21. A declaration signed by the Managing Director affirming compliance with the Company's Code of Conduct by the Board of Directors and Senior Management for the Financial Year 2020-21 as required under Regulation 26(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is included in the Corporate Governance Report which is appended as **Annexure II** and forms part of this Report.

48. DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013:

The Company has in place An Anti-Sexual Harassment Policy in line with the requirements of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013. Internal Complaints Committee (ICC) has been set up to redress complaints received regarding sexual harassment.

All employees are covered under this policy. During the year 2020-21, there were no complaints received by the committee.

49. EVENT BASED DISCLOSURES

During the year under review, the Company has not taken up any of the following activities except as mentioned:

1. Issue of sweat equity share: NA
2. Issue of shares with differential rights: NA
3. Issue of shares under employee's stock option scheme: NA
4. Disclosure on purchase by Company or giving of loans by it for purchase of its shares:NA
5. Buy back shares: NA
6. Disclosure about revision: NA
7. Preferential Allotment of Shares: NA

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

50. CORPORATE INSOLVENCY RESOLUTION PROCESS INITIATED UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016 (IBC):

There is no application filed for corporate insolvency resolution process, by a financial or operational creditor or by the company itself under the IBC before the NCLT.

51. CEO/ CFO Certification

The Managing Director cum CEO and CFO certification of the financial statements for the year 2020-2021 is annexed in this Annual Report.

52. APPRECIATION & ACKNOWLEDGEMENT:

The Directors wish to place on record their appreciation of the contribution made by the employees at all levels, to the continued growth and prosperity of your Company.

The Directors also wish to place on record their appreciation of business constituents, banks and other financial institutions and shareholders of the Company like SEBI, BSE, NSE, MCX, NSDL, CDSL, The Karur Vysya Bank, Oriental Bank of Commerce, Andhra Bank and State Bank of India etc. for their continued support for the growth of the Company.

**For and on behalf of the Board of
Jeevan Scientific Technology Limited**

**Place: Hyderabad
Date: 09.08.2021**

**Sd/-
K. Krishna Kishore
Vice Chairman and
Managing Director
(DIN: 00876539)**

**Sd/-
Snigdha Mothukuri
Director and CEO
(DIN: 08934860)**

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

ANNEXURE I

FORM MR-3

SECRETARIAL AUDIT REPORT

**(Pursuant to section 204(1) of the Companies Act, 2013 and
Rule 9 of the Companies (Appointment and Remuneration of
Managerial Personnel) Rules, 2014**

FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2021

To,

The Members

M/s. Jeevan Scientific Technology Limited

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by M/s. Jeevan Scientific Technology Limited (hereinafter called “the Company”). Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing our opinion thereon.

Based on our verification of the Company’s Books, Papers, Minutes Books, Forms and Returns filed and other Records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the company has, during the Financial Year commencing from 1st April, 2020 and ended 31st March, 2021 complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

1. We have examined the books, papers, minutes books, forms and returns filed and other records maintained by the Company for the financial year ended on 31st of March, 2021 according to the provisions of:
 - (i) The Companies Act, 2013 (the Act) and the rules made there under: Except the Company has not appoint Company Secretary as required under Section 203 of the Companies Act, 2013 for a period from 01.04.2020 to 24.11.2020.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- (ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the Rules made there under;
 - (iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed there under;
 - (iv) Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of Foreign Direct Investment (FDI), Overseas Direct Investment and External Commercial Borrowings;
2. Compliance status in respect of the provisions of the following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI ACT') is furnished hereunder for the financial year 2020-21:-
- i. The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011; **During the year under review, there was no instance to be reported by the Company under SEBI Takeover Code.**
 - ii. The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and Amended Regulations 2018; **The Company has framed code of conduct for regulating & reporting trading by insiders and for fair disclosure and displayed the same on the Company's website i.e. <http://www.jeevanscientific.com/>**
 - iii. The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018;
 - iv. The Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014; **Not Applicable as the Company has not issued any Employee Stock Options during the year under review.**
 - v. The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008 and SEBI (Issue and Listing of Debt Securities) (Amendment) Regulations, 2019; **Not Applicable as the Company has not issued any debt securities during the year under review.**
 - vi. The Securities and Exchange Board of India (Registrars to an issue and Share Transfer Agents) Regulations, 1993, regarding the Companies Act and dealing with client; **Not Applicable as the Company is not registered as Registrar to an Issue and Share Transfer Agent during the year under review. However, the company has CIL Securities Limited as its Share Transfer Agent.**

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- vii. The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009 and SEBI (Delisting of Equity Shares) (Amendment) Regulations, 2018; **Not Applicable as the company has not delisted/ proposed to delist its equity shares during the year under review.**
- viii. The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; **Not Applicable as the Company has not bought back/ proposed to buy-back any of its securities during the year under review.**
- ix. The Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018: **Complied with event based disclosures.**
- x. The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 were complied except the following:

Sl. No.	Observations	Compliance requirement under (Regulations/ circulars/ guidelines including specific clause)
1.	The company has not appointed Whole Time Company Secretary during the period from 01.04.2020 to 23.11.2020.	As per Regulation 6 (1) A listed Company shall appoint a qualified Company secretary as compliance officer of the company.
2.	The Company has not submitted Related party disclosure on half yearly basis for half year ended March, 2020.	Regulation 23 (9) The listed entity shall submit within 30 days from the date of publication of its standalone and consolidated financial results for the half year, disclosures of related party transactions on a consolidated basis.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- xi. Other applicable laws include the following:
1. Factories Act, 1948
 2. Industrial Disputes Act, 1947
 3. The Payment of Wages Act, 1936
 4. The Minimum Wages Act, 1948
 5. Employees' State Insurance Act, 1948
 6. The Employees' Provident Funds and Miscellaneous Provisions Act, 1952
 7. The Payment of Bonus Act, 1965
 8. The Payment of Gratuity Act, 1972
 9. The Contract Labour (Regulation & Abolition) Act, 1970
 10. The Maternity Benefit Act, 1961
 11. The Child Labour (Prohibition & Regulation) Act, 1986
 12. The Industrial Employment (Standing Order) Act, 1946
 13. The Employees' Compensation Act, 1923
 14. The Apprentices Act, 1961
 15. Equal Remuneration Act, 1976
 16. The Employment Exchange (Compulsory Notification of Vacancies) Act, 1959

Environmental Laws

1. Water (Prevention and Control of Pollution) Cess Act, 1977;
2. Air (Prevention and Control of Pollution) Act, 1981;
3. Environment (Protection) Act, 1986;

We have also examined compliance with the applicable clauses of the following:

- (i) Secretarial Standards issued by The Institute of Company Secretaries of India.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- (ii) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 were complied with to the extent applicable.

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above including the following:

- a) During the year the Company has conducted 4 meetings of the Board of Directors, 4 Meetings of Audit Committee meeting, 1 Nomination and Remuneration Committee Meeting and 1 meeting of Stakeholders and Relationship Committee Meeting. We have also examined compliance with the applicable clauses of the Secretarial Standards issued by the Institute of Company secretaries of India.
- b) As per the information and explanations provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we report that:
- (i) the provisions of the Foreign Exchange Management Act, 1999 and the Rules and Regulations made there under to the extent of:
- External Commercial Borrowings were not attracted to the Company under the financial year under report;
 - Foreign Direct Investment (FDI) was not attracted to the company under the financial year under report;
 - Overseas Direct Investment by Residents in Joint Venture/Wholly Owned Subsidiary abroad was not attracted to the company under the financial year under report.
- (ii) As per the information and explanations provided by the company, its officers, agents and authorized representatives during the conduct of Secretarial Audit, we report that the Company has not made any GDRs/ADRs or any Commercial Instrument under the financial year under report.

We further report that:

- During the period under review Mr. K. Krishna Kishore had resigned from the position of Chief Financial Officer of the Company and Consequently Mr. Srikanth Sasidhar Mathamsetty was appointed as the Chief Financial Officer of the Company w.e.f 16.02.2021. Further, Mrs. Sharvari Swapnil Shinde was appointed as Company Secretary and Compliance Officer w.e.f. 24.11.2020.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- The Company has appointed M/s. K P & Associates., Chartered Accountants as Internal Auditor for the Financial Year 2020-21 and M/s. Pavuluri & Co., as Statutory Auditor for the Financial Year 2020-21.
- The website of the Company contains policies as specified by SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 and the provisions of Companies Act, 2013.
- The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.
- Adequate notice of board meeting is given to all the directors along with agenda at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and meaningful participation at the meeting.
- As per the minutes of the meeting duly recorded and signed by the Chairman, the decisions of the Board were unanimous and no dissenting views have been recorded.
- We, further report that there are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.
- The compliance by the Company of applicable financial laws like Direct and Indirect tax laws has not been reviewed in this audit since the same have been subject to review by statutory financial audit and other designated professionals.

For S.S. Reddy & Associates

Sd/-

**S. Sarveswar Reddy
Proprietor**

**M. No. A12611, C.P. No: 7478
UDIN: A012611C000504465**

**Place: Hyderabad
Date: 23.06.2021**

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Annexure to the Secretarial Audit Report

To

The Members of

Jeevan Scientific Technology Limited

Our report of even date is to be read along with this letter.

1. Maintenance of secretarial record is the responsibility of the management of the company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
3. We have relied on the reports given by the concerned professionals in verifying the correctness and appropriateness of financial records and books of accounts of the company.
4. Where ever required, we have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.
5. The compliance of provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.
6. The secretarial Audit report is neither an assurance as to future viability of the company nor of the efficacy or effectiveness with which the management has conducted the affairs of the company

For S.S. Reddy & Associates

Sd/-

**S. Sarveswar Reddy
Proprietor**

**Place: Hyderabad
Date: 23.06.2021**

**M. No. A12611, C.P. No: 7478
UDIN: A012611C000504465**

Annexure II

CORPORATE GOVERNANCE

In accordance with Regulation 34 (3) read with Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the report containing the details of Corporate Governance systems and processes at Jeevan Scientific Technology Limited as follows:

1. COMPANY'S PHILOSOPHY ON CODE OF GOVERNANCE:

The Company's philosophy on Corporate Governance is backed by Principles of Concern, Commitment, Ethics, Excellence and Learning in all its acts and relationships with Stakeholders, Clients, Associates and Community at large. This philosophy revolves around fair and transparent governance and disclosure practices in line with the principles of Good Corporate Governance. The Corporate Governance Structure in the Company assigns responsibilities and entrusts authority among different participants in the organization viz. the Board of Directors, the Senior Management, Employees, etc. The Company believes that good Corporate Governance is a continuous process and strives to improve the Corporate Governance practices to meet shareholder's expectations.

2. BOARD DIVERSITY:

The Company recognizes and embraces the importance of a diverse board in its success. We believe that a truly diverse board will leverage differences in thought, perspective, knowledge, skill, regional and industry experience, cultural and geographical background, age, ethnicity, race and gender, which will help us, retain our competitive advantage. The Board has adopted the Board Diversity Policy which sets out the approach to diversity of the Board of Directors. The Board Diversity Policy is available on our website, www.jeevanscientific.com.

3. COMPOSITION OF THE BOARD:

The composition of the Board of Directors of the company is an appropriate combination of executive and non-executive Directors with right element of independence. As on March 31, 2021, the Company's Board comprises of Eight Directors. There are three Executive Directors out of which two are promoter, 2 Non - Executive Directors. In addition, there are three independent Directors on the Board. In terms of clause

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

17(1) (b) of SEBI (LODR) Regulations, 2015, the company is required to have one third of total Directors as independent Directors. The non-executive Directors are appointed or re-appointed based on the recommendation of the Nomination & Remuneration Committee which considers their overall experience, expertise and industry knowledge. One third of the non-executive Directors other than independent Directors, are liable to retire by rotation every year and are eligible for reappointment, subject to approval by the shareholders.

4. ATTENDANCE AND DIRECTORSHIPS HELD:

As mandated by the SEBI (LODR) Regulations, 2015, none of the Directors are members of more than ten Board-level committees nor are they chairman of more than five committees in which they are members. Further all the Directors have confirmed that they do not serve as an independent director in more than seven listed companies or where they are whole-time directors in any listed company, then they do not serve as independent director in more than three listed companies.

The names and categories of the Directors on the Board, their attendance at Board meeting during the year and at last Annual General Meeting, as also the number of Directorships and Committee memberships held by them in other companies are shown in **Table 1**.

Table-1								
Name of Director	Relationship with other Directors	Category	No. of Meetings Held	No. of Meetings Attended	Whether Attended Last AGM	No. of Outside Directorships of Public Companies	No. of Committee Memberships	No. of Committee Chairmanships
Mr. S.S.R Koteswara Rao	None	ID& NED	4	3	Yes	3	1	-
Mr. K. Krishna Kishore	Father of Jeevan Krishna Kuchipudi and Father in law of Mrs. Snigdha Mothukuri	P & ED	4	4	Yes	2	1	-
Mrs. Snigdha Mothukuri	Daughter in law of Mr. K. Krishna Kishore and wife of Mr. Jeevan Krishna Kuchipudi	ED	4	1	No	-	-	-

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Mr. T. Ravi Babu	None	Non-ID & NED	4	1	No	-	-	-
Mr. G. Bhanu Prakash	None	ID& NED	4	4	Yes	-	-	-
Dr. M. Rajendra Prasad*	None	ED and CEO	4	4	Yes	-	-	-
Mr. K. Rama Krishna Prasad	None	ID & NED	4	3	Yes	-	-	1
Mr. Jeevan Krishna Kuchipudi	Son of Krishna Kishore Kuchipudi and husband of Mrs. Snigdha Mothukuri	NED	4	1	No	-	-	-

*Resigned w.e.f 23.06.2021

The Name of other listed entities where directors of the company are directors and the category of directorship are shown in **Table 2**.

Table-2		
Name of Director	Name of listed entities in which the concerned Director is a Director	Category of Directorship
Mr. S.S.R Koteswara Rao	Tera Software Limited	Independent Director
Mr. K. Krishna Kishore	--	--
Mr. T. Ravi Babu	--	--
Mrs. Snigdha Mothukuri	--	--
Mr. Jeevan Krishna Kuchipudi	--	--
Mr. G. Bhanu Prakash	--	--
Mr. K. Rama Krishna Prasad	--	--
Mr. Y. Nageswar Rao	--	--

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Details of Skills/Expertise/Competence matrix of the Board of Directors:

S. No.	Name of the Director	
1.	Mr. S.S.R Koteswara Rao	Finance
2.	Mr. K. Krishna Kishore	Healthcare
3.	Mr. T. Ravi	Advertising and Consulting
4.	Mrs. Snigdha Mothukuri	Management Science, Civil Engineering
5.	Mr. Jeevan Krishna Kuchipudi	Information Technology, Operations and Finance
6.	Mr. G. Bhanu Prakash	Operations, marketing, sales, distribution and general management
7.	Mr. Y. Nageswar Rao	Management, Operations, Finance, Marketing and Administration
8.	Mr. K. Rama Krishna Prasad	Engineering

5. FAMILIARISATION PROGRAMME FOR INDEPENDENT DIRECTORS

Independent Directors are familiarized about the Company's operations and businesses. Interaction with the Business heads and key executives of the Company is also facilitated. Detailed presentations on important policies of the Company is also made to the directors. Direct meetings with the Chairman is further facilitated to familiarize the incumbent Director about the Company/its businesses and the group practices.

The details of familiarisation programme held in FY 2020-21 are also disclosed on the Company's website i.e. <http://www.jeevanscientific.com/>

6. Number of shares and convertible instruments held by Non-Executive Directors;

Number of Shares held by Non-executive Directors has been mentioned in "Pecuniary Relationship or Transactions of the Non-Executive Directors Vis-À-Vis The Listed Company" forms part of this corporate governance report.

7. COMMITTEES OF THE BOARD:

The Company has Board-level Committees - Audit Committee, Stakeholder Relationship Committee and Nomination & Remuneration Committee.

All decisions pertaining to the constitution of Committees, appointment of members and fixing of terms of service for Committee members are taken by the Board of Directors. Details on the role and composition of these Committees, including the number of meetings held during the financial year and the related attendance are provided in this report below.

8. AUDIT COMMITTEE:

A. BRIEF DESCRIPTION OF TERMS OF REFERENCE: -

A qualified and independent Audit Committee has been set up by the Board in compliance with the requirements of Regulation 18 of the Listing Regulations and Section 177 of the Act. The role of the Audit Committee is as under:

- i. Oversight of the Company's financial reporting process and the disclosure of its financial information to ensure that the financial statement is correct, sufficient and credible;
- ii. Recommending the appointment of External Auditors, fixation of audit fee, Terms of Appointment and approval for payment of any other services;
- iii. Reviewing the utilization of loans and/ or advances from/investment by the holding company in the subsidiary exceeding Rs. 100 Crores or 10% of the asset size of the subsidiary, whichever is lower including existing loans / advances / investments existing as on the date of coming into force of this provision.
- iv. Review with the management and statutory auditors of the annual financial statements before submission to the Board with particular reference to:
 - (a) Matters required to be included in the directors' responsibility statement to be included in the board's report in terms of clause (c) of sub-section (3) of Section 134 of the Act;
 - (b) Changes, if any, in accounting policies and practices and reasons for the same;

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- (c) Major accounting entries involving estimates based on the exercise of judgment by management;
- (d) Significant adjustments made in the financial statements arising out of audit findings;
- (e) Compliance with listing and other legal requirements relating to financial statements;
- (f) Disclosure of any related party transactions;
- (g) Modified opinion(s) in the draft audit report;
- v. Review of the quarterly and half yearly financial results with the management before submission to the board for approval;
- vi. reviewing, with the management, the statement of uses / application of funds raised through an issue (public issue, rights issue, preferential issue, etc.), the statement of funds utilized for purposes other than those stated in the offer document / prospectus / notice and the report submitted by the monitoring agency monitoring the utilization of proceeds of a public or rights issue, and making appropriate recommendations to the board to take up steps in this matter;
- vii. Review and monitor statutory auditor's independence and performance and effectiveness of audit process;
- viii. Approval or any subsequent modification of transactions with related parties;
- ix. Scrutiny of inter-corporate loans and investments;
- x. Review of valuation of undertakings or assets of the company wherever it is necessary;
- xi. Evaluation of internal financial controls and risk management systems;
- xii. Review with the management, statutory auditors and the internal auditors about the nature and scope of audits and of the adequacy of internal control systems;
- xiii. Reviewing the adequacy of internal audit function, if any, including the structure of the internal audit department, staffing and seniority of the official heading the department, reporting structure, coverage and frequency of internal audit;

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- xiv. discussion with internal auditors of any significant findings and follow up there on;
- xv. Reviewing the findings of any internal investigations by the internal auditors into matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the board;
- xvi. discussion with statutory auditors before the audit commences, about the nature and scope of audit as well as post-audit discussion to ascertain any area of concern;
- xvii. Look into the reasons for any substantial defaults in payment to the depositors, debenture-holders, shareholders (in case of non-payment of declared dividend) and creditors, if any;
- xviii. Review the functioning of the whistle blower mechanism;
- xix. Approval of appointment of Chief Financial Officer after assessing the qualifications, experience and background, etc. of the candidate
- xx. Review of the following information:
 - (a) Management discussion and analysis of financial condition and results of operations;
 - (b) Statement of significant related party transactions (as defined by the audit committee), submitted by management;
 - (c) Management letters / letters of internal control weaknesses issued by the statutory auditors;
 - (d) Internal audit reports relating to internal control weaknesses;
 - (e) The appointment, removal and terms of remuneration of the Chief Internal Auditor;
 - (f) Statement of deviations:
 - Quarterly statement of deviation(s) including report of monitoring agency, if applicable, submitted to stock exchange(s) in terms of Regulation 32(1) of the Listing Regulations.
 - Annual statement of funds utilized for purposes other than those stated in the offer document/prospectus in terms of Regulation 32(7) of the Listing Regulations.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- xxi. Carrying out any other function as may be referred to the Committee by the Board.
- xxii. Consider and comment on rationale, cost-benefits and impact of schemes involving merger, demerger, amalgamation etc., on the listed entity and its shareholders.
- xxiii. Authority to review / investigate into any matter covered by Section 177 of the Companies Act, 2013 and matters specified in Part C of Schedule II of the Listing Regulations.

B. COMPOSITION, MEETINGS & ATTENDANCE:

There were four (4) Audit Committee Meetings held during the year on 30.07.2020, 05.09.2020, 02.11.2020 and 27.01.2021.

Name	Designation	Category	No. of meetings held	No. of meeting attended
Mr. K. Rama Krishna Prasad	Chairman	NED(I)	4	2
Mr. K. Krishna Kishore	Member	ED	4	4
Mr. S.S.R Koteswara Rao	Member	NED(I)	4	3
Mr. G. Bhanu Prakash	Member	NED(I)	4	4

NED (I): Non Executive Independent Director

ED: Executive Director

- C. Previous Annual General Meeting of the Company was held on 29.09.2020 and Mr. K. Ramakrishna Prasad, Chairman of the Audit Committee attended previous AGM.

9. NOMINATION AND REMUNERATION COMMITTEE:

A. BRIEF DESCRIPTION OF TERMS OF REFERENCE:

The Nomination and Remuneration Committee set up by the Board is responsible for:

- i. formulation of the criteria for determining qualifications, positive attributes and independence of a director and recommend to the Board a policy, relating to the remuneration for the directors, key managerial personnel and other employees.
- ii. formulation of the criteria for evaluation of performance of independent directors and the board of directors.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- iii. devising a policy on diversity of board of directors.
- iv. identifying persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down, and recommend to the Board of Directors their appointment and removal.
- v. whether to extend or continue the term of appointment of the independent director, on the basis of the report of performance evaluation of Independent Directors.
- vi. recommend to the Board, remuneration, payable to senior management.
- vii. such other matters as may be specified by the Board from time to time.

B. COMPOSITION OF THE COMMITTEE, MEETINGS AND ATTENDANCE DURING THE YEAR:

There were one Nomination and Remuneration Committee Meetings held during the financial year on 27.01.2021.

Name	Designation	Category	No. of meetings held	No. of meeting attended
Mr. K. Rama Krishna Prasad	Chairman	NED(I)	1	1
Mr. T. Ravi Babu	Member	NED	1	1
Mr. S.S.R Koteswara Rao	Member	NED(I)	1	1

NED (I): Non Executive Independent Director

ED: Executive Director

C. PERFORMANCE EVALUATION CRITERIA FOR INDEPENDENT DIRECTORS:

The performance evaluation criteria for Independent Directors are already mentioned under the head "Board Evaluation" in Directors' Report.

POLICY FOR SELECTION OF DIRECTORS AND DETERMINING DIRECTORS' INDEPENDENCE

Scope:

This policy sets out the guiding principles for the Nomination & Remuneration Committee for identifying persons who are qualified to

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

become Directors and to determine the independence of Directors, in case of their appointment as independent Directors of the Company.

Terms and References:

- 2.1 “Director” means a director appointed to the Board of a Company.
- 2.2 “Nomination and Remuneration Committee means the committee constituted in accordance with the provisions of Section 178 of the Companies Act, 2013 and Reg. 19 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2.3 “Independent Director” means a director referred to in sub-section (6) of Section 149 of the Companies Act, 2013 and Regulation 16(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Policy:

1. The Nomination and Remuneration Committee, and the Board, shall review on annual basis, appropriate skills, knowledge and experience required of the Board as a whole and its individual members. The objective is to have a board with diverse background and experience that are relevant for the Company’s operations.
 2. In evaluating the suitability of individual Board member the NR Committee may take into account factors, such as:
 - General understanding of the company’s business dynamics, global business and social perspective;
 - Educational and professional background
 - Standing in the profession;
 - Personal and professional ethics, integrity and values;
 - Willingness to devote sufficient time and energy in carrying out their duties and responsibilities effectively.
- 2.1 The proposed appointee shall also fulfil the following requirements:
- shall possess a Director Identification Number;
 - shall not be disqualified under the companies Act, 2013;
 - shall endeavour to attend all Board Meeting and Wherever he is appointed as a Committee Member, the Committee Meeting;

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- shall abide by the code of Conduct established by the company for Directors and senior Management personnel;
- shall disclose his concern or interest in any company or companies or bodies corporate, firms, or other association of individuals including his shareholding at the first meeting of the Board in every financial year and thereafter whenever there is a change in the disclosures already made;
- Such other requirements as may be prescribed, from time to time, under the companies Act, 2013, SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and other relevant laws.

3. Criteria of independence

3.1 The Nomination & Remuneration Committee shall assess the independence of Directors at time of appointment/ re-appointment and the Board shall assess the same annually. The Board shall re-assess determinations of independence when any new interest or relationships are disclosed by a Director.

3.2 The criteria of independence shall be in accordance with guidelines as laid down in companies Act, 2013 and Regulation 16(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3.3 The independent Director shall abide by the “code for independent Directors “as specified in Schedule IV to the companies Act, 2013.

4. Other directorships/ committee memberships

4.1 The Board members are expected to have adequate time and expertise and experience to contribute to effective Board performance. Accordingly, members should voluntarily limit their directorships in other listed public limited companies in such a way that it does not interfere with their role as director of the company. The NR Committee shall take into account the nature of and the time involved in a director’s service on other Boards, in evaluating the suitability of the individual Director and making its recommendations to the Board.

4.2 A Director shall not serve as director in more than 20 companies of which not more than 10 shall be public limited companies.

4.3 A Director shall not serve as an independent Director in more than 7 listed companies and not more than 3 listed companies in case he is serving as a whole-time Director in any listed company.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

4.4 A Director shall not be a member in more than 10 committees or act as chairman of more than 5 committee across all companies in which he holds directorships.

For the purpose of considering the limit of the committee, Audit committee and stakeholder's relationship committee of all public limited companies, whether listed or not, shall be included and all other companies including private limited companies, foreign companies and companies under section 8 of the companies Act, 2013 shall be excluded.

10. STAKEHOLDER'S RELATIONSHIP COMMITTEE:

A. BRIEF DESCRIPTION OF TERMS OF REFERENCE:

The Committee's role includes:

- (i) Resolving the grievances of the security holders of the Company including complaints related to transfer/transmission of shares, non-receipt of annual report, non-receipt of declared dividends, issue of new/duplicate certificates, general meetings etc;
- (ii) Review of measures taken for effective exercise of voting rights by shareholders;
- (iii) Review of adherence to the service standards adopted by the Company in respect of various services being rendered by the Registrar & Share Transfer Agent;
- (iv) Review of the various measures and initiatives taken by the Company for reducing the quantum of unclaimed dividends and ensuring timely receipt of dividend warrants/annual reports/ statutory notices by the shareholders of the company;
- (v) Such other matter as may be specified by the Board from time to time.

B. COMPOSITION OF THE COMMITTEE, MEETINGS AND ATTENDANCE DURING THE YEAR:

There was one (1) Stakeholders' relationship Committee Meetings held during the year and it was held on 27.01.2021.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Name	Designation	Category	No. of meetings held	No. of meeting attended
Mr. K. Rama Krishna Prasad	Chairman	NED(I)	1	--
Mr. K. Krishna Kishore	Member	ED	1	1
Mr. S.S.R Koteswara Rao	Member	NED(I)	1	1
Mr. G. Bhanu Prakash	Member	NED(I)	1	1

NED (I): Non Executive Independent Director

ED: Executive Director

C. DETAILS OF COMPLAINTS/REQUESTS RECEIVED, RESOLVED AND PENDING DURING THE YEAR 2020-21:

Opening balance	Received during the year	Resolved during the year	Closing balance
0	0	0	0

D. NAME AND DESIGNATION OF COMPLIANCE OFFICER:

Ms. Sharvari Swapnil Shinde is the Company Secretary and compliance officer of the Company for the Financial Year 2020-21.

PECUNIARY RELATIONSHIP OR TRANSACTIONS OF THE NON-EXECUTIVE DIRECTORS VIS-À-VIS THE LISTED COMPANY:

Mr. T. Ravi has a pecuniary relationship to the extent of 2500 Equity shares held by him in the company and Mr. K. Krishna Kishore, Managing Director of the Company is the Father of Mr. K. Jeevan Krishna and Father in Law of Ms. Snigdha Mothukuri.

Mr. K. Krishna Kishore and Mr. K. Jeevan Krishan is holding 20,01,391 and 7,24,300 Equity shares respectively in the Company.

A. CRITERIA FOR MAKING PAYMENTS TO NON-EXECUTIVE DIRECTORS:

Policy:

1. Remuneration to Executive Director and key managerial personnel

1.1 The Board on the recommendation of the Nomination and Remuneration (NR) committee shall review and approve the remuneration payable to

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

the Executive Director of the company within the overall limit approved by the shareholders.

- 1.2 The Board on the recommendation of the NR committee shall also review and approve the remuneration payable to the key managerial personnel of the company.
- 1.3 The remuneration structure to the Executive Director and key managerial personnel shall include the following components:
 - (i) Basic pay
 - (ii) Perquisites and Allowances
 - (iii) Stock Options
 - (iv) Commission (Applicable in case of Executive Directors)
 - (v) Retrial benefits
- 1.4 The Annual plan and Objectives for Executive committee shall be reviewed by the NR committee and Annual performance Bonus will be approved by the committee based on the achievement against the Annual plan and Objectives.

2. Remuneration to Non – Executive Directors

- 2.1 The Board, on the recommendation of the NR Committee, shall review and approve the remuneration payable to the Non – Executive Directors of the Company within the overall limits approved by the shareholders.
 - 2.2 Non – Executive Directors shall be entitled to sitting fees attending the meetings of the Board and the Committees thereof. The Non- Executive Directors shall also be entitled to profit related commission in addition to the sitting fees.
3. Remuneration to other employees
- 3.1. Employees shall be assigned grades according to their qualifications and work experience, competencies as well as their roles and responsibilities in the organization. Individual remuneration shall be determined within the appropriate grade and shall be based on various factors such as job profile skill sets, seniority, experience and prevailing remuneration levels for equivalent jobs.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

B. REMUNERATION TO DIRECTORS PAID DURING THE FINANCIAL YEAR 2020-2021 AND OTHER DISCLOSURES:

Name of the Director	Salary(Rs)	Sitting fees(Rs)	Number of shares held	Service Contracts	Stock Option Details	Fixed Component	Performance Based Incentive
Mr. K. Krishna Kishore	54,00,000	–	20,01,391	–	–	–	–
Mrs. K Vanaja	–	50,000	15,73,800	–	–	–	–
Dr. M. Rajendra Prasad*	54,00,000	–	8,96,250	–	–	–	–
Mr. S.S.R Koteswara Rao	–	95,000	–	–	–	–	–
Mrs. Snigdha Mothukuri	10,00,000	–	–	–	–	–	–
Mr. T. Ravi Babu	–	65,000	2,500	–	–	–	–
Mr. G. Bhanu Prakash	–	1,10,000	3,000	–	–	–	–
Mr. K. Rama Krishna Prasad	–	60,000	–	–	–	–	–
Mr. Jeevan Krishna Kuchipudi	–	25,000	7,24,300	–	–	–	–

* Resigned w.e.f 23.06.2021

11. INDEPENDENT DIRECTORS' MEETING:

As per clause 7 of the schedule IV of the Companies Act (Code for Independent Directors), a separate meeting of the Independent Directors of the Company (without the attendance of Non-Independent directors) was held on 27.01.2021, to discuss:

1. Evaluation of the performance of Non Independent Directors and the Board of Directors as whole;
2. Evaluation of the quality, content and timelines of flow of information between the management and the Board that is necessary for the Board to effectively and reasonably perform its duties.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

All the Independent Directors of the Company were present at the meeting.

As required under Regulation 34(3) read with Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, the company regularly familiarizes Independent Directors with the Company, their roles, rights, responsibilities in the company, nature of the industry in which the company operates, business model of the company etc.

The Company confirms that in the opinion of the board, the independent directors fulfill the conditions specified in these regulations and are independent of the management.

12. REMUNERATION POLICY:

The objectives of the remuneration policy are to motivate Directors to excel in their performance, recognize their contribution and retain talent in the organization and reward merit.

The remuneration levels are governed by industry pattern, qualifications and experience of the Directors, responsibilities should and individual performance.

13. GENERAL BODY MEETINGS:

A. LOCATION, DATE AND TIME OF LAST THREE AGMS AND SPECIAL/ORDINARY RESOLUTIONS THERE AT AS UNDER:

Financial Year	Date	Time	Location	Special / Ordinary Resolution
2019-20	29.09.2020	11.00 AM	Video Conferencing and Other audio Visual Means	Yes
2018-19	30.09.2019	10.00 AM	3rd floor, North Block, Raghava Ratna Towers, Chirag Ali Lane, Abids, Hyderabad-500001	No
2017-18	28.09.2018	09.30 AM	3rd floor, North Block, Raghava Ratna Towers, Chirag Ali Lane, Abids, Hyderabad-500001	Yes

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

B. PASSING OF RESOLUTIONS BY POSTAL BALLOT

There were no resolutions passed by the Company through Postal Ballot during the financial year 2020-21.

14. MEANS OF COMMUNICATION

The Company regularly intimates its financial results, audited/limited reviewed, to the Stock Exchanges, as soon as the same are taken on record/approved. These financial results are published in the Business Standard in English and in Andhra Prabha, Telugu language respectively. These results are not distributed/ sent individually to the shareholders.

In terms of the requirements of SEBI (Listing Obligations & Disclosures Requirements), the un-audited financial results as well as audited financial results, shareholding pattern of the Company and Corporate Governance Report are electronically submitted, unless there are technical difficulties and are displayed through Corporate

Filing and Dissemination System viz., on www.listing.bseindia.com. The un-audited financial results as well as audited financial results, shareholding pattern of the Company and Report on Corporate Governance are displayed on www.bseindia.com.

All important information and official press releases are displayed on the website for the benefit of the public at large. Analysts 'Reports/ Research Report, if any, are also uploaded on the website of the Company.

15. RECOMMENDATIONS OF COMMITTEES

The Board has accepted and acted upon all the recommendations by the Audit & Nomination and Remuneration Committees.

16. GENERAL SHAREHOLDER INFORMATION:

A. ANNUAL GENERAL MEETING:

The Twenty Third Annual General Meeting of the Company will be held as per the following schedule:

Day	Wednesday
Date	15th September, 2021
Time	10.30 A.M
Venue	Video Conferencing and other audio visual means

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

B. FINANCIAL YEAR AND FINANCIAL YEAR CALENDAR 2021-22 (TENTATIVE SCHEDULE)

The financial calendar (tentative) shall be as under:

Financial Year	2021-22
First Quarterly Results	14.08.2021
Second Quarterly Results	14.11.2021
Third Quarterly Results	14.02.2021
Fourth Quarterly Results	30.05.2022
Annual General Meeting for year ending 31st March, 2022	30.09.2022

C. DIVIDEND PAYMENT DATE: The Board of Directors at their Meeting held on 23rd June 2021 has recommended final dividend of Rs. 0.50 per equity share for financial year 2020-21, subject to the approval from shareholders. The dividend if declared at the Annual General Meeting shall be paid on or after September 15, 2021 but within the statutory time limit, to the Members whose names appear on the Company's Register of Members as on the Record Date i.e., September 08, 2021, and in respect of the shares held in dematerialized mode, to the Members whose names are furnished by National Securities Depository Limited and Central Depository Services (India) Limited as beneficial owners as on that date.

D. NAME AND ADDRESS OF STOCK EXCHANGE WHERE THE COMPANIES SECURITIES ARE LISTED:

EXCHANGE: BSE LIMITED, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001.

E. LISTING ON STOCK EXCHANGES:

The equity shares of the Company are listed on BSE Ltd. The Company has paid the listing fees for the year 2021-2022 to BSE Limited.

F. STOCK CODE: JSTL (BSE Limited)

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

G. STOCK MARKET PRICE DATA:

Month	Open Price	High Price	Low Price	Close Price	No. of . Shares Traded
Apr 20	15.50	21.60	15.35	20.80	27,847
May 20	20.30	21.60	18.00	19.45	10,993
Jun 20	20.40	22.00	17.20	18.40	42,410
Jul 20	19.00	20.10	16.00	18.35	89,114
Aug 20	19.80	23.35	16.65	18.50	1,84,068
Sep 20	18.50	23.50	18.50	22.00	61,653
Oct 20	23.10	26.45	20.65	23.70	66,964
Nov 20	24.80	35.45	23.05	32.50	2,82,976
Dec 20	33.50	40.30	31.05	35.00	2,13,657
Jan 21	36.40	48.15	32.60	48.15	1,65,386
Feb 21	50.55	75.95	50.55	72.05	11,10,999
Mar 21	73.45	73.45	60.60	61.30	2,31,876

H. REGISTRAR AND SHARE TRANSFER AGENTS:

CIL Securities Limited,
214, R.R Towers, C.A. Lane,
Abids, Hyderabad – 500001
Vide SEBI Regn. No. INR 000002276

I. SHARE TRANSFER SYSTEM:

Shares received for transfer by the Company or its Registrar and Share Transfer Agent in physical mode are processed and all valid transfers are approved. The share certificate(s) is/are duly transferred and dispatched within a period of 15 days from the date of receipt.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

J. DISTRIBUTION OF SHAREHOLDING AS ON 31ST MARCH, 2021:

SL. NO.	No. of equity Shares held	No. of Shareholders	%	No. of Shares	%
1	Upto - 5000	1974	69.83	385505	2.52
2	5001 - 10000	308	10.92	266318	1.74
3	10001 - 20000	190	6.63	302085	1.97
4	20001 - 30000	98	3.80	253267	1.66
5	30001 - 40000	41	1.36	152092	0.99
6	40001 - 50000	46	1.69	220832	1.44
7	50001 - 100000	69	2.30	550074	3.59
8	100001 and above	98	3.47	13171292	86.08
	TOTAL	2824	100.00	15301465	100.00

K. DEMATERIALISATION & LIQUIDITY OF SHARES:

Trading in Company's shares is permitted only in dematerialized form for all investors. The ISIN allotted to the Company's scrip is INE427E01027. Investors are therefore advised to open a demat account with a Depository participant of their choice to trade in dematerialized form. Shares held in demat and Physical mode as on March 31, 2021 is as follows:

Particulars	No. of Shares	% Share Capital
NSDL	7275892	47.55
CDSL	7492140	48.96
PHYSICAL	533433	3.49
Total	15301465	100.00

To enable us to serve our investors better, we request shareholders whose shares are in the physical mode to dematerialize their shares and update their bank accounts with respective depository participants.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

L. Outstanding Global Depository Receipts Or American Depository Receipts Or Warrants Or Any Convertible Instruments, Conversion Date And Likely Impact On Equity: NIL

M. LOCATIONS & ADDRESS FOR CORRESPONDANCE:

Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir,
Near Lanco Hills, Golconda Post, Hyderabad 500008

N. BOOK CLOSURE DATE:

The date of Book Closure for the purpose of Annual General Meeting shall be from Thursday, 09th September, 2021 to Wednesday, 15th September, 2021 (both days inclusive).

O. ELECTRONIC CONNECTIVITY: Demat ISIN Number: INE237B01018

P. NATIONAL SECURITIES DEPOSITORY LIMITED

Trade World, Kamala Mills Compound
Senapati Bapat Marg, Lower Parel
Mumbai – 400 013.

Q. CENTRAL DEPOSITORY SERVICES (INDIA) LIMITED

Phiroze Jeejeebhoy Towers, 28th Floor
Dalal Street, Mumbai – 400 023.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

R. SHAREHOLDING PATTERN AS ON 31ST MARCH, 2021:

S. No	Category	No. of shares held	Percentage of shareholding
A	Shareholding of Promoter and Promoter group	-	-
1.	Indian	-	-
	Individual	55,46,691	36.24
	HUF	2,00,000	1.31
	Body Corporate	85,200	0.56
2.	Foreign	--	--
	Individual	--	--
	Sub-Total A	58,31,891	38.11
B	Public Shareholding	-	-
1.	Institutions	--	--
2.	Non-Institutions		
	a. Bodies Corporate	86,513	0.57
	b. Indian Public and Others	93,83,061	61.32
	Sub Total B	94,69,574	61.89
	Grand Total (A+B)	1,53,01,465	100.00

17. OTHER DISCLOSURES:

A. DISCLOSURES ON MATERIALLY SIGNIFICANT RELATED PARTY TRANSACTIONS THAT MAY HAVE POTENTIAL CONFLICT WITH THE INTERESTS OF LISTED ENTITY AT LARGE

In line with the requirements of the Companies Act, 2013 and Listing Regulations, your Company has formulated a Policy on Related Party Transactions which is also available on Company's Website www.jeevanscientific.com. The Policy intends to ensure that proper reporting, approval and disclosure processes are in place for all transactions between the Company and Related Parties.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

All Related Party Transactions are placed before the Audit Committee for review and approval. Prior omnibus approval is obtained for Related Party Transactions on a quarterly basis for transactions which are of repetitive nature and / or entered in the Ordinary Course of Business and are at Arm's Length. All Related Party Transactions are subjected to independent review by a reputed accounting firm to establish compliance with the requirements of Related Party Transactions under the Companies Act, 2013 and Listing Regulations.

All Related Party Transactions entered during the year were in Ordinary Course of the Business and on Arm's Length basis. Accordingly, the disclosure of Related Party Transactions as required under Section 134(3) (h) of the Companies Act, 2013 in Form AOC-2 in a separate section of this annual report.

B. WHISTLE BLOWER POLICY:

With a view to adopt the highest ethical standards in the course of business, the Company has a whistle blower policy in place for reporting the instances of conduct which are not in conformity with the policy. Directors, employees, vendors or any person having dealings with the Company may report non-compliance to the Chief Financial Officer of the company, who reviews the report. Confidentiality is maintained of such reporting and it is ensured that the whistle blowers are not subjected to any discrimination. No person was denied access to the Audit Committee.

C. DISCLOSURE OF COMMODITY PRICE RISKS AND COMMODITY HEDGING ACTIVITIES:

Price and demand of the Company's finished products are inherently volatile and remain strongly influenced by global economic conditions. Any fluctuation in finished product prices or currency has direct impact on the Company's revenue and profits.

The Company considers exposure to commodity price fluctuations to be an integral part of our business and its usual policy is to sell its products at prevailing market prices. The Company has a well-defined policy framework wherein no speculative positions are taken and limited commodity hedging is done with and endeavors to achieve month-average rates both in currency and metal prices. The Company follows the policy of taking forward cover for net foreign exposure, if the net is payable in foreign currency, with negligible exposure in non USD currencies All policies are periodically reviewed basis local and global economic environment.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

D. DISCLOSURE OF PENDING CASES / INSTANCES OF NON-COMPLIANCE:

There were no non-compliances by the Company and no instances of penalties and strictures imposed on the Company by the Stock Exchanges or SEBI or any other statutory authority on any matter related to the capital market during the last three years except the following:

BSE Limited has imposed a penalty of Rs. 1,07,380, Rs. 1,08,560 and Rs. 63,720 towards non-appointment of Company Secretary for Quarters 30.06.2020, 30.09.2020 and 31.12.2020 and the same was paid by the company.

E. DISCLOSURE IN RELATION TO THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013:

Particulars	Number
No. of Complaints filed during the financial year	Nil
No. of Complaints disposed of during the financial year	Nil
No. of Complaints pending as on end of the financial year	Nil

F. AUDIT FEES (INCLUDING SUBSIDIARY): The Audit Fee (including subsidiary) is as mentioned in the Financial Statements attached in the Financial Section to this Annual Report.

G. DETAILS OF UTILIZATION OF FUNDS RAISED THROUGH PREFERENTIAL ALLOTMENT OR QUALIFIED INSTITUTIONS PLACEMENT AS SPECIFIED UNDER REGULATION 32 (7A): NIL

H. SUBSIDIARY COMPANIES:

The Company does not have any material subsidiary as defined under Listing Regulations, however, the policy for determining its 'Material' Subsidiaries was formulated and the same is available on the website of the Company <http://www.jeevanscientific.com/>.

I. COMPLIANCE WITH THE DISCRETIONARY REQUIREMENTS UNDER LISTING REGULATIONS:

The Board of Directors periodically reviewed the compliance of all applicable laws and steps taken by the Company to rectify instances of non-compliance, if any. The Company is in compliance with all

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

mandatory requirements of Listing Regulations. In addition, the Company has also adopted the following non-mandatory requirements to the extent mentioned below:

- The Board & Separate posts of Chairman and CEO: The positions of the Chairman and the CEO are separately held in the company.
- Audit qualifications: Company's financial statements have no qualifications.
- Reporting of Internal Auditor: The Internal Auditor of the Company directly reports to the Audit Committee on functional matters.

J. COMPLIANCE WITH GOVERNANCE FRAMEWORK:

The Company has complied with all the mandatory requirements specified in Regulations 17 to 27 and clauses (b) to (i) of sub –regulation (2) of Regulation 46 of the Listing Regulations.

The Company has submitted quarterly compliance report on Corporate Governance with the Stock Exchanges, in accordance with the requirements of Regulation 27(2) (a) of the Listing Regulations.

**For and on behalf of the Board of
Jeevan Scientific Technology Limited**

**Place: Hyderabad
Date: 09.08.2021**

**Sd/-
K. Krishna Kishore
Vice Chairman and
Managing Director
(DIN: 00876539)**

**Sd/-
Snigdha Mothukuri
Director and CEO
(DIN: 08934860)**

ANNEXURE III

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

1. Industry Structure and Developments Summary

The global pharmaceuticals market is constantly growing given the worldwide increase in life expectancy, as well as the increasing incidence of chronic and infectious diseases. The increasing demand has led to a significant rise in R&D investment and to maintain a competitive edge, leading industry players allocate around 20% of their turnover to R&D. The industry, though dominated by the U.S. with a share of around 45%, global pharmaceutical giants are increasingly outsourcing R&D to emerging economies like India to take advantage of the scientific work pool and lower costs. The contract research organization (CRO) services market is projected to reach USD 86.5 billion by 2026 from USD 53.2 billion in 2021, at a CAGR of 10.7% during the forecast period.

A CRO provides its support to the pharmaceutical, biotechnology, and health companies by offering services like clinical research, product development, and process development including early-phase, clinical, laboratory, consulting and data management services, post-marketing surveillance, quality monitoring and management services for clinical trials and Pharmacovigilance. The clinical research services dominated the market in 2020, which can be attributed to rapid growth in the geriatric population, subsequent increase in the prevalence of chronic diseases, and rising demand for newer drugs. The India CRO Market was valued USD 970 million in 2020 and is expected to reach by USD 1962 million by 2025 with a CAGR of 12.7% during the forecast period. Availability of largest pool of patients and large number of hospitals, educated and accessible human resources, and low operational costs boost the Indian market. Also, continuous positive efforts by the regulatory authorities such as Director Controller General of India (DCGI), Indian Council of Medical Research (ICMR), and Directorate General of Foreign Trade (DGFT) are creating favorable conditions for the research in India.

Based on therapeutic area, the global CRO services market is broadly categorized into oncology, infectious diseases, neurology, cardiovascular system (CVS) disorders metabolic disorders/ endocrinology, immunological disorders, respiratory disorders, psychiatry, dermatology, hematology, ophthalmology, gastrointestinal diseases, genitourinary & women's health, and other therapeutic areas. The oncology is the largest segment in the CRO services market, which is attributed to the high incidence of cancer and pipeline of drugs in late-stage development.

Bioavailability and Bioequivalence (BA/BE) Market

Bioavailability (BA) refers to the relative amount of drug from an administered dosage from which enters the systemic circulation and the rate at which the drug appears in the systemic circulation. Bioequivalence (BE) of a drug product is achieved if its extent and rate of absorption are not statistically significantly different from those of the reference product when administered at the same molar dose. The office of Drugs Controller General (India) at CDSCO has been receiving applications requesting for the approval to carry out BA/BE studies with various pharmaceutical dosage formulations on Indian subjects. In the US, these applications are called Abbreviated New Drug Applications or ANDA's. Before launching a new generic drug into market, it is mandatory to ensure the demonstration of the of generics against corresponding innovator drugs and that they are comparable and safe for consumption by human subjects. An assessment of "interchangeability" between the investigational and the innovator product is carried out by a study of "in vivo equivalence" or "bioequivalence" (BE). The global bioanalytical testing services market size was valued at USD 3.3 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 8.6% from 2021 to 2028. Within the BA/BE market, Bio-similar is a new growth opportunity based on patent expiry trends. Most small and mid-sized pharma companies in India are still not addressing this opportunity, and the same is true for most CROs in India.

Pharmacovigilance (PV) Market

Following drug approval and manufacturing, as per regulations in most countries, drug companies need to monitor the safety of drug using post-marketing safety surveillance program. Through this, manufacturers, health professionals, and consumers report problems with approved drugs. It is mandatory to track and report adverse drug reactions (ADRs) after a drug is launched into the market. The service related to this activity is called Pharmacovigilance. This is a service required by both Generic Pharma companies and also Innovative pharma companies. The global pharmacovigilance market size was valued at USD 6.33 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 11.5% from 2021 to 2028. Hyderabad, where Jeevan Scientific Technology Limited (JSTL) is based, is one of the PV hubs in India. The other cities are Delhi, Mumbai, and Bangalore. Growth in the PV market is driven by increasing drug safety regulations globally and also an increased outsourcing trend.

Clinical Trials (CT) Market

Clinical trials aim to find out whether a medical strategy, treatment, or device is safe and effective for humans to use or consume. Clinical Trials are an important activity in the drug discovery process (Phase I to Phase III). To ensure participant safety, trials start with small groups and examine whether a new method causes any harm or unsatisfactory side effects. This is because a technique that is successful in a laboratory or in animals may not be safe or effective for humans. During Phase I for the first time the drug is tested on humans (a small number of healthy volunteers) to assess the safety and pharmacokinetics, absorption, metabolic, and elimination effects on the body, as well as any side effects for safe dosage ranges. Phase II and Phase III trials are done in Patient Population. Phase II assesses drug safety and efficacy in patients. Phase III enrolls more number patients, enabling medication labeling and instructions for proper drug use. Phase III trials require extensive collaboration, organization, and Independent Ethics Committee (IEC) or Institutional Review Board (IRB) coordination and regulation in anticipation of full-scale production following drug approval. Clinical Trials Market size was estimated at over USD 42.9 billion in 2020 and is projected to grow at 4.9% CAGR between 2021 and 2027. Increasing prevalence of chronic diseases coupled with growing demand for clinical trials in developing countries is escalating the market growth. Even in the Indian market, the domestic clinical trials market has started increasing due to changing regulations.

2. Opportunities:

In the BA/BE market, growth opportunities exist in innovation and also driving cost efficiency. As market trends indicate, the growing segments within BA/BE are specialty generics. JSTL has the ambition to become a full-service CRO by expanding its service portfolio. It will focus on building the PV and CT businesses. Within PV, JSTL would look at targeting small and medium-sized pharma companies and building its internal capabilities through automation. Within CT, JSTL would look at both international and domestic opportunities.

Threat:

In the BA/BE business, the barriers to entry are low, and this has resulted in many new players entering the market and creating a pricing pressure. To deal with this, CROs like JSTL will have to be highly efficient.

Regulatory changes are another threat to the business. Approvals by DCGI, USFDA approval of the facilities, and ANDA approvals create demand in CROs. In recent years, regulation both in India and the US has been favorable to pharma related businesses in India. So far JSTL has successfully faced about 10 regulatory audits including CDSCO, USFDA and WHO. JSTL also stands out for its adherence to high quality standards which can be clearly noted from all the successful regulatory audits and more than 60 multiple sponsor audits.

3. Outlook:

Based on recent market trends, the outlook for CRO services like BA/BE, PV, and CT looks positive. The company is positioned well to benefit from these market trends. The overall focus on digital and innovation in the company is high. Several automation projects have been initiated and are ongoing. Entry into new segments like complex generics (for example, Large Molecules) is being planned and executed. The overall focus of being a full-service CRO will enable the company to provide a range of services to its existing customer base. Focus on delivering high-quality services on time and at competitive prices should allow the company to improve customer satisfaction.

4. Risk and Concerns:

Intermittent lockdowns due to COVID 19 have caused supply chain disruptions and labor shortages. These have delayed the procurement of raw materials and value addition from outsourced work. This has posed challenges to our operations in FY 20-21, however, with our diligent procurement and production planning and operational excellence we were able to sail through the uncertain scenario and achieve our targets in FY 20-21. The pandemic has hit India in the form of second wave in March FY 21, and might pose challenges in terms of delay in procurement of raw materials, labor shortages, and customer clearances, which might affect the revenues of the company. However, we will try our best to effectively navigate through the uncertain times.

5. Internal Control systems and their Adequacy:

We have effective internal financial controls across all the functions including finance, supply chain, Quality, Operations, HR and IT to prepare reliable financial reports and effectively avoid any fraud. Our Internal financial controls are duly certified by our statutory auditor.

6. Financial Performance with respect to Operational Performance

Financial Review:

Income earned to the extent of Rs. 4,284.79 lakhs as against Rs. 2,308.85 lakhs of previous year and earned a profit of Rs. 1131.91 lakhs as against loss of Rs. (783.90) lakhs compared to last year.

7. Segment wise Performance:

The turnover is mainly from the core Clinical Research Services. The Business plan is to ensure at least two fold growth in business in the coming year(s) with the stable business. During the Financial Year under report, Clinical Research Services division has expanded into offering the complete portfolio of services as explained below:

JSTL has the advantage of fully integrated scientific expertise team in Clinical research functions. JSTL started offering a varied range of clinical research services like Bioavailability/Bioequivalence studies and Phase I to Phase IV services to pharmaceutical and biotechnology industries. The technical team at JSTL has immense experience in handling various projects in diverse therapeutic areas for different regulatory authorities. So far JSTL has successfully executed more than 400 clinical studies (BA/BE and CT) building up a broad clientele of about 50 across India and abroad as well which is a combination of big pharmaceutical giants and large and medium size companies. JSTL has also added about 20 clientele under Pharmacovigilance division and is working with a vision to expand the same.

a. Bioanalytical Research:

JSTL has established its Bioanalytical facility in Hyderabad at Plot No. 1 & 2, Sai Krupa Enclave, Near Lanco Hills, Golconda Post, Hyderabad, Telangana - 500008. Bioanalytical research laboratory is designed with state-of-the-art facility equipped with advanced analytical instrumentation having 2 processing labs and 4 LC-MS/MS rooms, which can accommodate up to 12 LC-MS/MS. However additional space in the facility can be utilized to accommodate upto 24 LC-MS/MS. During this financial year, JSTL has a total of 10 LC-MS/MS systems and one Multi Mode Micro Plate Reader (ELISA reader) and these were added over the period to accommodate maximum possible work. JSTL offers a unique combination of highly trained workforce enabled with well-equipped bioanalytical research and development (R&D) laboratory with provision for handling light-sensitive molecules. JSTL's bioanalytical laboratory located at Hyderabad is performing well and faced several

successful regulatory and client audits. The facility was inspected by USFDA, WHO and CDSCO.

b. Clinical Operations:

JSTL's prime focus being BA/BE studies, it has built a facility for executing the clinical phase of the BA/BE studies. In this regard, JSTL established its clinical pharmacology centre in Hyderabad at B-17, TIE, Phase II, Balanagar, Hyderabad, Telangana - 500037. This facility is spread over 20,000 sft and distributed in the 2nd, 3rd and 4th floors of the building. This facility accommodates a total of 132 beds distributed in to 4 clinical pharmacology units with bed capacity of 42(Clinic 1), 24(Clinic 2), 42(Clinic 3) and 24(Clinic 4). This facility also consists of special care areas (3+3 beds), emergency lift, tie-up with tertiary care hospital and a dedicated ambulance to handle any emergencies. This facility is capable of carrying out approximately 200 studies per year at a peak capacity. Experienced, trained medical and para-medical staff conducts all these studies at this facility as per GCP and applicable regulations.

The facility is in compliance with all the statutory requirements and also the applicable regulatory requirements like Drug Control General of India (DCGI). This facility being used to carry out the BA/BE studies for pharmaceutical companies who are developing generic molecules for global market. The facility was inspected by USFDA, WHO, and CDSCO. Another milestone includes successful completion of an exceptional and complex service portfolio of Glucose Clamping Technique Phase I unit in the FY 20-21. Despite of global COVID 19 pandemic challenges we successfully completed our first Glucose clamping study and many more studies that needed immediate attention while many other CROs were shutdown.

c. Pathology Laboratory

JSTL has started the pathology laboratory in 2019 and during the Financial Year the same has been moved to a facility in 1110 sft situated at S-13, Balanagar, Hyderabad-500037, T.S, India which is right opposite to the clinical pharmacology centre. JSTL's Clinical path lab has been assessed and accredited in accordance with the standard ISO 15189:2012 "Medical laboratories - Requirements for quality and competence" (NABL). JSTL is proud of the new addition as now almost all of the diagnostic tests are done in house.

d. Clinical Trials and Trial Management:

JSTL's Clinical operation team has a vast experience in executing

clinical projects of different therapeutic areas across the globe. JSTL has a rich pool of clinical investigator sites experienced in handling various phases of clinical projects including Pharmacokinetic and Pharmacodynamic studies across the India. The Project management team oversees the technical and administrative aspects of the study. The team is committed to ensure timely update of project status, and meeting the client requirements in agreed timelines. Again here JSTL is focusing on specialty drugs like Biosimilars and is building expertise on the same.

e. Regulatory Services:

JSTL's Medical Writing team is structured with a team of competent writers, with diverse portfolios. The team is currently supporting major pharma clients across the globe, to achieve their objectives in Regulatory & technical documents writing. JSTL provides expert services for the management of concerns with regulatory authorities and fulfill client expectations in a realistic and transparent manner.

f. Clinical Data Management and Statistical Analysis Services:

The Data Management team has hands on experience in handling clinical data, and the team ensures efficient and reliable management of the data in compliance with industry standards and regulatory requirements.

g. Pharmacovigilance Services:

JSTL offers a wide range of comprehensive pharmacovigilance and safety monitoring services. JSTL's aim at a rapid pace growth, and retains an experienced vigilance team, thus being able to provide a wide range Pharmacovigilance services for different regulatory bodies. During this financial year, JSTL by taking advantage of the experience of this pharmacovigilance services, initiated a good number of contracts with small and medium pharmaceutical companies across USA and India.

8. Material developments in Human Resources / Industrial Relations from, including number of people employed.

There are no material developments in Human Resources / Industrial Relations from FY 20 to FY 21. However, JSTL aims to add in more specialized talent particularly in Pharmacovigilance and Clinical Trials divisions in the coming Financial Year.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Particulars	31 March FY 21	31 March FY 20
Staff	251	210
Workmen	-	-
Third Party	-	-
Total	251	210

9. Details of significant changes in key financial ratios and return on net worth:

Particulars	2020-21	2019-20
Debtors turnover ratio	0.291	0.260
Inventory turnover ratio	0.081	0.041
Interest coverage ratio	8.415	-3.215
Current ratio	1.593	0.843
Debt equity ratio	0.285	0.720
Operating profit margin (%)	32.56	-47.50
Net profit margin (%)	26.42	-33.95
Return on Net worth	31.23	-31.44

10. Cautionary Statement

We cannot guarantee that the forward-looking statements made in Management Discussion and Analysis will be realized, although we believe we have been prudent in our assumptions. The achievement of results is subject to risks, uncertainties and even inaccurate assumptions. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results could vary materially from those anticipated, estimated or projected. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Disclosure of Accounting Treatment:

During the preparation of Financial Statement of F.Y. 2020-21 the treatment as prescribed in an Accounting Standard has been followed by the Company. There is no discrepancy in Accounting Treatment as followed by the Company in current financial year as compared to previous financial year.

Practicing Company Secretary's Certificate on Directors

To the Members of **Jeevan Scientific Technology Limited**

In my opinion and to the best of my information and according to the explanations given to me, and the representations made by the Directors and the management, I certify that none of the directors on the Board of the Company has been debarred or disqualified from being appointed or continuing as directors of companies by the Board/Ministry of Corporate Affairs or any such statutory authority.

For S.S Reddy & Associates

Sd/-

S. Sarveswar Reddy

Proprietor

ACS No. 12611

CP No. 7478

UDIN: A012611C000540787

Place: Hyderabad

Date: 23.06.2021

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

CEO/CFO Certification in respect of Financial Statements and Cash Flow Statement

(Pursuant to regulation 17 (8) of SEBI (Listing Obligations & Disclosure Requirements), Regulations, 2015 For the Financial Year ended March 31, 2021

We have reviewed the Financial Statements and the Cash Flow Statement for the year ended 31st March 2021 and we hereby certify and confirm to the best of our knowledge and belief the following:

- a. The Financial Statements and Cash Flow statement do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading.
- b. The Financial Statements and the Cash Flow Statement together present a true and fair view of the affairs of the Company and are in compliance with existing accounting standards, applicable laws and regulations.
- c. There are no transactions entered in to by the Company during the year ended 31st March 2021 which are fraudulent, illegal or violative of Company's Code of Conduct.
- d. We accept responsibility for establishing and maintaining internal controls for Financial Reporting and we have evaluated the effectiveness of these internal control systems of the Company pertaining to financial reporting. Deficiencies noted, if any, are discussed with the Auditors and Audit Committee, as appropriate, and suitable actions are taken to rectify the same.
- e. There have been no significant changes in the above mentioned internal controls over financial reporting during the relevant period.
- f. That there have been no significant changes in the accounting policies during the relevant period.
- g. We have not noticed any significant fraud particularly those involving the, management or an employee having a significant role in the Company's internal control system over Financial Reporting.

	Sd/-	Sd/-
Place: Hyderabad	Snigdha Mothukuri	Srikanth Sasidhar Mathamsetty
Date: 23.06.2021	Chief Executive Officer	Chief Financial Officer (CFO)

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

AUDITOR'S CERTIFICATE ON CORPORATE GOVERNANCE

To,

The Members of

Jeevan Scientific Technology Limited

We have examined the compliance of conditions of corporate governance by Jeevan Scientific Technology Limited ('the Company') for the year ended 31st March, 2021, as stipulated in Regulations 17 to 27, clauses (b) to (i) of sub-regulation (2) of regulation 46 and paragraph C, D and E of Schedule V of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The compliance of conditions of Corporate Governance is the responsibility of the Company's management. Our examination was limited to procedures and implementation thereof, adopted by the Company for ensuring the compliance of the conditions of the Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In our opinion and to the best of our information and according to the explanations given to us, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in the above mentioned Listing regulations.

We further state that such compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the management has conducted the affairs of the Company.

For S.S Reddy & Associates

Sd/-

S. Sarveswar Reddy

Proprietor

ACS No. 12611

CP No. 7478

UDIN: A012611C000540809

Place: Hyderabad

Date: 23.06.2021

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Annexure – IV

Form AOC – 1

Statement containing salient features of the financial statements of Subsidiaries (Pursuant to proviso to sub-section (3) of section 129 read with Rule 5 of the Companies (Accounts) Rules, 2014)

1. **Name of the Subsidiaries:** Enhops Solutions Private Limited

Enhops Inc. (U.S.A)

2. **Reporting Period:** 01.04.2020 to 31.03.2021

3. **Reporting Currency:** Indian Rupee

(Amt. in Rupees)

S. No.	Particulars	Enhops Solutions Private Limited	Enhops Inc. (U.S.A)
1.	Share Capital	1,00,00,000	2,69,070
2.	Reserves and surplus for the year ending	(1,25,46,387)	2,85,454
3.	Total Assets	9,26,94,462	49,04,207
4.	Total Liabilities	9,26,94,462	49,04,207
5.	Investments	-	-
6.	Turnover (Income)	5,90,83,626	58,87,984
7.	Profit / loss before Taxation	43,98,253	3,11,104
8.	Provision for Taxation	(98,056)	-
9.	Profit / loss after Taxation	44,96,309	3,11,104
10.	Proposed Dividend	-	-
11.	% of Shareholding	100%	100%

1. **Names of Subsidiaries which are yet to commence operation:** NA

2. **Names of subsidiaries which have been liquidated or sold during the year:** NA

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Annexure - V

Form No. AOC-2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

Form for disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arm's length transactions under third proviso thereto Related Party Disclosures

- a) Names of the related parties and nature of relationship (as per Ind AS 24):

Nature of Relationship	Name of Related Party
Key Management Personnel (KMP):	K. Krishna Kishore – Vice Chairman and Managing Director
	M Snigdha – CEO & Executive Director
	K Jeevan Krishna – Non Executive Director
	Y. Nageswara Rao – Executive Director
Relatives of Key Management Personnel (KMP):	K. Vanaja- Spouse of Mr. K. Krishna Kishore
	Jeevan Mitra Finance Corporation– HUF of Mr. K. Krishna Kishore
	Enhops Solutions Private Limited – Wholly owned subsidiary
	Enhops Inc - Wholly owned subsidiary

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

b) Transactions with related parties:

(Amt. in Rupees)

Particulars	As at March 31,2021	As at March 31, 2020
Rent Paid:		
- K. Krishna Kishore	4,80,000	4,80,000
- K. Vanaja	4,80,000	4,80,000
- Jeevan Mitra Finance Corporation	8,40,000	8,40,000
Remuneration Paid:		
- K. Krishna Kishore	54,00,000	54,00,000
- M. Rajendra Prasad	54,00,000	54,00,000
- M Snigdha	10,00,000	-
Loans and Advances given		
- Enhops Solutions Private Limited	9,88,84,634	7,68,79,725
Long term Borrowings		
- K. Krishna Kishore	52,50,000	6,02,25,000
- K. Vanaja	6,50,000	83,15,000
- M. Rajendra Prasad*	19,50,000	20,00,000
Interest paid on long term borrowings		
- K. Krishna Kishore	2,50,850	14,70,008
- K. Vanaja	69,257	2,95,481
- M. Rajendra Prasad*	184,624	1,47,760

Resigned w.e.f 23.06.2021

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

c) Related party balances:

Amount due to related parties

(Amt. in Rupees)

Particulars	As at March 31,2021	As at March 31, 2020
Long Term Borrowings		
- K. Krishna Kishore	-	54,00,000
- K. Vanaja	-	8,50,000
- M. Rajendra Prasad*	-	18,00,000

*Resigned w.e.f 23.06.2021

Amount due from related parties

(Amt. in Rupees)

Particulars	As at March 31,2021	As at March 31, 2020
Long Term Advances		
- Enhops Solutions Private Limited	6,52,86,870	6,21,46,546

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

ANNEXURE – VI (a)

STATEMENT SHOWING THE NAMES OF TOP TEN EMPLOYEES PURSUANT TO SEC. 197 READ WITH RULE 5 (1) (2) and (3) OF THE COMPANIES (APPOINTMENT AND REMUNERATION OF MANAGERIAL PERSONNEL) RULES, 2014

- The ratio of remuneration to each director to the median remuneration of the employees of the company for the financial year.

(Amount in INR)

Director	Total Remuneration	Ratio to median remuneration
K Krishna Kishore	54,00,000	1:0.04
M Rajendra Prasad*	54,00,000	
M Snigdha	10,00,000	

* Resigned w.e.f 23.06.2021

- The percentage increase in remuneration of each director, Chief Financial Officer, Chief Executive Officer, Company Secretary or Manager, if any, in the financial year.

(Amount in INR)

Name	Designation	Remuneration		Increase/ (Decrease) %
		FY 2020-21	FY 2019-20	
Srikanth Sasidhar M	Chief Financial Officer	2,19,642	-	-
Swapnil Sharvari Shinde	Company Secretary	95,250	-	-
Chandra Sekhar Tummala	Company Secretary	-	1,61,947	-

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

3. The percentage increase in the median remuneration of employees in the financial year

(Amount in INR)

Name	Remuneration		Increase/ (Decrease) %
	FY 2020-21	FY 2019-20	
Median Remuneration of all the employees per annum*	5,00,000	1,85,500	1:0.37

* Employees who have served for whole of the respective financial years have been considered.

4

Particulars	Number
The number of employees on the rolls of the company as on March 31, 2021	251

5. Average percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and details if there are any exceptional circumstances for increase in the managerial remuneration

Particulars	Increase/(Decrease) %
Average percentage increase in the remuneration of all Employees* (Other than Key Managerial Personnel)	15%
Average Percentage increase in the Remuneration of Key Managerial Personnel	-

*Employees who have served for whole of the respective financial years have been considered.

6. Affirmation that the remuneration is as per the remuneration policy of the company.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

ANNEXURE – VI (b)

Statement showing the names of the Top ten Employees in terms of Remuneration drawn as per Rule 5 (3) Of The Companies (Appointment And Remuneration Of Managerial Personnel) Rules, 2014

S No.	Name of the Employee	Designation of the employee	Remuneration received	Nature of employment whether contractual or otherwise	Qualification and experience of the employee	Date of commencement of employment	The age of employee	The last employment held by the employee within the Company	The percentage of equity shares held by the employee in the Company	Whether such employee is relatively to any of the managerial or director of the Company
1	Mr. Vasudev Sureddy	Vice President - Business Development	4,143,000	Permanent	M.Pharm & 18 years	01-Apr-14	42	Veeds CR Pvt Limited	-	NO
2	Mr. Y. K. Naidu	Senior General Manager - QA	3,172,000	Permanent	M.Pharm & 22 years	30-Oct-14	49	Azidus Laboratories	30,345	NO
3	Mr. Srigiri Sunil Kumar Namath	General Manager - Bioanalytical Research	2,596,000	Permanent	M.Sc. & 17 years	15-Oct-14	41	GVK Bio Sciences	-	YES
4	Mr. Srikanth Sasidhar M	Chief Financial Officer	1,800,000	Permanent	CA, ICWA & 7 years	16-Feb-21	34	Apex Frozen Foods Ltd	-	NO
5	Mr. Mulu P Kalyan Reddy	Deputy General Manager - Clinical Operations	1,745,000	Permanent	M.S. & 18 years	07-Feb-18	45	Axis Clinicals Pvt Ltd	-	NO
6	Mr. Gopi Krishna Komameni	Dy. General Manager - QA	1,672,000	Permanent	M.Pharm & 18 years	01-Feb-14	45	Novartis Health Care	-	NO
7	Dr. Sriharsa Rao Ramaraju	Senior Scientist	1,605,000	Permanent	BAMS, MD & 16 years	11-Apr-18	50	VLCC Personal Care Limited	-	NO
8	Dr. Suraj Kumar K	Senior Scientist	1,247,200	Permanent	MBBS & 4 years	03-Jul-20	45	Zenerise Research Pvt Limited	-	NO
9	Mr. R. Venkateswara Rao	Dy. General Manager - Finance & Accounts	1,044,000	Permanent	B.Com (CA) & 18 years	02-Dec-05	44	-	-	NO
10	Mr. Amarnath Reddy B	Senior Scientist	1,008,000	Permanent	M.Sc. & 16 years	16-Nov-15	40	GVK Bio Sciences	-	NO

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

INDEPENDENT AUDITOR'S REPORT

To the members of,

M/s. JEEVAN SCIENTIFIC TECHNOLOGY LIMITED,

Report on the Standalone Audit of Financial Statements:

Opinion

We have audited the accompanying standalone financial statements of M/s. JEEVAN SCIENTIFIC TECHNOLOGY LIMITED ("the Company"), which comprise the Balance Sheet as on 31st March, 2021, and the Statement of Profit and Loss (including other Comprehensive Income), statement of changes in equity and statement of cash flows for the year ended 31st March, 2021 and notes to the financial statements, including a summary of significant accounting policies and other explanatory information (hereinafter referred to as "the financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act 2013 (the "Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("IndAS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2021, the Profit and total comprehensive income, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined the matters described below as key audit matters to be communicated in our report.

Sl. No.	Key Audit Matter	Auditor's Response
1.	<p>Revenue Recognition</p> <p>Revenue is recognized to the extent that economic benefit will flow to the Company and the revenue can be reliably measured. It is measured at fair value consideration received or receivable, net of returns and allowances, discounts and rebates. The Company recognizes revenue when it satisfies its performance obligation by transferring the goods to the customers.</p> <p>Revenue is key driver of the business and judgment is involved in determining when contractual obligations have been performed and to the extent that the right to consideration has been earned.</p> <p>The management of the Company focuses on revenue as a key performance measure which could create an incentive for revenue to be recognized before the risks and rewards have been transferred. We therefore identified</p>	<p>Our audit work included, but was not restricted to:</p> <ul style="list-style-type: none">• We understood business revenue recognition policy and how they are applied, including the relevant controls, and tested controls over revenue recognition;• Analytical review of the revenue recognized over the year• Agreeing on a sample basis amounts of revenue to customer contracts and verifying the extent, timing and customer acceptance of goods, where relevant.• We performed cut-off testing for a sample of revenue transactions around the period end date, to check that they were recognized in the appropriate period;• We discussed key contractual arrangements with management and obtained relevant documentation, including in respect of rebate and returns arrangements.• The Company's accounting policy on Revenue recognition is shown in note XI to the financial statements and related disclosures are included in notes.• Based on our audit procedures we did not identify any evidence of material misstatement in the revenue recognized for the year ended 31st March 2021 in the standalone financial statements.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Information Other than the Standalone Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Financial Performance Highlights, Directors' Report including Annexures to Directors' Report, but does not include the standalone financial statements and our auditor's report thereon.

The other information as stated above not made available to us as of the date of signing of this report is expected to be made available to us after the date of this statutory auditor's report.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information when made available and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

When we read the other information, if we conclude that there is material misstatement therein, we are required to communicate the matter to those charged with governance.

Responsibilities of Management and Those Charged with Governance for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance, in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and

maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

adequate internal financial controls system in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2016 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the Annexure a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by Section 143(3) of the Act, we report that:
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books
 - c) The Balance Sheet, the Statement of Profit and Loss (including other comprehensive income), Statement of changes in equity and the Cash Flow Statement dealt with by this Report are in agreement with the books of accounts.
 - d) In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - e) On the basis of the written representations received from the directors as on 31st March, 2021 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2021 from being appointed as a director in terms of Section 164(2) of the Act.
 - f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure A".
 - g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- (i) The Company has no pending litigations which would impact its financial position.
- (ii) The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
- (iii) There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.

**For PAVULURI & Co.
Chartered Accountants
Firm Reg. No:012194S**

**Sd/-
(CA N. RAJESH)
PARTNER**

**Place : Hyderabad
Date : 23/06/2021.**

**M.No : 223169
UDIN #21223169AAAAEO7574**

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

“Annexure A” to the Independent Auditors’ Report

Referred to in paragraph 1 under the heading ‘Report on Other Legal & Regulatory Requirement’ of our report of even date to the Standalone financial statements of the Company for the year ended March 31, 2020:

- 1) (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets;
- (b) The Fixed Assets have been physically verified by the management in a phased manner, designed to cover all the items over a period of three years, which in our opinion, is reasonable having regard to the size of the company and nature of its business. Pursuant to the program, a portion of the fixed asset has been physically verified by the management during the year and no material discrepancies between the books records and the physical fixed assets have been noticed.
- (c) The title deeds of immovable properties are held in the name of the company.
- 2) (a) The management has conducted the physical verification of inventory at reasonable intervals.
- b) The discrepancies noticed on physical verification of the inventory as compared to books records which has been properly dealt with in the books of account were not material.
- 3) The Company has not granted any loans, secured or unsecured to companies, firms, Limited Liability partnerships or other parties covered in the Register maintained under section 189 of the Act. Accordingly, the provisions of clause 3 (iii) (a) to (c) of the Order are not applicable to the Company and hence not commented upon.
- 4) In our opinion and according to the information and explanations given to us, the company has complied with the provisions of section 185 and 186 of the Companies Act, 2013 in respect of loans, investments, guarantees, and security.
- 5) The Company has not accepted any deposits from the public and hence the directives issued by the Reserve Bank of India and the provisions of Sections 73 to 76 or any other relevant provisions of the Act and the Companies (Acceptance of Deposit) Rules, 2015 with regard to the deposits accepted from the public are not applicable.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- 6) As informed to us, the maintenance of Cost Records has not been specified by the Central Government under sub-section (1) of Section 148 of the Act, in respect of the activities carried on by the company.
- 7) (a) According to information and explanations given to us and on the basis of our examination of the books of account, and records, the Company has been generally regular in depositing undisputed statutory dues including Provident Fund, Employees State Insurance, Income-Tax, Sales tax, Service Tax, Duty of Customs, Duty of Excise, Value added Tax, Cess and any other statutory dues with the appropriate authorities though there has been slight delay in few cases.
- (b) According to the information and explanations given to us, the following are the disputed amounts payable relating to GST.

Name of the Statute	Nature of Dispute	Amount	Period to which the amount relates	Period to which the amount relates
Goods & Services Tax Act	Interest on GST	57,82,941/-	Various Years	Addl Commissioner GST- Rangareddy

- 8) In our opinion and according to the information and explanations given to us, the Company has not defaulted in the repayment of dues to banks.
- 9) Based upon the audit procedures performed and the information and explanations given by the management, the company has not raised moneys by way of initial public offer or further public offer including debt instruments and term Loans. Accordingly, the provisions of clause 3 (ix) of the Order are not applicable to the Company and hence not commented upon.
- 10) Based upon the audit procedures performed and the information and explanations given by the management, we report that no fraud by the Company or on the company by its officers or employees has been noticed or reported during the year.
- 11) Based upon the audit procedures performed and the information and explanations given by the management, the managerial remuneration has been paid or provided in accordance with the requisite approvals mandated by the provisions of section 197 read with Schedule V to the Companies Act;

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- 12) In our opinion, the Company is not a Nidhi Company. Therefore, the provisions of clause 4 (xii) of the Order are not applicable to the Company.
- 13) All transactions with the related parties are in compliance with sections 177 and 188 of the Companies Act, 2013 in so far as our examination of the proceedings of the meetings of the Audit Committee and Board of Directors are concerned. The details of related party transactions have been disclosed in the Standalone Ind AS Financial Statements as required by the applicable Accounting Standard.
- 14) The Company has not made any preferential allotment of shares during the year under review. The requirement specified under section 42 of the companies act 2013 has been complied.
- 15) Based upon the audit procedures performed and the information and explanations given by the management, the company has not entered into any non-cash transactions with directors or persons connected with him. Accordingly, the provisions of clause 3 (xv) of the Order are not applicable to the Company and hence not commented upon.
- 16) In our opinion, the company is not required to be registered under section 45 IA of the Reserve Bank of India Act, 1934 and accordingly, the provisions of clause 3 (xvi) of the Order are not applicable to the Company and hence not commented upon.

**For PAVULURI & Co.
Chartered Accountants
Firm Reg. No:012194S**

**Sd/-
(CA N. RAJESH)
PARTNER**

**M.No : 223169
UDIN #21223169AAAAE07574**

**Place : Hyderabad
Date : 23/06/2021.**

“Annexure B” to the Independent Auditor’s Report of even date on the Standalone Financial Statements of JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)

We have audited the internal financial controls over financial reporting of JEEVAN SCIENTIFIC TECHNOLOGY LIMITED (“the Company”) as of March 31, 2021 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management’s Responsibility for Internal Financial Controls

The Company’s management is responsible for establishing and maintaining internal financial controls based on “the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India”. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors’ Responsibility

Our responsibility is to express an opinion on the Company’s internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Standalone financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of Standalone financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of Standalone financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the Standalone financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2021, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

**For PAVULURI & Co.
Chartered Accountants
Firm Reg. No:012194S**

**Sd/-
(CA N. RAJESH)
PARTNER**

**M.No : 223169
UDIN #21223169AAAAEO7574**

**Place : Hyderabad
Date : 23/06/2021.**

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Stand alone Balance Sheet as at 31st Mar, 2021

(In Rupees)

Particulars	Note No.	As at 31.03.2021	As at 31.03.2020
Assets			
(1)Non-current Assets			
a) Property, Plant and Equipment	2	15,86,88,106	17,72,99,661
b) Other Intangible Assets	2	49,58,787	71,90,030
c) Intangible Assets Process Knowhow	2	4,16,42,037	5,23,61,147
d) Financial Assets			
i) Investments	3	1,02,69,070	1,02,69,070
ii) Loans	4	6,52,86,870	6,21,46,546
iii) Advances	5	4,13,00,902	3,69,09,796
c) Deferred tax asset (net)	6	60,61,921	1,57,38,838
(2)Current Assets			
a) Inventories	7	3,45,57,046	94,67,418
b) Financial Assets			
i) Trade receivables	8	12,45,84,286	6,00,11,297
ii) Cash and cash equivalents	9	2,72,84,585	1,82,59,938
iii) Bank balances other than (ii) above	10	2,95,63,173	5,63,173
iv) Loans & Advances (current)	11	51,10,498	70,87,171
v) Other Financial Assets	12	2,29,97,445	1,83,26,222
c) Current Tax Assets (Net)	13	4,59,52,303	4,14,85,587
d) Other Current Assets	14	1,95,09,389	1,16,36,078
Total		63,77,66,418	52,87,51,971
Equity and Liabilities			
Equity			
a) Equity Share Capital	A	15,30,14,650	15,30,14,650
b) Other Equity	B	20,94,73,657	9,62,82,842
Liabilities			
(1)Non-current Liabilities			
a) Financial liabilities			
Borrowings	15	7,76,99,329	7,90,27,246
b) Provisions	16	31,99,910	25,58,949
c) Deferred tax Liability (net)	6	0	0
(2)Current Liabilities			
a) Financial Liabilities			
i) Borrowings	17	5,06,177	7,36,50,912
ii) Trade Payables	18	2,63,58,431	2,45,73,412
iii) Other Financial liabilities	19	3,19,54,508	3,89,58,654
iv) Other Financial Creditors	20	70,42,253	2,08,57,086
b) Other current liabilities	21	11,11,59,011	3,66,75,179
c) Provisions	22	1,73,58,493	31,53,041
Total		63,77,66,419	52,87,51,971

Per our report of even Date
for PAVULURI & Co.
Chartered Accountants
Firm Regn No:012194S

for and on behalf of the Board of Directors
Jeevan Scientific Technology Limited

Sd/-
CA. N. Rajesh
Partner
Membership No:223169

Sd/-
K. Krishna Kishore
Vice Chairman & Managing Director
DIN: 00876539

Sd/-
M Snigdha
CEO & Executive Director
DIN: 08934860

Place: Hyderabad
Date: 23-06-2021

Sd/-
M Srikanth Sasidhar
Chief Financial Officer

Sd/-
Sharvari Swapnil Shinde
Company Secretary

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Statement of Stand alone Profit and Loss for the Year ended 31st March, 2021

(In Rupees)

Particulars	Note No.	For Year Ended 2020-21	For Year Ended 2019-20
Continuing Operations			
Income			
I. Revenue from operations	23	40,47,05,218	20,56,74,741
II. Other Income	24	1,84,73,981	1,56,30,385
III. Unbilled Revenue		53,00,000	95,80,000
III. Total revenue(I+II+III)		42,84,79,199	23,08,85,126
IV. Expenses			
Cost of Material consumed	25	2,74,54,611	1,56,89,057
Changes in Work in Progress	25	(2,10,30,000)	(70,40,000)
Employee benefit expenses	26	9,17,72,042	8,20,86,665
Finance costs	27	1,77,73,004	2,31,78,207
Depreciation	2	2,88,32,575	2,83,59,195
Amortisation on Process Knowhow	2	1,07,19,110	1,07,19,112
Other expenses	28	14,11,71,366	17,55,95,037
Total expenses		29,66,92,709	32,85,87,273
V. Profit/ (Loss) before tax (III)-(IV)		13,17,86,490	(9,77,02,147)
Tax expenses			
Current Tax		1,72,64,084	-
Less: Mat Credit (Entitlement) / utilization		(77,49,219)	-
Deferred Tax		96,76,917	(1,95,54,556)
Total tax expenses		1,91,91,782	(1,95,54,556)
Profit / (Loss) for the period from continuing operations		11,25,94,708	(7,81,47,592)
Profit / (Loss) from discontinuing operations			
Tax expense from discontinuing operations			
Profit / (Loss) from discontinuing operations (After tax)			
Profit / (loss) for the Period		11,25,94,708	(7,81,47,592)
Other Comprehensive Income			
A (i) Items that will not be reclassified to profit and loss Re-measurements of post-employment benefit obligations		5,96,107	(2,42,512)
(ii) Income tax relating to items that will not be reclassified to profit and loss			
B (i) Items that will be reclassified to profit and loss			
(ii) Income tax relating to items that will be reclassified to profit and loss			
Total Comprehensive Income		11,31,90,815	(7,83,90,104)
Earning per equity share			
(Face value of Rs.10/- each)			
Basic		7.40	(5.12)
Diluted		7.40	(5.12)

Per our report of even Date
for PAVULURI & Co.
Chartered Accountants
Firm Regn No:012194S

Sd/-
CA. N. Rajesh
Partner
Membership No:223169

Place: Hyderabad
Date: 23-06-2021

for and on behalf of the Board of Directors
Jeevan Scientific Technology Limited

Sd/-
K. Krishna Kishore
Vice Chairman & Managing Director
DIN: 00876539

Sd/-
M Srikanth Sasidhar
Chief Financial Officer

Sd/-
M Snigdha
CEO & Executive Director
DIN: 08934860

Sd/-
Sharvari Swapnil Shinde
Company Secretary

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Stand alone Cash flow statement for the Year ended 31st Mar, 2021

(In Rupees)

S.No	Particulars	As at 31.03.2021	As at 31.03.2020
A.	Cash flow from operating activities		
	Net Profit before tax and extraordinary items	13,17,86,490	-9,77,02,147
	Adjustments for:		
	Depreciation	3,95,51,686	3,90,78,307
	Other Comprehensive Income	5,96,107	-2,42,512
	Loss on Sale of Assets	0	3,06,407
	Interest	1,71,85,601	2,26,80,631
	Operating profit before working capital changes	18,91,19,883	-3,58,79,314
	Changes in Working Capital		
	Inventories	-2,50,89,628	-71,63,379
	Trade and other receivables	-8,71,38,996	5,53,58,815
	Trade and other Paybles	-68,28,467	2,11,39,122
	Cash generated from operations before Tax	8,37,19,726	-88,23,000
	Tax Provision	1,91,91,782	-1,95,54,556
	Proposed Dividend	0	0
	Interest paid	1,71,85,601	2,26,80,631
	Net cash from operating activity	4,73,42,343	-1,19,49,076
B.	Cash flow from investing activities		
	Purchase of fixed assets	79,89,778	1,10,09,324
	Investments	0	0
	Sale/ Transfer of fixed assets	0	8,50,676
	Net cash used in investing activity	-79,89,778	-1,01,58,648
C.	Cash flow from financing activity		
	Proceeds from loans	-13,27,917	43,72,256
	Increase in Capital	0	0
	Increase in Other Equity	0	0
	Net cash generated in financing activity	-13,27,917	43,72,256
	Net increase in cash and cash equivalents (A+B+C)	3,80,24,648	-1,77,35,468
	Cash and cash equivalents as at 31.03.2020	1,88,23,111	3,65,58,579
	Cash and cash equivalents as at 31.03.2021	5,68,47,758	1,88,23,111

Per our report of even Date
for PAVULURI & Co.
Chartered Accountants
Firm Regn No:012194S

Sd/-
CA. N. Rajesh
Partner
Membership No:223169

Place: Hyderabad
Date: 23-06-2021

for and on behalf of the Board of Directors
Jeevan Scientific Technology Limited

Sd/-
K. Krishna Kishore
Vice Chairman & Managing Director
DIN: 00876539

Sd/-
M Srikanth Sasidhar
Chief Financial Officer

Sd/-
M Snigdha
CEO & Executive Director
DIN: 08934860

Sd/-
Sharvari Swapnil Shinde
Company Secretary

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

STATEMENT OF CHANGES IN EQUITY

Jeevan Scientific Technology Limited
Statement of changes in Equity for the Period ended 31st Mar, 2021

	As at 31.03.2021	As at 31.03.2020
A. Equity Share Capital		
Authorised		
2,10,00,000 equity Shares of Rs. 10/- each	2,10,00,000	21,00,00,000
Issued, subscribed and paid-up		
1,53,07,465 (31st Mar, 2021) / 53,07,465(31st Mar, 2020) equity Shares of Rs. 10/- each fully paid-up	15,30,74,650	15,30,74,650
Issued, subscribed and paid-up		
Opening Balance	15,30,74,650	15,30,74,650
Add: issue of shares during the year	60	60
Total	15,30,74,650	15,30,74,650

The details of shares in the company held by each shareholder holding more than 5% shares :

Name of the Share holder	31-03-2021		31-03-2020	
	Number of Shares	% of Share Holding	Number of Shares	% of Share Holding
Sri K. Krishna Kishore	22,01,391	14.39%	22,01,391	14.39%
Smt. K. Vanaja	16,73,800	10.29%	16,73,800	10.29%
Dr. Shashi Prasad	8,97,600	5.86%	8,97,600	5.86%
Dr. Dipakant Prasad	8,97,200	5.86%	8,97,200	5.86%

B. Other Equity

Particulars	Share application money on pending allotment	Equity component of compound financial instruments	Capital Reserve	Reserves and Surplus			Money received against share warrants	Total
				Securities premium reserve	Shares forfeited reserves	Retained Earnings		
Balance at the beginning of the reporting period i.e. 1st April 2019				18,75,12,286	20,16,541	-1,48,57,111	1,250	17,46,72,946
Changes in accounting policy or error period errors								
Retained balance at the beginning of the reporting period				18,75,12,286	20,16,541	-1,48,57,111	1,250	17,46,72,946
Other comprehensive income for the year						-7,83,90,108		-7,83,90,108
Transfer to retained earnings								
Adjusted during the Year				0	0	0	0	0
Balance at the end of the reporting period i.e. 31st March 2020				18,75,12,286	20,16,541	-9,32,47,215	1,250	9,62,82,842
Particulars								
Balance at the beginning of the reporting period i.e. 1st April 2020				18,75,12,286	20,16,541	-9,32,47,215	1,250	9,62,82,842
Changes in accounting policy or error period errors								
Retained balance at the beginning of the reporting period				18,75,12,286	20,16,541	-9,32,47,215	1,250	9,62,82,842
Total comprehensive income for the year						11,31,90,815		11,31,90,815
Transfer to retained earnings								
Adjusted during the Year				0	0	0	0	0
Balance at the end of the reporting period i.e. 31st Mar 2021				18,75,12,286	20,16,541	1,99,43,800	1,250	20,94,73,877

Significant Accounting Policies and Notes on Accounts

Company Information

The Company was incorporated on 2nd February, 1999 to carry on the business Clinical research, Data management services.

1. Significant Accounting Policies

1.1 Basis of Preparation

a) Statement of Compliance

The standalone financial statements have been prepared in accordance with Indian Accounting Standards ("Ind AS") notified under the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016 and other relevant provisions of the Act.

b) Basis of measurement

The standalone financial statements have been prepared on a historical cost convention and on an accrual basis, except for the following material items that have been measured at fair value as required by relevant Ind AS:

- i. Certain financial assets and liabilities measured at fair value (refer accounting policy on financial instruments);
- ii. Defined benefit and other long-term employee benefits.

c) Functional and presentation currency

The standalone financial statements are presented in Indian rupees, which is the functional currency of the Company and the currency of the primary economic environment in which the entity operates. All financial information presented in Indian rupees.

d) Use of estimates and judgment

The preparation of standalone financial statements in conformity with Ind AS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Estimates and underlying assumptions are reviewed on a periodic basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

1.2 Summary of significant accounting policies

i. Functional and presentation currency

Items included in the financial statements of the Company are measured using the currency of the primary economic environment in which these entities operate (i.e. the "functional currency"). The standalone financial statements are presented in Indian Rupee, the national currency of India, which is the functional currency of the Company.

ii. Foreign currency transactions and balances

Transactions in foreign currency are translated into the respective functional currencies using the exchange rates prevailing at the dates of the respective transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at the exchange rates prevailing at reporting date of monetary assets and liabilities denominated in foreign currencies are recognized in the statement of profit and loss and reported within foreign exchange gains / (losses).

Non-monetary assets and liabilities denominated in a foreign currency and measured at historical cost are translated at the exchange rate prevalent at the date of transaction.

iii. Investment in subsidiaries

Investment in subsidiaries is measured at cost. Dividend income from subsidiaries is recognized when its right to receive the dividend is established.

iv. Financial instruments

All financial instruments are recognized initially at fair value. Transaction costs that are attributable to the acquisition of the financial asset (other than financial assets recorded at fair value through profit or loss) are included in the fair value of the financial assets. Purchase or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trade) are recognized on trade date. While, loans and borrowings and payable are recognized net of directly attributable transactions costs.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

For the purpose of subsequent measurement, financial instruments of the Company are classified in the following categories: non-derivative financial assets comprising amortized cost; non derivative financial liabilities at amortized cost.

The classification of financial instruments depends on the objective of the business model for which it is held. Management determines the classification of its financial instruments at initial recognition.

Financial instrument is derecognized only when the Company has transferred its right to receive/ extinguish its obligation to pay cash flow from such financial instruments.

a) **Non-derivative financial assets**

Financial assets at amortized cost

A financial asset shall be measured at amortized cost if both of the following conditions are met:

- the financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flows and
- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

They are presented as current assets, except for those maturing later than 12 months after the reporting date which are presented as non-current assets. Financial assets are measured initially at fair value plus transaction costs and subsequently carried at amortized cost using the effective interest method, less any impairment loss.

Amortized cost is represented by security deposits, cash and cash equivalents, employee and other advances and eligible current and non-current assets.

Cash and cash equivalents comprise cash on hand and in banks and demand deposits with banks which can be withdrawn at any time without prior notice or penalty on the principal.

For the purposes of the cash flow statement, cash and cash equivalents include cash on hand, in banks and demand deposits with banks, net of outstanding bank overdrafts that are repayable on demand and are considered part of the Company's cash management system.

b) Non-derivative financial liabilities

Financial liabilities at amortized cost

Financial liabilities at amortized cost represented by trade and other payables are initially recognized at fair value, and subsequently carried at amortized cost using the effective interest method.

v. Property plant and equipment:

Recognition and measurement: Normally Property, plant and equipment are measured at cost less accumulated depreciation and impairment losses, if any. Cost includes expenditures directly attributable to the acquisition of the asset. The Company has elected to apply the optional exemption to use this previous GAAP value as deemed cost at 1 April 2015, the date of transition.

Depreciation: Normally the Company depreciates property, plant and equipment over the estimated useful life of the assets as prescribed in Schedule II of the Companies Act 2013 on a straight-line basis from the date the assets are ready for intended use. Wherever the useful life is determined by technical assessment for certain assets, such assets are depreciated as per their assessed life. Assets acquired under finance lease and leasehold improvements are amortized over the lower of estimated useful life and related term. Depreciation methods, useful lives and residual values are reviewed at each reporting date.

When parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment. Subsequent expenditure relating to property, plant and equipment is capitalized only when it is probable that future economic benefits associated with these will flow to the Company and the cost of the item can be measured reliably. Repairs and maintenance costs are recognized in the statement of profit and loss when incurred. The cost and related accumulated depreciation are eliminated from the standalone financial statements upon sale or disposition of the asset and the resultant gains or losses are recognized in the statement of profit and loss.

The management estimates the useful lives for the following class of assets, based on internal assessment and independent technical evaluation carried out by external valuers, the management believes that useful lives as given below best represents the period over which the management expects to use these assets. Hence the useful lives for these assets is different from the useful lives as prescribed under Part - C of schedule II of the companies act 2013.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Plant and machinery	21 years
Electrical Installations	21 years
Computers	6 years
Vehicles- Motor car	10 years
Furniture and Fixtures	15 years
Office Equipment	21 years

Fixed Assets costing Rs.5,000/- or less are fully depreciated in the year of purchase

vi. Intangible assets

Intangible assets are stated at cost less accumulated amortization and impairment. Intangible assets are amortized over their respective estimated useful lives on a straight-line basis, from the date that they are available for use. The estimated useful life of an identifiable intangible asset is based on a number of factors including the effects of obsolescence, demand, competition and other economic factors (such as the stability of the industry and known technological advances) and the level of maintenance expenditures required to obtain the expected future cash flows from the asset.

Policy for accounting of expenses of Research & Development:

Clinical Research is a specified job and the ready availability of newly developed methods for BA / BE Analysis of drug samples is required to get the business from various Pharmaceutical Clients. JSTL has been in the process of developing process and new methods. Equipment, Machines, Manpower and consumables are used for development of new methods.

Investment in development method is calculated on the basis of proportionate of time spent by manpower, machines and also consumable for developing that particular method and the relative expenditure is capitalized as intangible asset. Each method will be of useful for a minimum period of 10-12 years. It is also decided by the Board that the amortization of the investment in process for developing methods should take place in a period 7 years from the date of the method put to use on quarterly basis in straight line method.

vii. Inventory

- a) Raw materials, Stores and Consumables, work in process and finished products are valued at lower of cost and net realizable value of the respective units.
- b) The basis of determining the cost is
- | | | |
|------------------------|---|-----------------------|
| Raw materials | : | Weighted average cost |
| Stores and Consumables | : | Weighted average cost |
- Work in process and finished goods :valued at lower of cost and net realizable value
- c) In case of identified Obsolete/Surplus/Non-moving items necessary provision is made and charged to revenue.

viii. Impairment

a) Financial assets

In accordance with Ind AS 109, the Company applies expected credit loss (ECL) model for measurement and recognition of impairment loss.

- i. The Company follows 'simplified approach' for recognition of impairment loss allowance on trade receivable.

The application of simplified approach does not require the Company to track changes in credit risk. Rather, it recognizes impairment loss allowance based on lifetime ECLs at each reporting date, right from its initial recognition.

For recognition of impairment loss on other financial assets and risk exposure, the Company determines that whether there has been a significant increase in the credit risk since initial recognition. If credit risk has not increased significantly, 12-month ECL is used to provide for impairment loss. However, if credit risk has increased significantly, lifetime ECL is used. If in subsequent period, credit quality of the instrument improves such that there is no longer a significant increase in credit risk since initial recognition, then the entity reverts to recognizing impairment loss allowance based on 12 month ECL.

Lifetime ECLs are the expected credit losses resulting from all possible default events over the expected life of a financial instrument. The 12 month ECL is a portion of the lifetime ECL which results from default

events that are possible within 12 months after the reporting date.

ECL is the difference between all contractual cash flows that are due to the Company in accordance with the contract and all the cash flows that the entity expects to receive (i.e. all shortfalls), discounted at the original EIR. When estimating the cash flows, an entity is required to consider:

- ii. All contractual terms of the financial instrument (including prepayment, extension etc.) over the expected life of the financial instrument. However, in rare cases when the expected life of the financial instrument cannot be estimated reliably, then the entity is required to use the remaining contractual term of the financial instrument.
- iii. Cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

ECL impairment loss allowance (or reversal) recognized during the period is recognized as income/ expense in the statement of profit and loss. The balance sheet presentation for various financial instruments is described below:

Financial assets measured at amortized cost, contractual revenue receivable: ECL is presented as an allowance, i.e. as an integral part of the measurement of those assets in the balance sheet. The allowance reduces the net carrying amount. Until the asset meets write off criteria, the Company does not reduce impairment allowance from the gross carrying amount.

b) Non-financial assets

The Company assesses at each reporting date whether there is any objective evidence that a non financial asset or a group of non financial assets is impaired. If any such indication exists, the Company estimates the amount of impairment loss.

An impairment loss is calculated as the difference between an asset's carrying amount and recoverable amount. Losses are recognized in profit or loss and reflected in an allowance account. When the Company considers that there are no realistic prospects of recovery of the asset, the relevant amounts are written off. If the amount of impairment loss subsequently decreases and the decrease can be related objectively to an event occurring after the impairment was recognized, then the previously recognized impairment loss is reversed through profit or loss.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

The recoverable amount of an asset or cash-generating unit (as defined below) is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the "cash-generating unit").

ix. Employee benefits

a) Gratuity & Provident Fund:

The Company's liability towards retirement benefits in the form of gratuity is provided in accordance with the payment of Gratuity Act, 1972 to all the employees other than the whole time Directors which is made on the basis of actuarial valuation.

- b) The Company's contribution to the provident fund is remitted to Government based on the percentage of the eligible employees' salary as per Provident Fund act.
- c) **Accrued Leave Salary:**

Liability towards Accrued Leave Salary, as at the end of the year is recognized on the basis of valuation made on basic salary. The balance PL's earned by every employee in the previous year, a maximum of 8 days will be paid out during the month of January. These 8 days will be paid as per the last drawn basic salary and taxes will be applicable as per law

x. Provisions

All the provision are recognized as per Ind AS 37. Provisions are recognized when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation.

The amount recognized as a provision is the best estimate of the consideration required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligation.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, the receivable is recognized as an asset, if it is virtually certain that reimbursement will be received and the amount of the receivable can be measured reliably.

Provisions for onerous contracts are recognized when the expected benefits to be derived by the Company from a contract are lower than the unavoidable costs of meeting the future obligations under the contract. Provisions for onerous contracts are measured at the present value of lower of the expected net cost of fulfilling the contract and the expected cost of terminating the contract.

xi. Revenue recognition:

Ind AS 115 recognizes revenue on transfer of the control of goods or services, either over a period of time or at a point in time, at an amount that the entity expects to be entitled in exchange for those goods or services. In order to align with Ind AS 115, the Accounting policy on revenue recognition was reviewed and revised.

xii. Finance income and expense

Finance income consists of interest income on funds invested, dividend income and gains on the disposal of Fair value through profit and loss account financial assets. Interest income is recognized as it accrues in the statement of profit and loss, using the effective interest method.

Dividend income is recognized in the statement of profit and loss on the date that the Company's right to receive payment is established.

Finance expenses consist of interest expense on loans and borrowings. Borrowing costs are recognized in the statement of profit and loss using the effective interest method.

Foreign currency gains and losses are reported on a net basis. This includes changes in the fair value of foreign exchange derivative instruments, which are accounted at fair value through profit or loss.

xiii. Income tax

Income tax comprises current and deferred tax. Income tax expense is recognized in the statement of profit and loss except to the extent it relates to items directly recognized in equity or in other comprehensive income.

a) Current income tax

Current income tax for the current and prior periods are measured at the amount expected to be recovered from or paid to the taxation authorities based on the taxable income for the period. The tax rates and tax laws used to compute the current tax amount are those that are enacted or substantively enacted by the reporting date and applicable for the period. The Company offsets current tax assets and current tax liabilities, where it has a legally enforceable right to set off the recognized amounts and where it intends either to settle on a net basis or to realize the asset and liability simultaneously.

b) MAT credit

Minimum Alternate Tax (MAT) credit is recognized as an asset only when and to the extent there is convincing evidence that the Company will pay normal income tax during the specified period. In the year in which the MAT credit becomes eligible to be recognized as an asset, in accordance with the provisions contained in the Guidance Note on Accounting for Credit Available under Minimum Alternative Tax, issued by the ICAI, the said asset is created by way of a credit to the Profit and Loss account and shown as "MAT Credit Entitlement". The Company reviews the same at each Balance Sheet date and writes down the carrying amount of MAT Credit Entitlement to the extent there is no longer convincing evidence to the effect that the Company will pay normal income tax during the specified period.

c) Deferred income tax

Deferred income tax is recognized using the balance sheet approach. Deferred income tax assets and liabilities are recognized for deductible and taxable temporary differences arising between the tax base of assets and liabilities and their carrying amount in financial statements, except when the deferred income tax arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and affects neither accounting nor taxable profits or loss at the time of the transaction. Deferred income tax asset are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilized. Deferred income tax liabilities are recognized for all taxable temporary differences. The carrying amount of deferred income tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilized. Deferred income tax

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

assets and liabilities are measured at the tax rates that are expected to apply in the period when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

xiv. Foreign currency transaction

i. Initial recognition

Foreign currency transactions are recorded in the reporting currency, by applying to the foreign currency amount the exchange rate between the reporting currency and the foreign currency at the date of the transaction.

ii. Conversion

Foreign currency monetary items denominated in foreign currencies at the yearend are restated at year end rates. In case of monetary items which are covered by foreign exchange contracts, the difference between the original entry dates to forward contract date is recognized as an exchange difference.

iii. Exchange differences

Exchange differences arising on the settlement of monetary items, or on reporting such monetary items of company at rates different from those at which they were initially recorded during the year, or reported in previous financial statements, are recognized as income or as expenses in the year in which they arise.

iv. Foreign currency Transactions.

Particulars	Current Year	Previous Year
Earnings in Foreign exchange	943.94	893.23
Expenditure in Foreign exchange	NIL	NIL

xv. Earnings per share

Basic earnings per share is computed using the weighted average number of equity shares outstanding during the year.

Diluted EPS is computed by dividing the net profit after tax by the weighted average number of equity shares considered for deriving basic EPS and also weighted average number of equity shares that could have been issued upon conversion of all dilutive potential equity shares.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Dilutive potential equity shares are deemed converted as of the beginning of the year, unless issued at a later date. Dilutive potential equity shares are determined independently for each year presented. The number of equity shares and potentially dilutive equity shares are adjusted for bonus shares, as appropriate.

xvi. Borrowing costs

Borrowings costs directly attributable to acquisition or construction of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the asset. All other borrowing costs are expensed in the period in which it occurs. Borrowing costs consist of interest and other costs that the entity incurs in connection with the borrowing of funds.

xvii. Ind AS 116 Leases:

Ministry of Corporate Affairs has notified 'The Companies (Indian Accounting Standards) Amendment Rules, 2019 dated March 30, 2019 which inter alia includes the new standard on Leases Ind AS 116 replacing the existing standard Ind AS 17, to be effective from the 1st April 2019. The Company has used the Modified Retrospective Approach for transitioning to Ind AS 116. There is no significant impact on the financials after implementation of this standard.

xviii. Contingent liabilities

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence of non-occurrence of one or more uncertain future events beyond the control of the company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably. The company does not recognize a contingent liability but discloses its existence in the financial statements.

The contingent liability is Rs. 4.13 Lakhs during the financial year.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

2. Property, plant and equipment											
S No	Description	Gross Block				Depreciation				NET BLOCK	
		As at 01.04.2020	Additions	Deletions	As at 31.03.2021	Up to 01.04.2020	Deletions	For the year	Up to 31.03.2021	As at 31.03.2021	As at 31.03.2020
1	LEASE HOLD BUILDINGS	81,65,864	0	0	81,65,864	81,65,864	0	0	81,65,864	0	0
2	PLANT & MACHINERY	162,59,803	2,94,005	0	165,53,808	75,40,238	16,52,812	91,93,050	93,60,758	107,19,565	107,19,565
	a. Electrical Installations	11,94,942			11,94,942	10,37,517	56,760	10,94,277	1,00,665	1,57,425	1,57,425
	b. Airconditioners	10,48,582			10,48,582	9,82,170	49,808	10,31,978	16,604	66,412	66,412
	c. U.P.S. Systems	2,75,203			2,75,203	2,14,878	13,072	2,27,950	47,293	60,325	60,325
	d. Inverter	207,78,530	2,94,005	0	210,72,535	97,74,803	0	17,72,452	115,47,655	95,25,280	110,03,727
3	COMPUTERS	201,91,632	17,12,377	0	219,04,009	165,87,444	20,50,188	186,37,632	32,66,377	36,04,188	36,04,188
	a. Computers	201,91,632	17,12,377	0	219,04,009	165,87,444	0	20,50,188	186,37,632	32,66,377	36,04,188
4	VEHICLES	168,88,280	0	0	168,88,280	42,71,936	18,58,400	61,30,336	107,57,945	126,16,344	126,16,344
	a. Motor Car	2,25,910			2,25,910	1,07,588	17,089	1,24,887	1,01,223	1,19,222	1,19,222
	b. Scooter	171,14,190	0	0	171,14,190	43,79,524	18,75,499	62,55,023	108,59,167	127,34,696	127,34,696
5	FURNITURE & FIXTURES	296,82,334	9,18,475	0	306,00,809	147,07,289	22,18,926	169,26,215	136,74,594	149,75,045	149,75,045
	a. Furniture	9,88,151			9,88,151	8,88,151	0	9,88,151	0	0	0
	b. Fixtures	306,70,485	9,18,475	0	315,88,960	156,95,440	22,18,926	179,14,386	136,74,594	149,75,045	149,75,045
6	OFFICE & LABORATORY EQUIPMENT	33,91,920	3,18,713	0	37,10,633	13,72,202	5,55,665	19,27,867	17,82,766	20,19,718	20,19,718
	a. Office Equipments	1838,59,411	42,46,208	0	1881,05,619	509,95,298	176,06,542	686,01,840	1195,03,779	1328,64,113	1328,64,113
	b. Laboratory Equipments	4,60,323			4,60,323	3,62,314	21,865	3,84,179	76,144	98,009	98,009
	c. E.P.A.B.X & Telephones	15,100			15,100	14,905	195	15,100	0	195	195
	d. Fax Machine	3,66,841			3,66,841	3,66,841	0	3,66,841	0	0	0
	e. Projector with LCD Panel	1880,93,595	45,64,921	0	1926,58,516	531,11,560	181,84,268	712,95,928	1213,62,688	1349,92,035	1349,92,035
7	LIBRARY:	89,983	0	0	89,983	89,983	0	89,983	0	0	0
	a. Books	89,983	0	0	89,983	89,983	0	89,983	0	0	0
	Total:	2851,04,279	74,89,778	0	2925,94,057	1078,04,618	261,01,333	1339,05,951	1586,88,106	1772,99,661	1772,99,661

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

II. Intangible Assets (in Rupees)												
S.No	Description	Gross Block				Depreciation				NET BLOCK		
		As at 01.04.2020	Additions	Deletions	As at 31.03.2021	Up to 01.04.2020	Deletions	For the year	Up to 31.03.2021	As at 31.03.2021	As at 31.03.2020	
1	COMPUTERS											
	Software	168,05,208	5,00,000		163,05,208	86,15,178	27,31,243	113,46,421	49,58,787	71,90,030		
		168,05,208	5,00,000	0	163,05,208	86,15,178	0	113,46,421	49,58,787	71,90,030		
2	COPYRIGHTS	12,04,000			12,04,000			12,04,000	0	0		
	Total:	170,09,208	5,00,000	0	175,09,208	98,19,178	0	125,50,421	49,58,787	71,90,030		

III. Intangible Assets Process Knowhow (in Rupees)												
S.No	Description	Gross Block				Depreciation				NET BLOCK		
		As at 01.04.2020	Additions	Deletions	As at 31.03.2021	Up to 01.04.2020	Deletions	For the year	Up to 31.03.2021	As at 31.03.2021	As at 31.03.2020	
1	Process Knowhow	750,33,772			750,33,772	226,72,625	107,19,110	333,91,735	416,42,037	523,61,147		
	Total:	750,33,772	0	0	750,33,772	226,72,625	0	333,91,735	416,42,037	523,61,147		

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Notes to financial statements for the Year ended 31st Mar, 2021

3. Non Current Investments

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Enhops Solutions Inc.	2,69,070	2,69,070
Enhops Solutions Pvt Ltd	1,00,00,000	1,00,00,000
Total	1,02,69,070	1,02,69,070

4. Long term Loans

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
i) Loans to Subsidiaries	6,52,86,870	6,21,46,546
Total	6,52,86,870	6,21,46,546

5. Advances

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
i) Capital Advances	3,65,00,000	3,25,00,000
ii) Security Deposit	48,00,902	44,09,796
iii) Other Advances	0	0
Total	4,13,00,902	3,69,09,796

6. Deferred Tax (Net)

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Deferred Tax Asset / (Liability) Opening	1,57,38,838	-38,15,718
Add/Less: Deferred Tax Asset / (Liability)	-96,76,917	1,95,54,556
Total	60,61,921	1,57,38,838

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

7. Inventories

PARTICULARS	As at	As at
	March 31, 2021	March 31, 2020
	Amount in Rs.	Amount in Rs.
Work in progress point of sale boxes	-	2,10,240
Consumables - R & D	64,87,046	22,17,178
Closing Work in Progress	2,80,70,000	70,40,000
Total	3,45,57,046	94,67,418

8. Trade receivables (Unsecured)

PARTICULARS	As at	As at
	March 31, 2021	March 31, 2020
	Amount in Rs.	Amount in Rs.
Debtors outstanding for more than Six months	-	-
Considered good	16,27,502	29,56,142
Doubtful debts	-	7,36,42,646
Other debts for less than six months		
Considered good	12,29,56,784	5,70,55,155
	12,45,84,286	13,36,53,943
Less: Bad Debts Written off	-	7,36,42,646
Total	12,45,84,286	6,00,11,297

9. Cash and Cash Equivalents

PARTICULARS	As at	As at
	March 31, 2021	March 31, 2020
	Amount in Rs.	Amount in Rs.
Cash and cash equivalents Balances with Banks	-	-
in current accounts	4,02,751	1,05,841
cash on hand	2,68,81,834	1,81,54,097
Total	2,72,84,585	1,82,59,938

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

10. Cash and Cash Equivalents

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Bank balances other than in fixed deposits more than 12 months	-	-
in fixed deposits Less than 12 months	5,63,173	5,63,173
	2,90,00,000	-
Total	2,95,63,173	5,63,173

11. Loans & Advances (current)

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Advances Given	51,10,498	70,87,171
Total	51,10,498	70,87,171

12. Other Financial Assets

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Interest Receivable	1,78,13,445	1,44,38,222
Rent Receivable	51,84,000	38,88,000
Total	2,29,97,445	1,83,26,222

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

13. Current Tax Assets (Net)

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Tax deducted at source	2,79,39,520	3,12,22,023
MAT Credit	1,80,12,783	1,02,63,564
Total	4,59,52,303	4,14,85,587

14. Other Current Assets

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Prepaid Expenses	37,17,155	13,31,233
Magma Finance	80,029	47,084
Tata Capital Finance	29,179	18,154
Hero Finance corporation	8,03,026	6,59,607
Unbilled Revenue	1,48,80,000	95,80,000
Total	1,95,09,389	1,16,36,078

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

15. Long term borrowings

PARTICULARS	Non Current portion		Current portion	
	As at 31.03.2021	As at 31.03.2020	As at 31.03.2021	As at 31.03.2020
Term Loan- secured	-	-	-	-
A) From Banks	-	-	-	-
i) Car Loans- Hypothecation against the Cars	25,48,255	33,49,847	20,79,417	40,64,496
ii) Machinery loans	4,86,51,074	6,31,74,282	2,24,76,153	1,86,72,997
iii) Business Loan	2,50,00,000	4,53,117	6,94,024	40,81,436
B) Intercorporate Loans	15,00,000	40,00,000	-	-
C) Loans and advances from related parties	-	80,50,000	-	-
Total	7,76,99,329	7,90,27,246	2,52,49,594	2,68,18,929

16. Long Term Provisions

PARTICULARS	As at	As at
	March 31, 2021	March 31, 2020
	Amount in Rs.	Amount in Rs.
Gratuity Payable	31,99,910	25,58,949
Total	31,99,910	25,58,949

17. Short Term Borrowings

PARTICULARS	As at	As at
	March 31, 2021	March 31, 2020
	Amount in Rs.	Amount in Rs.
Loan repayable on Demand	-	-
i) Loan From Banks (Guaranteed by Director)	5,06,177	7,36,50,912
Total	5,06,177	7,36,50,912

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

18. Trade Payables

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Trade payables (for services received)	2,63,58,431	2,45,73,412
Total	2,63,58,431	2,45,73,412

19. Other Financial liabilities

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Current maturities of Long term borrowings	2,52,49,594	2,68,18,929
Interest Payable	60,14,181	77,58,482
Rent Payable	6,90,733	43,81,243
Total	3,19,54,508	3,89,58,654

20. Other Financial Creditors

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Creditors for Capital Assets	70,42,253	2,08,57,086
Total	70,42,253	2,08,57,086

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

21. Other Current Liabilities

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
TDS Payable	25,34,537	47,75,228
Professional tax payable	34,550	19,600
GST Payable	53,89,405	22,22,965
Provident Fund payable	5,24,396	3,91,044
ESI payable	86,852	71,450
Salaries payable	65,65,567	52,61,378
Directors Remuneration Payable	5,96,500	34,33,739
Provision for expenses	83,120	3,23,696
Advance received from Customers	33,65,130	43,73,227
Prepaid Revenue	9,06,19,594	1,57,00,000
Other Payables	13,59,360	1,02,852
Total	11,11,59,011	3,66,75,179

22. Short Term Provisions

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Leave Encashment Payable	8,480	8,480
Bonus Payable	-	30,79,465
Provision for Income Tax	1,72,64,084	-
Gratuity Payable	85,929	65,096
Total	1,73,58,493	31,53,041

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

23. Revenue from operations

PARTICULARS	For Year Ended 2020-21	For Year Ended 2019-20
	Amount in Rs.	Amount in Rs.
Clinical Research Services- Domestic	31,03,10,232	11,63,51,831
Clinical Research Services- Export	9,43,94,986	8,93,22,910
Total	40,47,05,218	20,56,74,741

24. Other non operating income

PARTICULARS	For Year Ended 2020-21	For Year Ended 2019-20
	Amount in Rs.	Amount in Rs.
Interest on Income Tax Refund	15,80,080	13,41,840
Interest Received from Others	37,50,248	66,96,421
Miscellaneous Income	29,29,820	19,82,545
Profit on sale of Motor Car	-	49,324
Forex Gain	(2,17,385)	7,75,914
Creditors written Off	-	35,84,341
Rent Received	12,00,000	12,00,000
Pass Through & Storage Charges	92,31,218	-
Total	1,84,73,981	1,56,30,385

25. Cost of Material Consumed

PARTICULARS	For Year Ended 2020-21	For Year Ended 2019-20
	Amount in Rs.	Amount in Rs.
Hardware	-	-
Opening Stock	2,10,240	2,10,240
Purchases: Components & Software	-	-
	2,10,240	2,10,240
Less: Closing Stock		2,10,240
Total (A)	2,10,240.00	-

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Consumables - R & D

PARTICULARS	For Year Ended 2020-21	For Year Ended 2019-20
	Amount in Rs.	Amount in Rs.
Opening Stock	22,17,178	20,93,799
Purchases: Consumables	3,15,14,240	1,58,12,436
	3,37,31,418	1,79,06,235
Less: Closing Stock	64,87,046	22,17,178
Less: Transfer to Process Knowhow	0	0
Total (B)	2,72,44,371	1,56,89,057
Total (A+B)	2,74,54,611	1,56,89,057

Changes in WIP

PARTICULARS	For Year Ended 2020-21	For Year Ended 2019-20
	Amount in Rs.	Amount in Rs.
Opening WIP	70,40,000	0
Closing WIP	2,80,70,000	70,40,000
Total	-2,10,30,000	-70,40,000

26. Employees benefit expenses

PARTICULARS	For Year Ended 2020-21	For Year Ended 2019-20
	Amount in Rs.	Amount in Rs.
Salaries & Allowances	7,16,42,811	6,37,69,311
Contribution to Provident Fund & Others	31,94,657	30,43,001
Staff Welfare Expenses	24,09,706	16,75,935
Gratuity	11,62,963	10,52,060
Bonus	13,45,735	16,12,514
Leave encashment	2,16,170	1,33,844
Director's Remuneration	1,18,00,000	1,08,00,000
Total	9,17,72,042	8,20,86,665

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

27. Finance Cost

PARTICULARS	For Year Ended 2020-21	For Year Ended 2019-20
	Amount in Rs.	Amount in Rs.
Bank charges	1,71,465	85,728
Loan Processing Charges	4,15,938	4,11,848
Interest expense	-	-
on Vehicle Loans	5,46,162	6,30,895
on CCBBD	51,49,311	75,08,840
on Term loan from Bank	1,06,95,110	1,22,54,377
on Others	1,66,534	1,93,270
on Unsecured Loans	6,28,484	20,93,249
Total	1,77,73,004	2,31,78,207

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

28. Other expenses

PARTICULARS	For Year Ended 2020-21	For Year Ended 2019-20
	Amount in Rs.	Amount in Rs.
Rent	1,22,07,917	1,21,71,192
Electricity	78,24,138	79,02,980
Licenses & Renewals	1,20,68,535	65,29,757
Repairs & Maintenance	83,49,684	50,17,544
Insurance	21,46,774	19,99,856
Communication Charges	17,74,157	27,92,989
Travelling, Conveyance	9,23,086	18,15,040
Printing & Stationery	10,22,798	10,65,632
Advertisement ,Publicity & Business Promotion	6,50,817	5,71,655
Commission Charges	31,81,685	13,77,551
Professional Charges	2,41,92,183	89,35,406
Technical Services (Outsourcing)	0	6,47,786
Outsourcing Services	19,59,750	0
Audit Fee: As Auditors	1,10,000	60,000
: For Certification	40,000	40,000
General Expenses	24,19,276	16,97,602
Office Maintenance	10,24,514	16,21,554
Director's Sitting fees	4,05,000	2,70,000
Registrar's fee	57,867	68,459
Garden Maintenance	66,000	70,480
Donation	5,00,116	0
BSE Listing Fee	3,00,000	3,00,000
ROC Filing Fee	22,100	4,800
Interest on delay Payments for Statutory dues	10,43,762	24,75,811
GST Paid	5,11,446	86,538
TDS interest & late filing fee	-	20,71,130
Volunteer Expenses	1,41,41,001	1,53,51,027
Volunteer Study Payments	4,01,16,765	2,63,00,532
Bad Debts Written off	-	7,39,23,514
Foreign Exchange Variance Loss	-	86,578
RLD Charges	39,41,890	-
Water Bill Paid	1,70,106	33,220
Loss on Sale of Assets	-	3,06,405
Total	14,11,71,366	17,55,95,037

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Note-29: OTHER DISCLOSURES:

i. Gratuity:

The Company has conducted Actuarial valuation of its Gratuity as on 31st Mar 2021.

Accounting Disclosures Statement **GRATUITY**

Period of accounting	1-Apr-20 to 31-Mar-21 <i>(all figures in Indian Rupees)</i>	
Valuation Result as at	31-Mar-21	31-Mar-20
I Changes in present value of obligations		
PVO at beginning of period	2,624,045	1,839,877
Interest cost	175,444	139,779
Current Service Cost	987,519	912,281
Past Service Cost- (non -vested benefits)	-	-
Past Service Cost -(vested benefits)	-	-
Benefits Paid	(108,968)	-
Contributions by plan participants	-	-
Business Combinations	-	-
Curtailments	-	-
Settlements	-	-
Actuarial (Gain)/Loss on obligation	(392,201)	(267,892)
PVO at end of period	3,285,839	2,624,045
II Interest Expenses		
Interest cost	175,444	139,779
III Fair Value of Plan Assets		
Fair Value of Plan Assets at the beginning	-	-
Interest Income	-	-
IV Net Liability		
PVO at beginning of period	2,624,045	1,839,877

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

	Fair Value of the Assets at beginning report	-	-
	Net Liability	2,624,045	1,839,877
V	Net Interest		
	Interest Expenses	175,444	139,779
	Interest Income	-	-
	Net Interest	175,444	139,779
VI	Actual return on plan assets	-	-
	Less Interest income included above	-	-
	Return on plan assets excluding interest income	-	-
VII	Actuarial (Gain)/loss on obligation		
	Due to Demographic Assumption*	-	-
	Due to Financial Assumption	11,697	269,684
	Due to Experience	(403,898)	(537,576)
	Total Actuarial (Gain)/Loss	(392,201)	(267,892)
*This figure does not reflect interrelationship between demographic assumption and financial assumption when a limit is applied on the benefit, the effect will be shown as an experience			
VIII	Fair Value of Plan Assets		
	Opening Fair Value of Plan Asset	-	-
	Adjustment to Opening Fair Value of Plan Asset	-	-
	Return on Plan Assets excl. interest income	-	-
	Interest Income	-	-
	Contributions by Employer	108,968	-
	Contributions by Employee-	-	-
	Benefits Paid	(108,968)	-
	Fair Value of Plan Assets at end	-	-

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

IX Past Service Cost Recognised

Past Service Cost- (non vested benefits)	-	-
Past Service Cost -(vested benefits)	-	-
Average remaining future service till vesting of the benefit	-	-
Recognised Past service Cost- non vested benefits	-	-
Recognised Past service Cost- vested benefits	-	-
Unrecognised Past Service Cost- non vested benefits	-	-

X Amounts to be recognised in the balance sheet and statement of profit & loss account

PVO at end of period	3,285,839	2,624,045
Fair Value of Plan Assets at end of period	-	-
Funded Status	(3,285,839)	(2,624,045)
Net Asset/(Liability) recognized in the balance sheet	(3,285,839)	(2,624,045)

XI Expense recognized in the statement of P & L A/C

Current Service Cost	987,519	912,281
Net Interest	175,444	139,779
Past Service Cost- (non -vested benefits)	-	-
Past Service Cost -(vested benefits)	-	-
Curtailement Effect	-	-
Settlement Effect	-	-
Unrecognized Past Service Cost- non vested benefits	-	-
Expense recognized in the statement of P & L A/C	1,162,963	1,052,060

XII Other Comprehensive Income (OCI)

Actuarial (Gain)/Loss recognized for the period	(392,201)	(267,892)
Asset limit effect	-	-
Return on Plan Assets excluding net interest	-	-
Unrecognized Actuarial (Gain)/Loss from previous period	-	-

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Total Actuarial (Gain)/Loss recognized in (OCI)	(392,201)	(267,892)
XIII Movements in the Liability recognized in Balance Sheet		
Opening Net Liability	2,624,045	1,839,877
Adjustment to opening balance	-	-
Expenses as above	1,162,963	1,052,060
Contribution paid	(108,968)	-
Other Comprehensive Income(OCI)	(392,201)	(267,892)
Closing Net Liability	3,285,839	2,624,045
XIV Schedule III of The Companies Act 2013		
Current Liability	85,929	65,096
Non-Current Liability	3,199,910	2,558,949
Projected Service Cost 31 Mar 2022		
XV	1,217,086	-

XVI Asset Information	Target Allocation	
Cash and Cash Equivalents	Total Amount	%
Gratuity Fund ()	-	0%
Debt Security - Government Bond		
Equity Securities - Corporate debt securities		
Other Insurance contracts		
Property		
Total Itemized Assets	-	0%

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

XVII Assumptions as at	31-Mar-21	31-Mar-20
Mortality	IALM (2012-14) Ult.	IALM (2012-14) Ult.
Interest / Discount Rate	6.74%	6.77%
Rate of increase in compensation	4.00%	4.00%
Annual increase in healthcare costs		
Future Changes in maximum state healthcare benefits		
Expected average remaining service	16.47	16.83
Employee Attrition Rate(Past Service (PS))PS: 0 to 40 : 3%PS: 0 to 40 : 3%		

Note-31: Related parties

a. Key management personnel

Name of the personnel	Nature of relationship
K Krishna Kishore	Vice chairman & Managing Director
M Rajendra Prasad	Executive Director & CEO
K Vanaja	Non-Executive Director
S S R Koteswara Rao	Independent Director- Chairman
T Ravi Babu	Non-Executive Director
G Bhanu Prakash	Independent Director
K R K Prasad	Independent Director
K Jeevan Krishna	Non- Executive Director
M Snigdha	Executive Director
M Srikanth Sasidhar	Chief Financial Officer
Swapnil Sharvari Shinde	Company secretary

b. Name of the related party

Name of the entity	Nature of relation ship
Jeevana Mitra Finance corporation	Enterprise owned by Key managerial person
Enhops Solutions Pvt Ltd	Wholly owned subsidiary
Enhops Inc, USA	Wholly owned subsidiary

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

c. Particulars of transactions with related party

PARTICULARS	As at	As at
	March 31, 2021	March 31, 2020
	Amount in Rs.	Amount in Rs.
Rent Paid	-	-
a) Jeevana Mitra Finance corporation	8,40,000	8,40,000
b) K Krishna Kishore	4,80,000	4,80,000
c) K Vanaja	4,80,000	4,80,000
Long term Borrowings		
a) K Krishna Kishore	52,50,000	6,02,25,000
b) K Vanaja	6,50,000	83,15,000
c) M Rajendra Prasad	19,50,000	20,00,000
Interest paid on long term borrowings		
a) K Krishna Kishore	2,50,850	14,70,008
b) K Vanaja	69,257	2,95,481
c) M Rajendra Prasad	184,624	1,47,760
Remuneration Paid		
a) K Krishna Kishore	54,00,000	54,00,000
b) M Rajendra Prasad	54,00,000	54,00,000
C) M Snigdha	10,00,000	0
Loans and Advances given		
Enhops Solutions Pvt Ltd	9,88,84,634	7,68,79,725

d. The Company has the following amounts due from / to related parties:

(i) Due to related parties.

PARTICULARS	As at	As at
	March 31, 2021	March 31, 2020
	Amount in Rs.	Amount in Rs.
Long term Borrowings		
a) K Krishna Kishore	-	54,00,000
b) K Vanaja	-	8,50,000
C) M Rajendra Prasad	-	18,00,000

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

(ii) Due from related parties.

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Long term advances		
Enhops Solutions Pvt Ltd	6,52,86,870	6,21,46,546

Note No. 32: Earnings per share (IND AS-33): The details are as under:

PARTICULARS	For Year Ended 31-MAR-21	For Year Ended 31-MAR-20
	Amount in Rs.	Amount in Rs.
1. Profit after Tax (Rs)	11,31,90,815	(7,83,90,104)
2. No of Equity shares	1,53,01,465	1,53,01,465
3. Nominal value per Equity share (Rs.)	10	10
4. Basic Earnings per share (Rs.)	7.40	(5.12)
5. Weighted Average No of Equity Shares	1,53,01,465	1,53,01,465
6. Diluted Earnings per share (Rs.)	7.40	(5.12)

Note No. 33 General:

- i. Expenses are accounted under prepaid expenses only where the amounts relating to unexpired period are material.
- ii. Some of the balances appearing under Trade receivables, Trade payables, advances, Security deposits and other payables are subject to confirmations.
- iii. Figures for the previous year have been regrouped/rearranged wherever considered necessary so as to confirm to the classification of the current year.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

34.1 Disclosures – Revenue (Ind AS 115)

a) Disaggregated revenue information

Set out below is the disaggregation of the Company's revenue from contract with customers

Segment	Current Year 31-Mar-21	Previous Year 31-Mar-20
	Rs. In Lakhs	Rs. In Lakhs
Clinical Research Services	4284.79	2308.85

Segment	Current Year 31-Mar-21	Previous Year 31-Mar-20
	Rs. In Lakhs	Rs. In Lakhs
Total revenue from contracts with customers		
India	3340.85	1,415.62
Outside India	943.94	893.23
Types revenue from contracts with customers	4284.79	2,308.85
Timing of revenue recognition		
Services transferred over time	4284.79	2,308.85
Total revenue from contracts with customers	4284.79	2,308.85

Per our report of even Date
for PAVULURI & Co.
Chartered Accountants
Firm Regn No:012194S

Sd/-
CA. N. Rajesh
Partner
Membership No:223169

Place: Hyderabad
Date: 23-06-2021

for and on behalf of the Board of Directors
Jeevan Scientific Technology Limited

Sd/-
K. Krishna Kishore
Vice Chairman & Managing Director
DIN: 00876539

Sd/-
M Srikanth Sasidhar
Chief Financial Officer

Sd/-
M Snigdha
CEO & Executive Director
DIN: 08934860

Sd/-
Sharvari Swapnil Shinde
Company Secretary

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

INDEPENDENT AUDITOR'S REPORT

To the members of,

M/s. JEEVAN SCIENTIFIC TECHNOLOGY LIMITED,

Report on the Consolidated Audit of Financial Statements:

Opinion

We have audited the accompanying consolidated financial statements of M/s. JEEVAN SCIENTIFIC TECHNOLOGY LIMITED ("the Holding Company"), and its subsidiaries (collectively referred to as "the Group") which comprise the Consolidated Balance Sheet as on 31st March, 2021, and the Consolidated Statement of Profit and Loss (including other Comprehensive Income), statement of changes in equity and Consolidated statement of cash flows for the year ended 31st March, 2021 and notes to the financial statements, including a summary of significant accounting policies and other explanatory information (hereinafter referred to as "the Consolidated financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated financial statements give the information required by the Companies Act 2013 (the "Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the group as at March 31, 2021, the Profit and total comprehensive income, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined the matters described below as key audit matters to be communicated in our report.

Sl. No.	Key Audit Matter	Auditor's Response
1.	<p>Revenue Recognition</p> <p>Revenue is recognized to the extent that economic benefit will flow to the Company and the revenue can be reliably measured. It is measured at fair value consideration received or receivable, net of returns and allowances, discounts and rebates. The Company recognizes revenue when it satisfies its performance obligation by transferring the goods to the customers.</p> <p>Revenue is key driver of the business and judgment is involved in determining when contractual obligations have been performed and to the extent that the right to consideration has been earned.</p> <p>The management of the Company focuses on revenue as a key performance measure which could create an incentive for revenue to be recognized before the risks and rewards have been transferred. We therefore identified</p> <p>Revenue Recognition as a significant risk and key audit matter.</p>	<p>Our audit work included, but was not restricted to:</p> <ul style="list-style-type: none">• We understood business revenue recognition policy and how they are applied, including the relevant controls, and tested controls over revenue recognition;• Analytical review of the revenue recognized over the year• Agreeing on a sample basis amounts of revenue to customer contracts and verifying the extent, timing and customer acceptance of goods, where relevant.• We performed cut-off testing for a sample of revenue transactions around the period end date, to check that they were recognized in the appropriate period;• We discussed key contractual arrangements with management and obtained relevant documentation, including in respect of rebate and returns arrangements.• The Company's accounting policy on Revenue recognition is shown in note XI to the financial statements and related disclosures are included in notes.• Based on our audit procedures we did not identify any evidence of material misstatement in the revenue recognized for the year ended 31st March 2021 in the consolidated financial statements.

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance, in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Other Matters

We did not audit the financial statements of 2 subsidiaries, Enhops Inc. and Enhops Solutions Pvt Ltd. These financial statements have been audited by other auditors whose reports have been furnished to us by the Management and our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and our report in terms of sub-sections (3) and (11) of Section 143 of the Act, insofar as it relates to the aforesaid subsidiaries is based solely on the reports of the other auditors.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2016 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the Annexure a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by Section 143(3) of the Act, we report that:
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books
 - c) The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss (including other comprehensive income), Consolidated Statement of changes in equity and the Consolidated Cash Flow Statement dealt with by this Report are in agreement with the books of accounts.
 - d) In our opinion, the aforesaid consolidated financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

- e) On the basis of the written representations received from the directors as on 31st March, 2021 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2021 from being appointed as a director in terms of Section 164(2) of the Act.
- f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in “Annexure A”.
- g) With respect to the other matters to be included in the Auditor’s Report in accordance with the requirements of section 197(16) of the Act, as amended:

In our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act

- h) With respect to the other matters to be included in the Auditor’s Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - (i) The Company has no pending litigations which would impact its financial position.
 - (ii) The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - (iii) There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.

**For PAVULURI & Co.
Chartered Accountants
Firm Reg. No:012194S**

**Sd/-
(CA N. RAJESH)
PARTNER**

**Place : Hyderabad
Date : 23/06/2021**

**M.No : 223169
UDIN # 21223169AAAAEP9264**

“Annexure A” to the Independent Auditor’s Report of even date on the Consolidated Financial Statements of JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)

We have audited the internal financial controls over financial reporting of JEEVAN SCIENTIFIC TECHNOLOGY LIMITED (“the Company”) as of March 31, 2021 in conjunction with our audit of the consolidated financial statements of the Company for the year ended on that date.

Management’s Responsibility for Internal Financial Controls

The Company’s management is responsible for establishing and maintaining internal financial controls based on “the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India”. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors’ Responsibility

Our responsibility is to express an opinion on the Company’s internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2021, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

**For PAVULURI & Co.
Chartered Accountants
Firm Reg. No:012194S**

**Sd/-
(CA N. RAJESH)
PARTNER**

**Place : Hyderabad
Date : 23/06/2021**

**M.No : 223169
UDIN # 21223169AAAAEP9264**

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Consolidated Balance Sheet as at 31st Mar, 2021

(In Rupees)

Particulars	Note No.	As at 31.03.2021	As at 31.03.2020
Assets			
(1)Non-current Assets			
a) Property, Plant and Equipment	2	15,88,01,128	17,74,37,573
b) Other Intangible Assets	2	50,35,963	73,73,434
c) Intangible Assets Process Knowhow	2	10,99,12,943	12,06,32,053
d) Financial Assets			
i) Investments	3		-
ii) Loans	4		
iii) Advances	5	4,13,00,902	3,69,09,796
c) Deferred tax asset (net)	6	60,30,046	1,56,08,907
(2)Current Assets			
a) Inventories	7	3,45,57,046	94,67,418
b) Financial Assets			
i) Trade receivables	8	14,44,54,440	6,84,32,795
ii) Cash and cash equivalents	9	3,25,51,931	2,13,98,972
iii) Bank balances other than (ii) above	10	2,95,63,173	5,63,173
iv) Loans	11	51,91,862	70,87,171
v) Other Financial Assets	12	2,29,97,445	1,83,26,222
c) Current Tax Assets (Net)	13	4,96,94,322	4,38,86,278
d) Other Current Assets	14	1,96,86,073	1,16,36,078
Total		65,97,77,275	53,87,59,869
Equity and Liabilities			
Equity			
a) Equity Share Capital	A	15,30,14,650	15,30,14,650
b) Other Equity	B	19,72,12,727	7,92,14,498
Liabilities			
(1)Non-current Liabilities			
a) Financial liabilities			
Borrowings	15	7,76,99,329	7,90,27,246
b) Provisions	16	31,99,910	25,58,949
c) Deferred tax Liability (net)	6	0	
(2)Current Liabilities			
a) Financial Liabilities			
i) Borrowings	17	5,06,177	7,36,50,912
ii) Trade Payables	18	3,25,96,752	2,45,73,412
iii) Other Financial liabilities	19	5,49,51,953	5,72,84,876
iv) Other Financial Creditors	20	70,42,253	2,08,57,086
b) Other current liabilities	21	11,61,95,032	4,54,25,199
c) Provisions	22	1,73,58,493	31,53,041
Total		65,97,77,275	53,87,59,869

Per our report of even Date
for PAVULURI & Co.
Chartered Accountants
Firm Regn No:012194S

for and on behalf of the Board of Directors
Jeevan Scientific Technology Limited

Sd/-
CA. N. Rajesh
Partner
Membership No:223169

Sd/-
K. Krishna Kishore
Vice Chairman & Managing Director
DIN: 00876539

Sd/-
M Snigdha
CEO & Executive Director
DIN: 08934860

Place: Hyderabad
Date: 23-06-2021

Sd/-
M Srikanth Sasidhar
Chief Financial Officer

Sd/-
Sharvari Swapnil Shinde
Company Secretary

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Consolidated Statement of Profit and Loss for the year ended 31st Mar, 2021

(In Rupees)

Particulars	Note No.	For the Year Ended 2020-21	For the Year Ended 2019-20
Continuing Operations			
Income			
I. Revenue from operations	23	46,95,28,241	23,94,09,551
II. Other Income	24	1,86,22,568	1,57,60,619
III. Unbilled Revenue		53,00,000	95,80,000
IV. Total revenue(II+III)		49,34,50,809	26,47,50,170
V. Expenses			
Cost of Material consumed	25	2,74,54,611	1,56,89,057
Changes in Work in Progress	25	(2,10,30,000)	(70,40,000)
Employee benefits expenses	26	12,53,34,006	10,44,52,576
Finance costs	27	2,15,52,599	2,78,86,134
Depreciation	2	2,89,63,694	2,84,86,014
Amortisation on Process Knowhow	2	1,07,19,110	1,07,19,112
Other expenses	28	16,39,60,941	18,99,87,809
Total expenses		35,69,54,961	37,01,80,702
VI. Profit/ (Loss) before tax (V)-(IV)		13,64,95,847	(10,54,30,532)
Tax expenses			
Current Tax		1,72,64,084	-
Less: Mat Credit Entitlement/ utilization		(77,49,219)	-
Deferred Tax		95,78,861	(1,95,70,433)
Total tax expenses		1,90,93,726	(1,95,70,433)
Profit / (Loss) for the period from continuing operations		11,74,02,121	(8,58,60,099)
Profit / (Loss) from discontinuing operations		-	-
Tax expense from discontinuing operations		-	-
Profit / (Loss) from discontinuing operations (After tax)		11,74,02,121	(8,58,60,099)
Profit / (loss) for the Period		11,74,02,121	(8,58,60,099)
Other Comprehensive Income			
A (i) Items that will not be reclassified to profit and loss Re-measurements of post-employment benefit obligations)			
		5,96,107	(2,42,512)
(ii) Income tax relating to items that will not be reclassified to profit and loss			
		-	-
B (i) Items that will be reclassified to profit and loss			
(ii) Income tax relating to items that will be reclassified to profit and loss			
		-	-
Total Comprehensive Income		11,79,98,228	(8,61,02,612)
Earning per equity share			
(Face value of Rs.10/- each)			
Basic		7.71	(5.63)
Diluted		7.71	(5.63)

Per our report of even Date
for PAVULURI & Co.
Chartered Accountants
Firm Regn No:012194S

for and on behalf of the Board of Directors
Jeevan Scientific Technology Limited

Sd/-
CA. N. Rajesh
Partner
Membership No:223169

Sd/-
K. Krishna Kishore
Vice Chairman & Managing Director
DIN: 00876539

Sd/-
M Snigdha
CEO & Executive Director
DIN: 08934860

Place: Hyderabad
Date: 23-06-2021

Sd/-
M Srikanth Sasidhar
Chief Financial Officer

Sd/-
Sharvari Swapnil Shinde
Company Secretary

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Consolidated Cash flow statement for the year ended 31st Mar, 2021

(In Rupees)

S.No	Particulars	As at 31.03.2021	As at 31.03.2020
A.	Cash flow from operating activities		
	Net Profit before tax and extraordinary items	13,64,95,847	(10,54,30,532)
	Adjustments for:		
	Depreciation	3,96,82,804	3,92,05,126
	Other Comprehensive Income	5,96,107	(2,42,512)
	Loss on Sale of Assets	-	3,06,407
	Interest	2,09,35,849	2,73,12,291
	Operating profit before working capital changes	19,77,10,607	-3,88,49,220
	Changes in Working Capital		
	Inventories	-2,50,89,628	-71,63,379
	Trade and other receivables	-9,70,46,707	6,17,90,468
	Trade and other Paybles	-1,39,25,959	81,29,975
	Cash generated from operations before Tax	8,95,00,231	76,47,894
	Tax Provision	1,90,93,726	-1,95,70,433
	Provision for Dividend	-	-
	Interest paid	2,09,35,849	2,73,12,291
	Net cash from operating activity	4,94,70,657	-93,964
B.	Cash flow from investing activities		
	Purchase of fixed assets	79,89,778	1,98,67,888
	Investments		
	Sale/ Transfer of fixed assets	-	8,50,673
	Net cash used in investing activity	-79,89,778	-1,90,17,215
C.	Cash flow from financing activity		
	Proceeds from loans	-13,27,917	43,72,256
	Increase in Capital	-	-
	Increase in Other Equity	-	-
	Net cash generated in financing activity	-13,27,917	43,72,256
	Net increase in cash and cash equivalents (A+B+C)	4,01,52,961	-1,47,38,923
	Cash and cash equivalents as at 31.03.2020	2,19,62,145	3,67,01,068
	Cash and cash equivalents as at 31.03.2021	6,21,15,106	2,19,62,145

Per our report of even Date
for PAVLURI & Co.
Chartered Accountants
Firm Regn No:012194S

for and on behalf of the Board of Directors
Jeevan Scientific Technology Limited

Sd/-
CA. N. Rajesh
Partner
Membership No:223169

Sd/-
K. Krishna Kishore
Vice Chairman & Managing Director
DIN: 00876539

Sd/-
M Snigdha
CEO & Executive Director
DIN: 08934860

Place: Hyderabad
Date: 23-06-2021

Sd/-
M Srikanth Sasidhar
Chief Financial Officer

Sd/-
Sharvari Swapnil Shinde
Company Secretary

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

STATEMENT OF CHANGES IN EQUITY

Jeevan Scientific Technology Limited
Statement of changes in Equity for the Period ended 31st March 2021

	AS at 31.03.2021	AS at 31.03.2020
A. Equity Share Capital		
Authorised		
2,10,00,000 Equity Shares of Rs. 10/- each	21000000	21000000
Issued, subscribed and paid-up		
1,53,07,485 (31st Mar. 2021) / 1,53,01,485 (equity Shares of Rs. 10/- each fully paid-up	153014850	153014850
Issued, subscribed and paid-up		
AS at 31.03.2021	153014850	153014850
AS at 31.03.2020	153014850	153014850
Total	153014850	153014850

The details of shares in the company held by each shareholder holding more than 5% shares :

Name of the Share holder	AS at 31.03.2021		AS at 31.03.2020	
	Number of Shares	% of Share Holding	Number of Shares	% of Share Holding
Sr. K. Krishna Gopinath	2016541	13.19%	2016541	13.19%
Sr. K. Yashini	573800	3.75%	573800	3.75%
Dr. Dinesh Duraisai	830000	5.42%	830000	5.42%
Sr. M. Rajendra Prasad	862550	5.63%	862550	5.63%

	Share application money on account of pending financial	Equity component of financial	Reserves and Surplus				Money received against share warrants	Total
			Capital Reserve	Securities premium reserve	Shares reserved reserves	Retained Earnings		
Balance at the beginning of the reporting period i.e. 1st April 2019				187512286	2016541	-24272947	1250	185317110
Change in accounting policy or prior period errors								
Retained balance at the beginning of the reporting period				187512286	2016541	-24272947	1250	185317110
Total comprehensive income for the year						-8670837		-8670837
Dividends								
Transfer to reserve accounts								
Balance at the end of the reporting period i.e. 31st March 2020				187512286	2016541	-110315559	1250	7974488

	Share application money on pending financial	Equity component of financial	Reserves and Surplus				Money received against share warrants	Total
			Capital Reserve	Securities premium reserve	Shares reserved reserves	Retained Earnings		
Balance at the beginning of the reporting period i.e. 1st April 2020				187512286	2016541	-110315559	1250	7974488
Change in accounting policy or prior period errors								
Retained balance at the beginning of the reporting period				187512286	2016541	-110315559	1250	7974488
Total comprehensive income for the year						-11788228		-11788228
Dividends								
Transfer to reserve accounts								
Balance at the end of the reporting period i.e. 31st Mar. 2021				187512286	2016541	7889270	1250	19742727

Significant Accounting Policies and Notes on Accounts

Company Information

The Company was incorporated on 2nd February, 1999 to carry on the business Clinical research, Data management and Information Technology services.

1. Significant Accounting Policies

1.1 Basis of Preparation

a) Statement of Compliance

The consolidated financial statements have been prepared in accordance with Indian Accounting Standards ("Ind AS") notified under the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016 and other relevant provisions of the Act.

b) Basis of measurement

The consolidated financial statements have been prepared on a historical cost convention and on an accrual basis, except for the following material items that have been measured at fair value as required by relevant Ind AS:

- i. Certain financial assets and liabilities measured at fair value (refer accounting policy on financial instruments);
- ii. Defined benefit and other long-term employee benefits.

c) Functional and presentation currency

The Consolidated financial statements are presented in Indian rupees, which is the functional currency of the Company and the currency of the primary economic environment in which the entity operates. All financial information presented in Indian rupees.

d) Use of estimates and judgment

The preparation of consolidated financial statements in conformity with Ind AS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Estimates and underlying assumptions are reviewed on a periodic basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

1.2 Summary of significant accounting policies

i. Functional and presentation currency

Items included in the financial statements of the Company are measured using the currency of the primary economic environment in which these entities operate (i.e. the "functional currency"). The Consolidated financial statements are presented in Indian Rupee, the national currency of India, which is the functional currency of the Company.

ii. Foreign currency transactions and balances

Transactions in foreign currency are translated into the respective functional currencies using the exchange rates prevailing at the dates of the respective transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at the exchange rates prevailing at reporting date of monetary assets and liabilities denominated in foreign currencies are recognized in the statement of profit and loss and reported within foreign exchange gains / (losses).

Non-monetary assets and liabilities denominated in a foreign currency and measured at historical cost are translated at the exchange rate prevalent at the date of transaction.

iii. Investment in subsidiaries

Investment in subsidiaries is measured at cost. Dividend income from subsidiaries is recognized when its right to receive the dividend is established.

iv. Financial instruments

All financial instruments are recognized initially at fair value. Transaction costs that are attributable to the acquisition of the financial asset (other than financial assets recorded at fair value through profit or loss) are included in the fair value of the financial assets. Purchase or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trade) are recognized on trade date. While, loans and borrowings and payable are recognized net of directly attributable transactions costs.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

For the purpose of subsequent measurement, financial instruments of the Company are classified in the following categories: non-derivative financial assets comprising amortized cost; non derivative financial liabilities at amortized cost.

The classification of financial instruments depends on the objective of the business model for which it is held. Management determines the classification of its financial instruments at initial recognition.

Financial instrument is derecognized only when the Company has transferred its right to receive/ extinguish its obligation to pay cash flow from such financial instruments.

a) **Non-derivative financial assets**

Financial assets at amortized cost

A financial asset shall be measured at amortized cost if both of the following conditions are met:

- the financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flows and
- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

They are presented as current assets, except for those maturing later than 12 months after the reporting date which are presented as non-current assets. Financial assets are measured initially at fair value plus transaction costs and subsequently carried at amortized cost using the effective interest method, less any impairment loss.

Amortized cost is represented by security deposits, cash and cash equivalents, employee and other advances and eligible current and non-current assets.

Cash and cash equivalents comprise cash on hand and in banks and demand deposits with banks which can be withdrawn at any time without prior notice or penalty on the principal.

For the purposes of the cash flow statement, cash and cash equivalents include cash on hand, in banks and demand deposits with banks, net of outstanding bank overdrafts that are repayable on demand and are considered part of the Company's cash management system.

b) Non-derivative financial liabilities

Financial liabilities at amortized cost

Financial liabilities at amortized cost represented by trade and other payables are initially recognized at fair value, and subsequently carried at amortized cost using the effective interest method.

v. Property plant and equipment:

Recognition and measurement: Normally Property, plant and equipment are measured at cost less accumulated depreciation and impairment losses, if any. Cost includes expenditures directly attributable to the acquisition of the asset. The Company has elected to apply the optional exemption to use this previous GAAP value as deemed cost at 1 April 2015, the date of transition.

Depreciation: Normally the Company depreciates property, plant and equipment over the estimated useful life of the assets as prescribed in Schedule II of the Companies Act 2013 on a straight-line basis from the date the assets are ready for intended use. Wherever the useful life is determined by technical assessment for certain assets, such assets are depreciated as per their assessed life. Assets acquired under finance lease and leasehold improvements are amortized over the lower of estimated useful life and related term. Depreciation methods, useful lives and residual values are reviewed at each reporting date.

When parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment. Subsequent expenditure relating to property, plant and equipment is capitalized only when it is probable that future economic benefits associated with these will flow to the Company and the cost of the item can be measured reliably. Repairs and maintenance costs are recognized in the statement of profit and loss when incurred. The cost and related accumulated depreciation are eliminated from the Consolidated financial statements upon sale or disposition of the asset and the resultant gains or losses are recognized in the statement of profit and loss.

The management estimates the useful lives for the following class of assets, based on internal assessment and independent technical evaluation carried out by external valuers, the management believes that useful lives as given below best represents the period over which the management expects to use these assets. Hence the useful lives for these assets is different from the useful lives as prescribed under Part - C of schedule II of the companies act 2013.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Plant and machinery	21 years
Electrical Installations	21 years
Computers	6 years
Vehicles- Motor car	10 years
Furniture and Fixtures	15 years
Office Equipment	21 years

Fixed Assets costing Rs.5,000/- or less are fully depreciated in the year of purchase

vi. Intangible assets

Intangible assets are stated at cost less accumulated amortization and impairment. Intangible assets are amortized over their respective estimated useful lives on a straight-line basis, from the date that they are available for use. The estimated useful life of an identifiable intangible asset is based on a number of factors including the effects of obsolescence, demand, competition and other economic factors (such as the stability of the industry and known technological advances) and the level of maintenance expenditures required to obtain the expected future cash flows from the asset.

Policy for accounting of expenses of Research & Development:

Clinical Research is a specified job and the ready availability of newly developed methods for BA/ BE Analysis of drug samples is required to get the business from various Pharmaceutical Clients. JSTL has been in the process of developing process and new methods. Equipment, Machines, Manpower and consumables are used for development of new methods.

Investment in development of a method is calculated on the basis of proportionate of time spent by manpower, machines and also consumable for developing that particular method and the relative expenditure is capitalized as intangible asset. Each method will be of useful for a minimum period of 10-12 years. It is also decided by the Board that the amortization of the investment in process for developing methods should take place in a period 7 years from the date of the method put to use on quarterly basis in straight line method.

vii. Inventory

a) Raw materials, Stores and Consumables, work in process and finished products are valued at lower of cost and net realizable value of the respective units.

b) The basis of determining the cost is

Raw materials : Weighted average cost

Stores and Consumables : Weighted average cost

Work in process and finished goods: valued at lower of cost and net realizable value

c) **In case of identified Obsolete/Surplus/Non-moving items necessary provision is made and charged to revenue.**

viii. Impairment

a) Financial assets

In accordance with Ind AS 109, the Company applies expected credit loss (ECL) model for measurement and recognition of impairment loss.

i. The Company follows 'simplified approach' for recognition of impairment loss allowance on trade receivable.

The application of simplified approach does not require the Company to track changes in credit risk. Rather, it recognizes impairment loss allowance based on lifetime ECLs at each reporting date, right from its initial recognition.

For recognition of impairment loss on other financial assets and risk exposure, the Company determines that whether there has been a significant increase in the credit risk since initial recognition. If credit risk has not increased significantly, 12-month ECL is used to provide for impairment loss. However, if credit risk has increased significantly, lifetime ECL is used. If in subsequent period, credit quality of the instrument improves such that there is no longer a significant increase in credit risk since initial recognition, then the entity reverts to recognizing impairment loss allowance based on 12 month ECL.

Lifetime ECLs are the expected credit losses resulting from all possible default events over the expected life of a financial instrument. The 12 month ECL is a portion of the lifetime ECL which results from default

events that are possible within 12 months after the reporting date.

ECL is the difference between all contractual cash flows that are due to the Company in accordance with the contract and all the cash flows that the entity expects to receive (i.e. all shortfalls), discounted at the original EIR. When estimating the cash flows, an entity is required to consider:

- ii. All contractual terms of the financial instrument (including prepayment, extension etc.) over the expected life of the financial instrument. However, in rare cases when the expected life of the financial instrument cannot be estimated reliably, then the entity is required to use the remaining contractual term of the financial instrument.
- iii. Cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

ECL impairment loss allowance (or reversal) recognized during the period is recognized as income/ expense in the statement of profit and loss. The balance sheet presentation for various financial instruments is described below:

Financial assets measured at amortized cost, contractual revenue receivable: ECL is presented as an allowance, i.e. as an integral part of the measurement of those assets in the balance sheet. The allowance reduces the net carrying amount. Until the asset meets write off criteria, the Company does not reduce impairment allowance from the gross carrying amount.

b) Non-financial assets

The Company assesses at each reporting date whether there is any objective evidence that a non financial asset or a group of non financial assets is impaired. If any such indication exists, the Company estimates the amount of impairment loss.

An impairment loss is calculated as the difference between an asset's carrying amount and recoverable amount. Losses are recognized in profit or loss and reflected in an allowance account. When the Company considers that there are no realistic prospects of recovery of the asset, the relevant amounts are written off. If the amount of impairment loss subsequently decreases and the decrease can be related objectively to an event occurring after the impairment was recognized, then the previously recognized impairment loss is reversed through profit or loss.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

The recoverable amount of an asset or cash-generating unit (as defined below) is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the "cash-generating unit").

ix. Employee benefits

a) Gratuity & Provident Fund:

The Company's liability towards retirement benefits in the form of gratuity is provided in accordance with the payment of Gratuity Act, 1972 to all the employees other than the whole time Directors which is made on the basis of actuarial valuation.

b) The Company's contribution to the provident fund is remitted to Government based on the percentage of the eligible employees' salary as per Provident Fund act.

c) Accrued Leave Salary:

Liability towards Accrued Leave Salary, as at the end of the year is recognized on the basis of valuation made on basic salary. The balance PL's earned by every employee in the previous year, a maximum of 8 days will be paid out during the month of January. These 8 days will be paid as per the last drawn basic salary and taxes will be applicable as per law

x. Provisions

All the provision are recognized as per Ind AS 37. Provisions are recognized when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation.

The amount recognized as a provision is the best estimate of the consideration required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligation.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, the receivable is recognized as an asset, if it is virtually certain that reimbursement will be received and the amount of the receivable can be measured reliably.

Provisions for onerous contracts are recognized when the expected benefits to be derived by the Company from a contract are lower than the unavoidable costs of meeting the future obligations under the contract. Provisions for onerous contracts are measured at the present value of lower of the expected net cost of fulfilling the contract and the expected cost of terminating the contract.

xi. Revenue recognition:

Ind AS 115 recognizes revenue on transfer of the control of goods or services, either over a period of time or at a point in time, at an amount that the entity expects to be entitled in exchange for those goods or services. In order to align with Ind AS 115, the Accounting policy on revenue recognition was reviewed and revised.

xii. Finance income and expense

Finance income consists of interest income on funds invested, dividend income and gains on the disposal of Fair value through profit and loss account financial assets. Interest income is recognized as it accrues in the statement of profit and loss, using the effective interest method.

Dividend income is recognized in the statement of profit and loss on the date that the Company's right to receive payment is established.

Finance expenses consist of interest expense on loans and borrowings. Borrowing costs are recognized in the statement of profit and loss using the effective interest method.

Foreign currency gains and losses are reported on a net basis. This includes changes in the fair value of foreign exchange derivative instruments, which are accounted at fair value through profit or loss.

xiii. Income tax

Income tax comprises current and deferred tax. Income tax expense is recognized in the statement of profit and loss except to the extent it relates to items directly recognized in equity or in other comprehensive income.

a) Current income tax

Current income tax for the current and prior periods are measured at the amount expected to be recovered from or paid to the taxation authorities based on the taxable income for the period. The tax rates and tax laws used to compute the current tax amount are those that are enacted or substantively enacted by the reporting date and applicable for the period. The Company offsets current tax assets and current tax liabilities, where it has a legally enforceable right to set off the recognized amounts and where it intends either to settle on a net basis or to realize the asset and liability simultaneously.

b) MAT credit

Minimum Alternate Tax (MAT) credit is recognized as an asset only when and to the extent there is convincing evidence that the Company will pay normal income tax during the specified period. In the year in which the MAT credit becomes eligible to be recognized as an asset, in accordance with the provisions contained in the Guidance Note on Accounting for Credit Available under Minimum Alternative Tax, issued by the ICAI, the said asset is created by way of a credit to the Profit and Loss account and shown as "MAT Credit Entitlement". The Company reviews the same at each Balance Sheet date and writes down the carrying amount of MAT Credit Entitlement to the extent there is no longer convincing evidence to the effect that the Company will pay normal income tax during the specified period.

c) Deferred income tax

Deferred income tax is recognized using the balance sheet approach. Deferred income tax assets and liabilities are recognized for deductible and taxable temporary differences arising between the tax base of assets and liabilities and their carrying amount in financial statements, except when the deferred income tax arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and affects neither accounting nor taxable profits or loss at the time of the transaction. Deferred income tax asset are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilized. Deferred income tax liabilities are recognized for all taxable temporary differences. The carrying amount of deferred income tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilized. Deferred income tax

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

assets and liabilities are measured at the tax rates that are expected to apply in the period when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

xiv. Foreign currency transaction

i. Initial recognition

Foreign currency transactions are recorded in the reporting currency, by applying to the foreign currency amount the exchange rate between the reporting currency and the foreign currency at the date of the transaction.

ii. Conversion

Foreign currency monetary items denominated in foreign currencies at the yearend are restated at year end rates. In case of monetary items which are covered by foreign exchange contracts, the difference between the original entry dates to forward contract date is recognized as an exchange difference.

iii. Exchange differences

Exchange differences arising on the settlement of monetary items, or on reporting such monetary items of company at rates different from those at which they were initially recorded during the year, or reported in previous financial statements, are recognized as income or as expenses in the year in which they arise.

iv. Foreign currency Transactions.

(in lakhs)

Particulars	Current Year	Previous Year
Earnings in Foreign exchange	1167.62	1002.18
Expenditure in Foreign exchange	NIL	NIL

xv. Earnings per share

Basic earnings per share is computed using the weighted average number of equity shares outstanding during the year.

Diluted EPS is computed by dividing the net profit after tax by the weighted average number of equity shares considered for deriving basic EPS and also weighted average number of equity shares that could have been issued upon conversion of all dilutive potential equity shares.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Dilutive potential equity shares are deemed converted as of the beginning of the year, unless issued at a later date. Dilutive potential equity shares are determined independently for each year presented. The number of equity shares and potentially dilutive equity shares are adjusted for bonus shares, as appropriate.

xvi. Borrowing costs

Borrowings costs directly attributable to acquisition or construction of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the asset. All other borrowing costs are expensed in the period in which it occurs. Borrowing costs consist of interest and other costs that the entity incurs in connection with the borrowing of funds.

xvii. Ind AS 116 Leases :

Ministry of Corporate Affairs has notified 'The Companies (Indian Accounting Standards) Amendment Rules, 2019 dated March 30, 2019 which inter alia includes the new standard on Leases Ind AS 116 replacing the existing standard Ind AS 17, to be effective from the 1st April 2019. The Company has used the Modified Retrospective Approach for transitioning to Ind AS 116. There is no significant impact on the financials after implementation of this standard.

xviii. Contingent liabilities

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence of non-occurrence of one or more uncertain future events beyond the control of the company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably. The company does not recognize a contingent liability but discloses its existence in the financial statements.

The contingent liability is Rs. 4.13 Lakhs during the financial year.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

I. Tangible Assets											
S No	Description	Gross Block				Depreciation				NET BLOCK	
		As at 01.04.2020	Additions	Deletions	As at 31.03.2021	Up to 01.04.2020	Deletions	For the year	Up to 31.03.2021	As at 31.03.2021	As at 31.03.2020
1	LEASE HOLD BUILDINGS	81,65,864	0	0	81,65,864	81,65,864	0	0	81,65,864	0	0
2	PLANT & MACHINERY	182,59,803	2,94,005	0	185,53,808	75,40,238	16,52,812	91,93,050	93,60,758	107,19,565	
	a. Electrical Installations	11,94,942			11,94,942	10,37,517	96,760	10,94,277	1,00,685	1,57,425	
	b. Airconditioners	10,48,582			10,48,582	9,82,170	49,808	10,31,978	16,604	66,412	
	c. U.P.S. Systems	2,75,203			2,75,203	2,14,878	13,072	2,27,950	47,253	60,325	
	d. Inverter	207,78,530	2,94,005	0	210,72,535	97,74,803	17,72,452	115,47,255	95,25,280	110,03,727	
3	COMPUTERS	217,36,521	17,12,377	0	234,48,898	179,94,421	20,75,079	200,69,500	33,79,398	37,42,100	
	a. Computers	217,36,521	17,12,377	0	234,48,898	179,94,421	20,75,079	200,69,500	33,79,398	37,42,100	
4	VEHICLES	168,88,280	0	0	168,88,280	42,71,936	18,58,400	61,30,336	107,57,944	126,16,344	
	a. Motor Car	2,25,910			2,25,910	1,07,588	17,699	1,24,697	1,01,223	1,18,322	
	b. Scooter	171,14,190			171,14,190	43,79,524	18,75,699	62,55,023	106,59,167	127,34,666	
5	FURNITURE & FIXTURES	296,82,334	9,18,475	0	306,00,809	147,07,289	22,18,926	169,26,215	1,36,74,594	149,75,045	
	a. Furniture	9,88,151			9,88,151	9,88,151	0	9,88,151	0	0	
	b. Fixtures	306,70,485	9,18,475	0	315,88,960	156,95,440	22,18,926	179,14,366	1,36,74,594	149,75,045	
6	OFFICE & LABORATORY EQUIPMENT	33,81,920	3,18,713	0	37,00,633	13,72,202	5,55,665	19,27,867	17,82,786	20,19,718	
	a. Office Equipments	1838,59,411	42,46,208	0	1881,05,619	509,95,298	178,06,442	686,01,840	1195,03,779	1328,64,113	
	b. Laboratory Equipments	4,60,323			4,60,323	3,62,314	21,865	3,84,179	76,144	98,009	
	c. E.P.A.B.X & Telephones	15,100			15,100	14,905	195	15,100	0	195	
	d. Fax Machine	3,66,841			3,66,841	3,66,841	0	3,66,841	0	0	
	e. Projector with LCD Panel	1880,93,595	45,64,921	0	1926,58,516	531,11,560	181,84,267	712,95,827	1213,62,689	1349,82,025	
7	LIBRARY:	89,983	0	0	89,983	89,983	0	89,983	0	0	
	a. Books	89,983	0	0	89,983	89,983	0	89,983	0	0	
	Total:	2886,49,168	74,89,778	0	2961,38,946	1092,11,595	261,26,232	1355,37,818	1586,01,128	1774,37,573	

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

II. Intangible Assets (in Rupees)												
S.No	Description	Gross Block				Depreciation				NET BLOCK		
		As at 01.04.2020	Additions	Deletions	As at 31.03.2021	Up to 01.04.2020	Deletions	For the year	Up to 31.03.2021	As at 31.03.2021	As at 31.03.2020	
1	COMPUTERS											
	Software	163,36,347	5,00,000		168,36,347	89,62,913		28,37,471	118,00,384		50,35,963	73,73,434
		163,36,347	5,00,000	0	168,36,347	89,62,913	0	28,37,471	118,00,384		50,35,963	73,73,434
2	COPYRIGHTS											
		12,04,000			12,04,000	12,04,000		0	12,04,000		0	0
	Total:	175,40,347	5,00,000	0	180,40,347	101,66,913	0	28,37,471	130,04,384		50,35,963	73,73,434

III. Intangible Assets Process Knowhow (in Rupees)												
S.No	Description	Gross Block				Depreciation				NET BLOCK		
		As at 01.04.2020	Additions	Deletions	As at 31.03.2021	Up to 01.04.2020	Deletions	For the year	Up to 31.03.2021	As at 31.03.2021	As at 31.03.2020	
1	Process Knowhow											
		1433,04,678			1433,04,678	226,72,625		107,19,110	333,91,735		1099,12,943	1206,32,053
	Total:	1433,04,678	0	0	1433,04,678	226,72,625	0	107,19,110	333,91,735		1099,12,943	1206,32,053

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Consolidated Notes to financial statements for the year ended 31st March, 2021

3. Non Current Investments

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Enhops Solutions Inc.	-	-
Enhops Solutions Pvt Ltd	-	-
Total	-	-

4. Long term Loans

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
iii) Loans and advances to related parties	-	-
iv) Other Loans and advances	-	-
Total	-	-

5. Advances

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
i) Capital Advances	3,65,00,000	3,25,00,000
ii) Security Deposit	48,00,902	44,09,796
iii) Other Advances	0	0
Total	4,13,00,902	3,69,09,796

6. Deferred Tax (Net)

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Deferred Tax Asset / (Liability) Opening	1,56,08,907	-39,61,526
Add/Less: Deferred Tax Asset / (Liability)	-95,78,861	1,95,70,433
Total	60,30,046	1,56,08,907

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

7. Inventories

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Work in progress point of sale boxes	-	2,10,240
Consumables - R & D	64,87,046	22,17,178
Closing Work in Progress	2,80,70,000	70,40,000
Total	3,45,57,046	94,67,418

8. Trade receivables (Unsecured)

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Debtors outstanding for more than Six months	-	-
Considered good	30,74,139	30,61,630
Doubtful debts	0	7,36,42,646
Other debts for less than six months		
Considered good	14,13,80,301	6,53,71,165
	14,44,54,440	14,20,75,441
Less: Bad Debts Written off		7,36,42,646
Total	14,44,54,440	6,84,32,795

9. Cash and Cash Equivalents

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Cash and cash equivalents Balances with Banks	-	-
in current accounts	56,70,097	32,44,875
cash on hand	2,68,81,834	1,81,54,097
Total	3,25,51,931	2,13,98,972

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

10. Cash and Cash Equivalents

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Bank balances other than in fixed deposits more than 12 months	-	-
in fixed deposits Less than 12 months	5,63,173	5,63,173
	2,90,00,000	0
Total	2,95,63,173	5,63,173

11. Loans & Advances (current)

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Advances Given	51,91,862	70,87,171
Total	51,91,862	70,87,171

12. Other Financial Assets

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Interest Receivable	1,78,13,445	1,44,38,222
Rent Receivable	51,84,000	38,88,000
Total	2,29,97,445	1,83,26,222

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

13. Current Tax Assets (Net)

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Tax deducted at source	3,16,81,539	3,36,22,714
MAT Credit	1,80,12,783	1,02,63,564
Total	4,96,94,322	4,38,86,278

14. Other Current Assets

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Prepaid Expenses	38,93,839	13,31,233
Hero Finance corporation	8,03,026	6,59,607
Magma Finance	80,029	47,084
Tata Capital Finance	29,179	18,154
Unbilled Revenue	1,48,80,000	95,80,000
Total	1,96,86,073	1,16,36,078

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

15. Long term borrowings

PARTICULARS	Non Current Portion		Current portion	
	As at 31.03.2021	As at 31.03.2020	As at 31.03.2021	As at 31.03.2020
Term Loan- secured	-	-	-	-
A) From Banks	-	-	-	-
i) Car Loans- Hypothecation against the Cars	25,48,255	33,49,847	20,79,417	40,64,496
ii) Machinery loans	4,86,51,074	6,31,74,282	2,24,76,153	1,86,72,997
iii) Business Loan	2,50,00,000	4,53,117	6,94,024	40,81,436
B) Intercorporate Loans	15,00,000	40,00,000	-	-
C) Loans and advances from related parties	0	80,50,000	-	-
Total	7,76,99,329	7,90,27,246	2,52,49,594	2,68,18,929

16. Long Term Provisions

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Gratuity Payable	31,99,910	25,58,949
Total	31,99,910	25,58,949

17. Short Term Borrowings

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Loan repayable on Demand	-	-
i) Loan From Banks (Guaranteed by Director)	5,06,177	7,36,50,912
Total	5,06,177	7,36,50,912

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

18. Trade Payables

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Trade payables (for services received)	3,25,96,752	2,45,73,412
Total	3,25,96,752	2,45,73,412

19. Other Financial liabilities

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Current maturities of Long term borrowings	2,52,49,594	2,68,18,929
Interest Payable	2,38,27,626	2,21,96,704
Rent Payable	58,74,733	82,69,243
Total	5,49,51,953	5,72,84,876

20. Other Financial Creditors

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Creditors for Capital Assets	70,42,253	2,08,57,086
Total	70,42,253	2,08,57,086

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

21. Other Current Liabilities

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
TDS Payable	32,59,431	66,87,463
Professional tax payable	41,650	28,400
GST Payable	58,43,242	33,35,172
Provident Fund payable	6,72,470	5,44,072
ESI payable	94,078	76,703
Salaries payable	92,52,971	79,53,750
Directors Remuneration Payable	14,86,092	43,40,931
Provision for expenses	2,01,014	10,10,025
Advance received from Customers	33,65,130	43,73,227
Prepaid Revenue	9,06,19,594	1,57,00,000
Other Payables	13,59,360	13,75,456
Total	11,61,95,032	4,54,25,199

22. Short Term Provisions

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Leave Encashment Payable	8,480	8,480
Bonus Payable	0	30,79,465
Gratuity Payable	85,929	65,096
Provision for Income Tax	1,72,64,084	-
Total	1,73,58,493	31,53,041

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

23. Revenue from operations

PARTICULARS	For Year Ended 2020-21	For Year Ended 2019-20
	Amount in Rs.	Amount in Rs.
IT Consultancy Service Charges - Export	2,23,77,318	1,08,95,145
IT Consultancy Service Charges - Domestic	4,24,45,705	2,28,39,665
Clinical Research Services- Domestic	31,03,10,232	11,63,51,831
Clinical Research Services- Export	9,43,94,986	8,93,22,910
Total	46,95,28,241	23,94,09,551

24. Other non operating income

PARTICULARS	For Year Ended 2020-21	For Year Ended 2019-20
	Amount in Rs.	Amount in Rs.
Interest on Income Tax Refund	15,80,080	13,41,840
Interest Received from Others	37,50,248	66,96,421
Miscellaneous Income	30,77,424	21,12,779
Profit on Sale of Motor Car	-	49,324
Exchange Variance Profit	(2,16,402)	7,75,914
Creditors Written Off	-	35,84,341
Rent Received	12,00,000	12,00,000
Pass Through & Storage Charges	92,31,218	0
Total	1,86,22,568	1,57,60,619

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

25. Cost of Material Consumed

PARTICULARS	For Year Ended 2020-21	For Year Ended 2019-20
	Amount in Rs.	Amount in Rs.
Hardware	-	-
Opening Stock	2,10,240	2,10,240
Purchases: Components & Software	2,10,240	2,10,240
Less: Closing Stock	0	2,10,240
Total (A)	2,10,240.00	-

Consumables - R & D

PARTICULARS	For Year Ended 2020-21	For Year Ended 2019-20
	Amount in Rs.	Amount in Rs.
Opening Stock	22,17,178	20,93,799
Purchases: Consumables	3,15,14,240	1,58,12,436
	3,37,31,418	1,79,06,235
Less: Closing Stock	64,87,046	22,17,178
Less: Transfer to Process Knowhow	-	-
Total (B)	2,72,44,371	1,56,89,057
Total (A+B)	2,74,54,611	1,56,89,057

Changes in WIP

PARTICULARS	For Year Ended 2020-21	For Year Ended 2019-20
	Amount in Rs.	Amount in Rs.
Opening WIP	70,40,000	0
Closing WIP	2,80,70,000	70,40,000
Total	-2,10,30,000	-70,40,000

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

26. Employees benefit expenses

PARTICULARS	For Year Ended 2020-21	For Year Ended 2019-20
	Amount in Rs.	Amount in Rs.
Salaries & Allowances	10,12,43,586	8,44,54,568
Contribution to Provident Fund&Others	40,76,011	36,21,533
Welfare Expenses	24,89,541	16,90,557
Gratuity	11,62,963	10,52,060
Bonus	13,45,735	16,12,514
Leave encashment	2,16,170	1,33,844
Director's Remuneration	1,48,00,000	1,18,87,500
Total	12,53,34,006	10,44,52,576

27. Finance Cost

PARTICULARS	For Year Ended 2020-21	For Year Ended 2019-20
	Amount in Rs.	Amount in Rs.
Bank charges	2,00,812	1,61,995
Loan Processing Charges	4,15,938	4,11,848
Interest expense		
on Vehicle Loans	5,46,162	6,30,895
on Bank Overdraft	51,49,311	75,08,840
on Term loan from Bank	1,06,95,110	1,22,54,377
on Others	1,66,534	1,93,270
on Unsecured Loans	43,78,732	67,24,909
Total	2,15,52,599	2,78,86,134

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

28. Other expenses

PARTICULARS	For Year Ended 2020-21	For Year Ended 2019-20
	Amount in Rs.	Amount in Rs.
Rent	1,34,07,917	1,29,66,192
Electricity	78,24,138	79,02,980
Repairs & Maintenance	91,16,987	51,44,997
Insurance	22,62,972	23,20,202
Licenses & Renewals	1,20,76,357	66,27,287
Communication Charges	20,54,707	30,51,461
Travelling, Conveyance	59,71,601	68,17,414
Printing & Stationery	10,22,798	10,75,154
Advertisement ,Publicity & Business Promotion	6,77,310	5,83,764
Commission Charges	31,81,685	13,77,551
Professional Charges	3,88,62,355	1,49,93,960
Technical Services	0	6,47,786
Outsourcing Services	19,59,750	0
Audit Fee: As Auditors	1,60,000	1,00,000
: For Certification	40,000	40,000
General Expenses	28,92,043	21,00,191
Office Maintenance	10,24,514	16,21,554
Audit Expenses	0	3,32,690
Director's Sitting fees	4,05,000	2,70,000
Registrar's expenses	57,867	68,459
Garden Maintenance	66,000	70,480
Donation	5,00,116	0
BSE Listing Fee	3,00,000	3,00,000
ROC Filing Fee	22,100	23,500
Interest on delay Payments for Statutory dues	10,58,401	24,90,917
GST Paid	5,11,446	86,538
TDS interest & late filing fee	0	29,46,760
Volunteer Expenses	1,41,41,001	1,53,51,027
Volunteer Study Payments	4,01,16,765	2,63,00,532
Bad debts Written off	1,05,488	7,39,23,514
Foreign Exchange Variance Loss	29,628	1,13,275
RLD Charges	39,41,890	0
Water Bill Paid	1,70,106	33,220
Loss on Sale of Assets	0	3,06,405
Total	16,39,60,941	18,99,87,809

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Note-29: OTHER DISCLOSURES:

i. Gratuity:

The Company has conducted Actuarial valuation of its Gratuity as on 31st Mar 2021.

Accounting Disclosures Statement **GRATUITY**

Period of accounting	1-Apr-20 to 31-Mar-21 <i>(all figures in Indian Rupees)</i>	
Valuation Result as at	31-Mar-21	31-Mar-20
I Changes in present value of obligations		
PVO at beginning of period	2,624,045	1,839,877
Interest cost	175,444	139,779
Current Service Cost	987,519	912,281
Past Service Cost- (non -vested benefits)	-	-
Past Service Cost -(vested benefits)	-	-
Benefits Paid	(108,968)	-
Contributions by plan participants	-	-
Business Combinations	-	-
Curtailments	-	-
Settlements	-	-
Actuarial (Gain)/Loss on obligation	(392,201)	(267,892)
PVO at end of period	3,285,839	2,624,045
II Interest Expenses		
Interest cost	175,444	139,779
III Fair Value of Plan Assets		
Fair Value of Plan Assets at the beginning	-	-
Interest Income	-	-
IV Net Liability		
PVO at beginning of period	2,624,045	1,839,877

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

	Fair Value of the Assets at beginning report	-	-
	Net Liability	2,624,045	1,839,877
V	Net Interest		
	Interest Expenses	175,444	139,779
	Interest Income	-	-
	Net Interest	175,444	139,779
VI	Actual return on plan assets	-	-
	Less Interest income included above	-	-
	Return on plan assets excluding interest income	-	-
VII	Actuarial (Gain)/loss on obligation		
	Due to Demographic Assumption*	-	-
	Due to Financial Assumption	11,697	269,684
	Due to Experience	(403,898)	(537,576)
	Total Actuarial (Gain)/Loss	(392,201)	(267,892)
*This figure does not reflect interrelationship between demographic assumption and financial assumption when a limit is applied on the benefit, the effect will be shown as an experience			
VIII	Fair Value of Plan Assets		
	Opening Fair Value of Plan Asset	-	-
	Adjustment to Opening Fair Value of Plan Asset	-	-
	Return on Plan Assets excl. interest income	-	-
	Interest Income	-	-
	Contributions by Employer	108,968	-
	Contributions by Employee-	-	-
	Benefits Paid	(108,968)	-
	Fair Value of Plan Assets at end	-	-

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

IX Past Service Cost Recognised

Past Service Cost- (non vested benefits)	-	-
Past Service Cost -(vested benefits)	-	-
Average remaining future service till vesting of the benefit	-	-
Recognised Past service Cost- non vested benefits	-	-
Recognised Past service Cost- vested benefits	-	-
Unrecognised Past Service Cost- non vested benefits	-	-

X Amounts to be recognised in the balance sheet and statement of profit & loss account

PVO at end of period	3,285,839	2,624,045
Fair Value of Plan Assets at end of period	-	-
Funded Status	(3,285,839)	(2,624,045)
Net Asset/(Liability) recognized in the balance sheet	(3,285,839)	(2,624,045)

XI Expense recognized in the statement of P & L A/C

Current Service Cost	987,519	912,281
Net Interest	175,444	139,779
Past Service Cost- (non -vested benefits)	-	-
Past Service Cost -(vested benefits)	-	-
Curtailement Effect	-	-
Settlement Effect	-	-
Unrecognized Past Service Cost- non vested benefits	-	-
Expense recognized in the statement of P & L A/C	1,162,963	1,052,060

XII Other Comprehensive Income (OCI)

Actuarial (Gain)/Loss recognized for the period	(392,201)	(267,892)
Asset limit effect	-	-
Return on Plan Assets excluding net interest	-	-
Unrecognized Actuarial (Gain)/Loss from previous period	-	-

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Total Actuarial (Gain)/Loss recognized in (OCI)	(392,201)	(267,892)
XIII Movements in the Liability recognized in Balance Sheet		
Opening Net Liability	2,624,045	1,839,877
Adjustment to opening balance	-	-
Expenses as above	1,162,963	1,052,060
Contribution paid	(108,968)	-
Other Comprehensive Income(OCI)	(392,201)	(267,892)
Closing Net Liability	3,285,839	2,624,045
XIV Schedule III of The Companies Act 2013		
Current Liability	85,929	65,096
Non-Current Liability	3,199,910	2,558,949
Projected Service Cost 31 Mar 2022		
XV	1,217,086	-

XVI Asset Information	Target Allocation	
Cash and Cash Equivalents	Total Amount	%
Gratuity Fund ()	-	0%
Debt Security - Government Bond		
Equity Securities - Corporate debt securities		
Other Insurance contracts		
Property		
Total Itemized Assets	-	0%

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

XVII Assumptions as at	31-Mar-21	31-Mar-20
Mortality	IALM (2012-14) Ult.	IALM (2012-14) Ult.
Interest / Discount Rate	6.74%	6.77%
Rate of increase in compensation	4.00%	4.00%
Annual increase in healthcare costs		
Future Changes in maximum state healthcare benefits		
Expected average remaining service	16.47	16.83
Employee Attrition Rate(Past Service (PS))PS: 0 to 40 : 3%PS: 0 to 40 : 3%		

Note-30: Segment Reporting as per Ind-AS-108

A. Basis for segmentation

An operating segment is a component of the Company that engages in business activities from which it may earn revenues and incur expenses and for which discrete financial information is available. All operating segments' operating results are reviewed regularly by the Board of Directors to make decisions about resources to be allocated to the segments and assess their performance.

The Company has two reportable segments, as described below, which are the company's strategic business units. These business units offer different services, and are managed separately because they require different technology and marketing strategies. For each of the business units, the company's Board reviews internal management reports on a periodic basis.

The following summary describes the operations in each of the Company's reportable segments:

B. Information about reportable segments

Information regarding the results of each reportable segment is included below. Performance is measured based on segment profit (before tax), segment revenue and segment capital employed as included in the internal management reports that are reviewed by the board of directors. Segment profit is used to measure performance as management believes that such information is the most relevant in evaluating the results of certain segments relative to other entities that operate within these industries.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Reportable Segments

Segment Reporting as on 31-03-2021

Rs. In Lakhs

Particulars	Clinical Research services	Information Technology Services	Unallocated	Total
Revenue from External Customers	4284.79	649.71	-	4934.50
Segment Result	1317.85	47.09	-	1364.94
Assets	6377.66	220.11	-	6597.77
Liabilities	6377.66	220.11	-	6597.77
Depreciation and Amortization	395.51	1.31	-	396.82
Capital Expenditure during the year	79.89	-	-	79.89

Segment Reporting as on 31-03-2020

Rs. In Lakhs

Particulars	Clinical Research services	Information Technology Services	Unallocated	Total
Revenue from External Customers	2,308.85	338.65	-	2,647.50
Segment Result	(237.78)	(77.29)	-	(315.07)
Assets	5,287.52	100.08	-	5,387.60
Liabilities	5,287.52	100.08	-	5,387.60
Depreciation and Amortization	390.78	1.27	-	392.05
Capital Expenditure during the year	110.09	88.59	-	198.68

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Note-31: Related parties

a. Key management personnel

Name of the personnel	Nature of relationship
K Krishna Kishore	Vice chairman & Managing Director
M Rajendra Prasad	Executive Director & CEO
K Vanaja	Non-Executive Director
S S R Koteswara Rao	Independent Director- Chairman
T Ravi Babu	Non-Executive Director
G Bhanu Prakash	Independent Director
K R K Prasad	Independent Director
K Jeevan Krishna	Non-Executive Director
M Snigdha	Executive Director
M Srikanth Sasidhar	Chief Financial Officer
Swapnil Sharvari Shinde	Company secretary

b. Name of the related party

Name of the entity	Nature of relation ship
Jeevana Mitra Finance corporation	Enterprise owned by Key managerial person
Enhops Solutions Pvt Ltd	Wholly owned subsidiary
Enhops Inc, USA	Wholly owned subsidiary

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

c. Particulars of transactions with related party

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Rent Paid	-	-
a) Jeevana Mitra Finance corporation	8,40,000	8,40,000
b) K Krishna Kishore	4,80,000	4,80,000
c) K Vanaja	4,80,000	4,80,000
Long term Borrowings		
a) K Krishna Kishore	52,50,000	6,02,25,000
b) K Vanaja	6,50,000	83,15,000
c) M Rajendra Prasad	19,50,000	20,00,000
Interest paid on long term borrowings		
a) K Krishna Kishore	2,50,850	14,70,008
b) K Vanaja	69,257	2,95,481
c) M Rajendra Prasad	184,624	1,47,760
Remuneration Paid		
a) K Krishna Kishore	54,00,000	54,00,000
b) M Rajendra Prasad	54,00,000	54,00,000
C) M Snigdha	10,00,000	-
C) K Jeevan Krishna	30,00,000	15,00,000

d. The Company has the following amounts due from / to related parties:

(i) Due to related parties.

PARTICULARS	As at March 31, 2021	As at March 31, 2020
	Amount in Rs.	Amount in Rs.
Long term Borrowings		
a) K Krishna Kishore	-	54,00,000
b) K Vanaja	-	8,50,000
C) M Rajendra Prasad	-	18,00,000

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Note No. 32: Earnings per share (IND AS-33): The details are as under:

PARTICULARS	For Year Ended 31-MAR-21	For Year Ended 31-MAR-20
	Amount in Rs.	Amount in Rs.
1. Profit after Tax (Rs)	11,79,98,228	(8,61,02,612)
2. No of Equity shares	1,53,01,465	1,53,01,465
3. Nominal value per Equity share (Rs.)	10	10
4. Basic Earnings per share (Rs.)	7.71	(5.63)
5. Weighted Average No of Equity Shares	1,53,01,465	1,53,01,465
6. Diluted Earnings per share (Rs.)	7.71	(5.63)

Note No. 33 General:

- i. Expenses are accounted under prepaid expenses only where the amounts relating to unexpired period are material.
- ii. Some of the balances appearing under Trade receivables, Trade payables, advances, Security deposits and other payables are subject to confirmations.
- iii. Figures for the previous year have been regrouped/rearranged wherever considered necessary so as to confirm to the classification of the current year.

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

34.1 Disclosures – Revenue (Ind AS 115)

a) Disaggregated revenue information

Set out below is the disaggregation of the Company's revenue from contract with customers

Segment	Current Year 31-Mar-21	Previous Year 31-Mar-20
	Rs. In Lakhs	Rs. In Lakhs
Types of goods or service		
Sale of Service		
Clinical Research Services	4284.79	2,308.85
Information Technology Services	649.71	338.65

Segment	Current Year 31-Mar-21	Previous Year 31-Mar-20
	Rs. In Lakhs	Rs. In Lakhs
Total revenue from contracts with customers		
India	3766.78	1,645.32
Outside India	1167.72	1,002.18
Types revenue from contracts with customers	4934.50	2,647.50
Timing of revenue recognition		
Services transferred over time	4934.50	2,647.50
Total revenue from contracts with customers	4934.50	2,647.50

Per our report of even Date
for PAVULURI & Co.
Chartered Accountants
Firm Regn No:012194S

Sd/-
CA. N. Rajesh
Partner
Membership No:223169

Place: Hyderabad
Date: 23-06-2021

for and on behalf of the Board of Directors
Jeevan Scientific Technology Limited

Sd/-
K. Krishna Kishore
Vice Chairman & Managing Director
DIN: 00876539

Sd/-
M Srikanth Sasidhar
Chief Financial Officer

Sd/-
M Snigdha
CEO & Executive Director
DIN: 08934860

Sd/-
Sharvari Swapnil Shinde
Company Secretary



Enhops Solutions Pvt. Ltd., India and Enhops, Inc., USA are fully owned “subsidiary” companies of **Jeevan Scientific Technology Limited.**

Services Overview



Test Advisory
Services



Test
Automation



Performance
Testing



Security
Testing



Mobile
Testing



TCoE



DevOps



Functional
Manual Testing



Process Framework
Establishment

**Clinical Pharmacology Unit
Balanagar, Hyderabad**



If undelivered, please return to :

Jeevan Scientific Technology Limited

Registered Office: Plot No. 1&2, Sai Krupa Enclave,
Manikonda Jagir, Near Lanco Hills,
Golconda (PO) Hyderabad - 500 008.

Ph : +91-40-67364700

Email: info@jeevanscientific.com, Web : www.jeevanscientific.com